THERAPEUTIC CHROMONE COMPOUNDS

COMPOSES DE CHROMONE THERAPEUTIQUES

English Abstract

Provided herein is a compound of the formula (I) wherein said compound is
useful for the treatment of psychiatric disorders including but not limited to
depression, generalized anxiety, eating, disorders, dementia, panic disorder,
and sleep disorders. The compounds may also be useful in the treatment of
gastrointestinal disorders, cardiovascular regulation, motor disorders,
endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT
1B antagonists. Also provided herein are processes for making compounds of
Formula (I) and intermediate compounds.

French Abstract

La présente invention concerne un composé de formule (I), ledit composé pouvant être utilisé pour traiter les troubles psychiques comprenant, entre autres, la dépression, l'anxiété généralisée, les troubles de l'alimentation, la démence, les troubles paniques, et les troubles du sommeil. Lesdits composés peuvent également être utilisés pour traiter les troubles gastro-intestinaux, pour la régulation cardio-vasculaire, pour traiter les troubles moteurs, les troubles du système endocrinien, le vasospasme, et les troubles d'ordre sexuel. Les composés sont des antagonistes de 5HT ¿1B? et de 5HT ¿1D?. Cette invention concerne également des procédés permettant la préparation des composés de formule (I) et de composés intermédiaires.

Claims

-133-
CLAIMS
We claim:
1. A compound of the formula (I):
<IMG>
wherein
R1 is, at each position, independently represented by hydrogen, optionally
substituted alkyl,
optionally substituted cycloalkyl, , thiomethoxy, -NHA, -NA2, -NHC(=O)A,
aminocarbonyl,
-C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted
alkenyl or optionally substituted alkynyl;
R2 is represented by (i), (ii), (iii), or (iv) below:
<IMGS>
R3 is independently at each position represented by ~H, optionally substituted
C1-6alkyl,
optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl,
optionally substituted
C3-6cycloalkyl or -AOH;
n is 2, 3 or 4;
P is a heterocyclic ring;
R6 is -H or methyl;

-134-
Y is -C(=O)NH-, -C(=O)NA-, -C(=O)N(A)-, -NHC(=O)-, -C(=S)NH-, -CH2NH-, -C(=O)-
,
-C(=O)CH2-, -CH2C(=O)-, -C(=O)-piperazine-, -NAC(=O)-,
-C(=S)N(A)-, -CH2NA-, -NACH2- or a 5-membered heterocyclic.
R7 is a monocyclic or bicyclic aromatic ring or a heterocycle, optionally
substituted by one or
more substituents selected from R8-R9 and R10; wherein R7 is connected to Y
either by a
single bond or by a ring fusion;
R8 is -CH2-, -C(=O)-, -SO2-, - SO2NH-, -C(=O)NH-, -O-, -S-, -S(=O)-, a single
bond as tether
from R7 to R9, a five membered heterocyclic connected to R7 by a ring fusion
or single bond
as tether;
R9 is optionally substituted heterocycle, optionally substituted aryl,
optionally substituted
piperazinyl-R11, optionally substituted morpholinyl-R11, optionally
substituted
thiomorpholinyl , or -C(=O)A;
R10 is optionally substituted alkyl, optionally substituted cycloalkyl,
hydroxy, aryl, cyano,
halogen, -C(=O)NH2-; methylthio, -NHA, -NA2, -NHC(=O)A, -C(=O)NHA, -C(=O)NA2
or
OA;
R11 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9,
-alkylR9, -C(=O)A, -C(=O)NH2, -C(=O)NHA, -C(=O)NA2 or ~C(=O)OA; or a
pharmaceutically acceptable salt of said compound.
2. The compound as recited in Claim 1 wherein the R1 is, at each position,
independently
represented by hydrogen, alkyl, cycloalkyl, methoxy, thiomethoxy, -NHA, -NA2, -
NHC(=O)A, aminocarbonyl, -C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or
aryl
wherein alkyl and cycloalkyl are optionally substituted with halogen, nitro,
cyano, hydroxy,
trifluoromethyl, amino, carboxy, carboxamindo, amidino, carbamoyl, mercapto,
sulfamoyl,
C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C1-
4 alkoxy, C1-4
alkanoyl, C1-4 alkanoyloxy, N-(C1-4 alkyl), N(C1-4 alkyl)2, C1-4
alkanoylamino, (C1-4
alkanoyl)2amino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4)2carbamoyl, (C1-4 alkyl)S,
(C1-4
alkyl)S(=O), (C1-4 alkyl)SO2, (C1-4) alkoxycarbonyl, N-(C1-4 alkyl)sulfamoyl,
N,N-C1-4
alkyl)sulfamoyl, C1-4 alkylsolfonylamino or heterocyclic.

-135-
3. The compound as recited in Claims 1-2 wherein A represents an alkyl
optionally
substituted with halogen, nitro, cyano, hydroxy, trifluoromethyl, amino,
carboxy,
carboxamindo, amidino, carbamoyl, mercapto, sulfamoyl, C1-4 alkyl, C2-4
alkenyl, C2-4
alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C1-4 alkoxy, C1-4 alkanoyl, C1-4
alkanoyloxy, N-
(C1-4 alkyl), N(C1-4 alkyl)2, C1-4 alkanoylamino, (C1-4 alkanoyl)2amino, N-(C1-
4
alkyl)carbamoyl, N,N-(C1-4)2carbamoyl, (C1-4alkyl)S, (C1-4 alkyl)S(=O), (C1-
4alkyl)SO2, (C1-4)
alkoxycarbonyl, N-(C1-4 alkyl)sulfamoyl, N,N-C1-4 alkyl)sulfamoyl, C1-4
alkylsolfonylamino
or heterocyclyl.
4. The compound as recited in Claim 3 wherein R3 represents ~H, C1-6alkyl C2-
6alkenyl,
C2-6alkynyl, C3-6cycloalkyl or AOH, wherein the C1-6alkyl C2-6alkenyl, C2-
6alkynyl, C3-
6cycloalkyl and A are optionally substituted with halogen, nitro, cyano,
hydroxy,
trifluoromethyl, amino, carboxy, carboxamindo, amidino, carbamoyl, mercapto,
sulfamoyl,
C1-4 alkyl, C2-4alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C1-
4 alkoxy, C1-4
alkanoyl, C1-4 alkanoyloxy, N-(C1-4 alkyl), N(C1-4 alkyl)2, C1-4
alkanoylamino, (C1-4
alkanoyl)2amino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4)2carbamoyl, (C1-4 alkyl)S,
(C1-4
alkyl)S(=O), (C1-4 alkyl)SO2, (C1-4) alkoxycarbonyl, N-(C1-4 alkyl)sulfamoyl,
N,N-C1-4
alkyl)sulfamoyl, C1-4 alkylsolfonylamino, or heterocyclic.
5. The compound as recited in Claims 1-4 wherein R7 is a monocyclic or
bicyclic
aromatic ring optionally incorporating at least one heteroatom selected from
N, O and S.
6. The compound as recited in Claim 5 wherein the aromatic ring optionally
incorporating a heteroatom comprising phenyl, 1- and 2-naphthyl, 2-, 3- and 4-
pyridyl, 2- and
3-thienyl, 2- and 3-furyl, quinolyl, isoquinolyl, indolyl, benzothienyl,
benzofuryl, 1-, 2- and 3-
pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl,
isoxazolyl, 1,2,3-triazolyl,
1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl,
1,2,4-oxadiazolyl,
1,3,4-triazolyl, 1,3,4-thiadiazolyl, 1,3,4 oxadiazolyl, benzimidazolyl,
benzthiazolyl,
benzoxazolyl or triazinyl.
7. The compound as recited in Claim 6 wherein R7 is represented by the formula
(v):

-136-
<IMG>
wherein R7 is optionally substituted by at least one substituent selected from
R8-R9 and R10
wherein R8 is a single bond, -C(=O)-, -CH2-, -O-, -S-, -SO2-, or -S(=O)- as
tether or a five
membered heterocycle connected to R7 by a single bond or by ring fusion and R9
is
represented by an optionally substituted heterocyclic optionally substituted
on carbon with at
least one substituent selected from A and further substituted on a heteroatom
apposite to the
heteroatom attached to the tether, wherein the substituent is represented by
R11, -C(=O)A, an
aryl or a heterocyclic; wherein the aryl or heterocyclic is optionally
substituted with halogen,
nitro, cyano, hydroxy, trifluoromethyl, amino, carboxy, carboxamindo, amidino,
carbamoyl,
mercapto, sulfamoyl, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl,
C3-6 cycloalkenyl,
C1-4 alkoxy, C1-4 alkanoyl, C1-4 alkanoyloxy, NH-(C1-4alkyl), N(C1-4 alkyl)2,
C1-4
alkanoylamino, (C1-4 alkanoyl)2amino, N-(C1-4alkyl)carbamoyl, N,N-(C1-
4)2carbamoyl, (C1-4
alkyl)S-, (C1-4 alkyl)S(=O)-, (C1-4 alkyl)SO2-, (C1-4)alkoxycarbonyl, N-(C1-4
alkyl)sulfamoyl,
N,N-C1-4 alkyl)sulfamoyl, C1-4 alkylsolfonylamino or heterocyclic.
8. The compound as recited in Claim 7 wherein R10 is alkyl, hydroxy, cyano, OA
or
halogen.
9. The compound as recited in Claim 8 wherein R10 is cyano, hydroxy, methoxy,
ethoxy
or halogen.
10. The compound as recited in claim 1 wherein R7 is represented by the
Formula (vi):
<IMG>
wherein R8 is a single bond as tether and R9 is methoxy, cyano, a five-
membered
heterocycle or a compound represented by the Formulas (vii) (viii) or (ix):

-137-
<IMGS>
11. The compound as recited in claim 10 wherein R11 is -H, -SO2CH3, -
SO2CH2CH3,-
SO2-n-C3H7, -SO2-i-C3H7, -SO2-n C4H10, -SO2-t-C4H10, -S2NH2, SO2N(CH3)2, -
C(=O)NH2, -
C(=O)NH-cyclohexyl, -C(=O)-cyclopentyl, -C(=O)-pyrrolidine, -C(=O)N(CH3)2, -
C(=O)-
morpholine, -C(=O)CH3, -C(=O)CH2CH3, -C(=O)-n-C3H7, -C(=O)-i-C3H7, -C(=O)-n-
C4H10,
-C(=O)-i-C4H10, -C(=O)-t-C4H10, CH3OH, SO2CH(CH3)2, SO2NHCH2CH(CH3)2,-
CH2CH2OH, -C(=O)CH2CH2OH, -C(=O)NHCH2CH3 or C(=O)OC4H10.
12. The compound as recited in Claims 1-11 wherein Y is a five-membered
heterocyclic
ring comprising one or more heteroatoms selected from S, N or O.
13. The compound as recited in Claim 12 wherein Y is pyrrole, thiophene,
furan,
imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-
triazole, 1,2,3-thiadiazole,
1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-
triazole, 1,3,4-
thiadiazole or 1,3,4-oxadiazole.
14. The compound as recited in Claim 12 wherein Y is -C(=O)NH-, -C(=O)N(CH3)-,
-NHC(=O)- or -C(=O)-piperazine-.

-138-
15.~A compound of the formula (I):
<IMG>
wherein
R1 is, at each position, independently represented by hydrogen, optionally
substituted alkyl,
optionally substituted cycloalkyl, thiomethoxy, -NHA, -NA2, -NHC(=O)A,
aminocarbonyl,
-C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or aryl;
A is alkyl, cycloalkyl, alkenyl or alkynyl;
R2 is represented by (i), (ii), (iii), or (iv) below:
<IMGS>
R3 is -H , C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl or AOH;
n is 2 or 3;
P is a heterocyclic ring;
R6 is -H or methyl;
Y is -C(=O)NH-, -C(=O)NA-, -C(=O)N(A)-, -NHC(=O)-, -C(=S)NH-, -CH2NH-, -C(=O)-
,
-C(=O)CH2-, -CH2C(=O)-, -C(=O)-piperazine-,, -NAC(=O)-,
-C(=S)N(A)-, -CH2N(A), -N(A)CH2- or a 5-membered heterocyclic.
R7 is a monocyclic or bicyclic aromatic ring or a heterocycle, optionally
substituted by one or
more substituents selected from R8-R9 and R10; wherein R7 is connected to Y
either by a
single bond or by a ring fusion;

-139-
R8 is -CH2-, -C(=O)-, -SO2-, - SO2NH-, -C(=O)NH-, -O-, -S-, -S(=O)-, a single
bond as
tether from R7 to R9, a five membered heterocyclic connected to R7 by a ring
fusion or single
bond as tether;
R9 is is optionally substituted heterocycle, optionally substituted aryl,
optionally substituted
piperazinyl-R11, optionally substituted morpholinyl-R11, optionally
substituted
thiomorpholiny or -C(=O)A;
R10 is optionally substituted alkyl, optionally substituted cycloalkyl,
hydroxy, aryl, cyano,
halogen, -C(=O)NH2-, methylthio, -NHA, -NA2, -NHC(=O)A, -C(=O)NHA, -C(=O)NA2,
or
OA;
R11 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9,
-alkylR9, -C(=O)A, -C(=O)NH2, -C(=O)NHA, -C(=O)NA2 or -C(=O)OA; or a
pharmaceutically acceptable salt of said compound.
16. The compound as recited in Claim 15 wherein R1 is, at each position,
independently
represented by hydrogen or an alkyl having 1-6 carbon atoms.
17. The compound as recited in Claim 15 wherein R1 is, at each position,
independently
represented by a cycloalklyl having 3-6 carbon atoms.
18. The compound as recited in Claim 14 wherein R1 is, at each position,
independently
represented by hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, tert-butyl,
cyclopentyl or cyclohexyl.
19. The compound as recited in Claim 15 wherein R1 is, at each position,
independently
represented by OA wherein A represents alkyl.
20. The compound as recited in Claim 15 wherein R1 is, at each position,
independently
represented by halogen.
21. The compound as recited in Claim 20 wherein R1 is, at each position,
independently
represented by bromine, chlorine or flourine.

-140-
22. ~The compound as recited in Claim 15 wherein R1 is, at each position,
independently
represented by hydrogen.
23. ~The compound as recited in any one of Claims 15-22 wherein R3 is -H or C1-
6 alkyl.
24. ~The compound as recited in any one of Claims 15-22 wherein R7 is
represented by the
Formula (v):
<IMG>
wherein R7 is optionally substituted by at least one substituent selected from
R8-R9 and R10
wherein R8 represents a single bond as tether or a five-membered heterocycle
connected to R7
by a ring fusion and R9 is morpholine, thiomorpholine or C(=O)A
25. The compound as recited in Claims 15 wherein R10 is at least one
substituent selected
from alkyl, cycloalkyl, OA, halogen, and cyano.
26. The compound as recited in Claim 24 wherein R10 is cyano, hydroxy,
methoxy,
ethoxy, chlorine, bromine or fluorine.
27. The compound as recited in claim 15-26 wherein R7 is represented by the
formula (vi):
<IMG>
wherein R8 is a single bond as tether and R9 is methoxy, cyano or a compound
selected
from a compound of Formula (vii) (viii) or (ix):
<IMG>

-141-
<IMGS>
wherein R11 is -SO2CH3, -SO2CH2CH3, -SO2-n-C3H7, -SO2-i-C3H7, -SO2-n-C4H10, -
SO2-i-
C4H10, -SO2-t-C4H10, -SO2NH2, -SO2N(CH3)2, -C(=O)NH2, -C(=O)NCH2CH3, C(=O)NH-
cyclo-C6H12, C(=O)-cyclo-C5H10, -C(=O)-pyrrolidone, -C(=O)N(CH3)2, -C(=O)-
morpholine,
-C(=O)CH3, -C(=O)CH2CH3, -C(=O)-n-C3H7, -C(=O)-i-C3H7, C(=O)CH2CH2OH, C(=O)-n-
C4H10, -C(=O)-i-C4H10, -C(=O)-t-C4H10, -CH3OH, CH2CH2OH or-C(=O)OC4H10.
28. The compounds as recited in Claims 15-27 wherein Y is a five-membered
heterocyclic
ring comprising one or more heteroatoms selected from S, N and O.
29. The compound as recited in Claim 27 wherein Y is furan, diazol,
oxadiazole, pyrrole,
thiophene, furan, imidazole, thiazole, oxazole, pyrazole, isothiazole,
isoxazole, 1,2,3-triazole,
1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-
oxadiazole, 1,3,4-
triazole, 1,3,4-thiadiazole or 1,3,4-oxadiazole.
30. The compound as recited in Claims 15-29 wherein Y is -C(=O)NH-, -
C(=O)N(CH3)-,
-NHC(=O)- or -C(=O)-piperazine-.
31. A compound of the formula (I):

-142-
<IMG>
wherein R1 is, at each position, independently represented by hydrogen, C1-6
alkyl, halogen,
hydroxy, -OA or cyano;
wherein A is alkyl;
R2 is:
<IMG>
R3 is -H or C1-6alkyl;
n is 2;
R6 is -H or methyl;
Y is -C(=O)NH or -C(=O)-piperazine-;
R7 is phenyl optionally substituted by one or more substituents selected from
R8-R9 or R10,;
R8 is a five-membered heterocycle connected to R7 by a ring fusion or a single
bond as tether;
R9 is morpholine, thiomorpholine, -C(=O)A or piperazin-R11;
R10 is alkyl, hydroxy, cyano, halogen or OA;
R10 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9,
-alkylR9, -C(=O)A, -C(=O)NH2, -C(=O)NHA, -C(=O)NA2 or -C(=O)OA;
or a pharmaceutically acceptable salt of said compound.

-143-
32. The compound as recited in Claim 31 wherein R1 is, at each position,
independently
represented by -H, C1-C6 alkyl, C3-6cycloalkyl, halogen or OA.
33. The compound as recited in Claim 32 wherein R1 is, at each position,
independently
represented by fluorine, chorine, bromine, methoxy, ethoxy or methyl.
34. The compound as recited in Claim 33 wherein R3 is methyl.
35. The compound as recited in Claims 33-34 wherein Y is -C(=O)NH-.
36. The compound as recited in Claim 35 wherein R7 is phenyl optionally
substituted by
one or more substituents selected from R8-R9 and R10 wherein R8 is a five-
membered
heterocyclic connected to R7 by a ring fusion or a single bond as tether and
R9 is morpholine
optionally substituted on carbon with at least one substituent selected from
A, piperazine-R11
and thiomorpholine.
37. The compound as recited in 36 wherein R9 is morpholine.
38. The compound as recited in Claim 37 wherein R10 is cyano, OA, OH or
halogen.
39. The claims as recited in Claim 38 wherein R10 is cyano, methoxy, ethoxy,
fluorine,
chlorine, bromine or hydroxyl.
40. The compound of Claim 36 wherein R9 is piperazine-R11, wherein R11 is -
SO2CH3,
-SO2CH2CH3, -SO2-n-C3H7, -SO2-i-C3H7, -SO2-n-C4H10, -SO2-i-C4H10, -SO2-t-
C4H10,
-SO2NH2, -SO2N(CH3)2, ,-C(=O)NH2, -C(=O)NCH2CH3, C(=O)NH-cyclo-C6H12,
-C(=O)-cyclo-C5H10, -C(=O)-pyrrolidone, -C(=O)N(CH3)2, -C(=O)-morpholine, -
C(=O)CH3,
-C(=O)CH2CH3, -C(=O)-n-C3H7, -C(=O)-i-C3H7, C(=O)CH2CH2OH, C(=O)-n-C4H10,
-C(=O)-i-C4H10, -C(=O)-t-C4H10, -CH3OH, CH2CH2OH or-C(=O)OC4H10.
41. A compound of any one of claims 1-40 for use in the treatment of
depression,
generalized anxiety, eating disorders, dementia, panic disorder, sleep
disorders,

-144-
gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm
and sexual
dysfunction of an animal in need of such therapy.
42. A method of treatment of a human or animal suffering from depression,
generalized
anxiety, eating disorders, dementia, panic disorder, sleep disorders,
gastrointestinal disorders,
motor disorders, endocrine disorders, vasospasm and sexual dysfunction
administering to
such animal an effective amount of a compound of Formula I or a
pharmaceutically
acceptable salt of said compound.
43. The use of any one of the compounds in claims 1-40 in the preparation of a
medicament for the treatment of depression, generalized anxiety, eating
disorders,
dementia, panic disorder, sleep disorders, gastrointestinal disorders, motor
disorders, endocrine disorders, vasospasm and sexual dysfunction.
44. A pharmaceutical composition comprising a compound as recited in any one
of
Claims 1-40 or a pharmaceutically acceptable salt thereof and a
pharmaceutically
acceptable carrier.
45. A compound of the Formula (VIe):
<IMG>
wherein R1 is, at each position, independently represented by hydrogen,
optionally substituted
alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy, -NHA, -NA2, -
NHC(=O)A,
aminocarbonyl, -C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or aryl;

-145-
A is optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted
alkenyl or optionally substituted alkynyl;
R2 is represented by (i), (ii), (iii), or (iv) below:
<IMGs>
and X is represented by O; and a pharmaceutically acceptable salt of said
compound.
46. The compound of Formula (VIf):
<IMG>
wherein R1 is, at each position, independently represented by hydrogen,
optionally substituted
alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy, -NHA, -NA2, -
NHC(=O)A,
aminocarbonyl, -C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted
alkenyl or optionally substituted alkynyl;
R2 is represented by (i), (ii), (iii), or (iv) below:

-146-
<IMGS>
and X is represented by O; or a pharmaceutically acceptable salt of salt
compound.
47. A compound of Formula (VIg)
<IMG>
wherein R1 is, at each position, independently represented by hydrogen,
optionally substituted
alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy, -NHA, -NA2, -
NHC(=O)A,
aminocarbonyl, -C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted
alkenyl or optionally substituted alkynyl;
L represents a leaving group.
R2 is represented by (i), (ii), (iii), or (iv) below:

-147-
<IMGS>
and X is represented by O; or a pharmaceutically acceptable of said compound.
48. A compound of Formula (VIh)
<IMG>
wherein R1 is, at each position, independently represented by hydrogen,
optionally substituted
alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy, -NHA, -NA2, -
NHC(=O)A,
aminocarbonyl, -C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted
alkenyl or optionally substituted alkynyl;
R2 is represented by (r), (ii), (iii), or (iv) below:
<IMGS>
and X is represented by O; or a pharmaceutically acceptable salt of said
compound.

-148-
49. A process for preparing a compound of Formula (VIe) as recited in Claims
45
comprising reacting a compound of Formula (VId):
<IMG>
with HR2 in the presence of a catalyst and a base.
50. A process for preparing a compound of Formula (VIf) as recited in Claim 46
comprising heating a compound a of Formula (VIe) as recited in Claim 45 in the
presence of
an acid and water.
51 A process for preparing a compound of Formula (VIg) as recited in Claim 47
comprising replacing the hydroxyl group of the carboxyl ate moiety of Formula
(Vig) with a
leaving group.
52. A process for preparing a compound of Formula (VIh) as recited in Claim 48
comprising reacting a compound of (VIf) as recited in Claim 46 with H2R7,
wherein R7 is a
monocyclic or bicyclic aromatic ring or a heterocycle, optionally substituted
by one or more
substituents selected from R8-R9 and R10; wherein R7 is connected to Y either
by a single
bond or by a ring fusion;

-149-
R8 is -CH2-, -C(=O)-, -SO2-, - SO2NH-, -C(=O)NH-, -O-, -S-, -S(=O)-, a five
membered
heterocyclic connected to R7 by a ring fusion or single bond as tether;
R9 is morpholine optionally substituted with at least one substituent selected
from A,
thiomorpholine, piperazin-R11, optionally substituted aryl, optionally
substituted heterocyclic,
or -C(=O)CA;
R10 is optionally substituted alkyl, optionally substituted cycloalkyl,
hydroxy, aryl, cyano,
halogen, -C(=O)NH2-, methylthio, -NHA, -NA2, -NHC(=O)A, -C(=O)NHA, -C(=O)NA2,
or
OA;
R11 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9,
-alkylR9, C(=O)A, C(=O)NH2, C(=O)NHA, C(=O)NA2 or -C(=O)OA.
53. A process for preparing a compound of Formula (VIh) as recited in Claim 48
comprising reacting a compound of Formula (VIg) with H2R7 wherein R7 is a
monocyclic or
bicyclic aromatic ring or a heterocycle, optionally substituted by one or more
substituents
selected from R8-R9 and R10; wherein R7 is connected to Y either by a single
bond or by a ring
fusion;
R8 is -CH2-, -C(=O)-, -SO2-, - SO2NH-, -C(=O)NH-, -O-, -S-, -S(=O)-, a five
membered.
heterocyclic connected to R7 by a ring fusion or single bond as tether;
R9 is morpholine optionally substituted with at least one substituent selected
from A,
thiomorpholine, piperazin-R11, optionally substituted aryl, optionally
substituted heterocyclic,
or -C(=O)CA;
R10 is optionally substituted alkyl, optionally substituted cycloalkyl,
hydroxy, aryl, cyano,
halogen, -C(=O)NH2-, methylthio, -NHA, -NA2, -NHC(=O)A, -C(=O)NHA, -C(=O)NA2,
or
OA;
R11 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9,
-alkylR9, C(=O)A, C(=O)NH2, C(=O)NHA, C(=O)NA2 or-C(=O)OA.

Description

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
_j_
THERAPEUTIC CHROMONE COMPOUNDS
Field of the Invention
This invention relates to novel 8-amino derivatives, methods for their
preparation,
S pharmaceutical compositions containing them and their use in thexapy.
Background of the Invention
Serotonin (S-HT) has been implicated in many psychiatric disorders including
but not
limited to depression, generalized anxiety, eating disorders, dementia,~panic
disorder, and
sleep disorders. Furthermore serotonin has been implicated in gastrointestinal
disorders,
cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and
sexual
dysfunction. Serotonin receptors have been subdivided into at least 14
subtypes, see Barnes
and Sharp, Neuropharmacology, 1999, 38, 1083-1152, incorporated herein by
reference.
These various subtypes are responsible for serotonin's action in many
pathophysicogical
conditions. The S-HTl family of receptors has high affinity for serotonin and
consists of five
1 S related receptors. This family includes the S-HT1B and S-HTID receptor
subtypes.
Compounds that interact with the S-HT~ family are known to have therapeutic
potential in the
above mentioned disorders and diseases. In particular, compounds that are
SHT1B and SHT1D
antagonist have been known to be antidepressant and anxiolytic agents.
Compounds that are
SHT1B and SHT1D agonists have been used in the treatment of migraine.
Summary of the Invention
Provided herein is a compound having the formula (I):
O
R
wherein
R'
R1 is, at each position, independently represented by hydrogen, optionally
substituted alkyl,
2S optionally substituted cycloalkyl, thiomethoxy, -NHA, -NA2, -NHC(=O)A,
aminocarbonyl, -
C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or aryl;

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-2-
A is optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted
alkenyl or optionally substituted alkynyl;_
RZ is represented by (i), (ii), (iii), or (iv) below:
N
N(CH2)n R3 /N (CH2)n p R
r l
R3 /N~R3 -R3 s
R3 R
R3
(i) (ii) (iii) (iv)
R3 is independently at each position represented by-H, optionally substituted
C1_6alkyl,
optionally substituted C2_6alkenyl, optionally substituted CZ_6allcynyl,
optionally substituted
C3_6cycloalkyl or -AOH;
n is 2, 3 or 4;
P is a heterocyclic ring;
R6 is -H or methyl;
Y is -C(=O)NH-, -C(=O)NA-, HC(=O)N(A)-, -NHC(=O)-, -C(=S)NH-, -CHaNH-, -C(=O)-
,-
C(=O)CHa-, -CHZC(=O)-, -C(=O)-piperazine-, , -[NAC(=O)-,
-C(=S)N(A)-, -CH2NA-, -NACH2- or a 5-merribered heterocyclic.
R' is a monocyclic or bicyclic aromatic ring or a heterocycle, optionally
substituted by one or
more substituents selected from R8R9 and RI°; wherein R' is connected
to Y either by a single
bond or by a ring fusion;
R$ is -CHa-, -C(=O)-, -SOZ-, - S02NH-, -C(=O)NH-, -O-, -S-, -S(=O)-; a single
bond as tether
from R' to Rg, a five membered heterocyclic connected to R' by either a single
bond or by
ring fusion;
R9 is optionally substituted heterocycle, optionally substituted aryl,
optionally substituted
piperazinyl-Rl 1, optionally substituted morpholinyl-R11 or optionally
substituted
thiomorpholinyl- or -C(=O)A;
R1° is optionally substituted alkyl, optionally substituted cycloalkyl,
hydroxy, aryl, cyano,
halogen, -C(=O)NHZ-, methylthio, -NHA, -NA2, -NHC(=O)A, -C(=O)NHA, -C(=O)NA2
or
OA;

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-3-
R11 is -H, alkyl, -AOH, -SOZA, -S02NH2, -SOZNHA, -S02NA2, -SO2NHAR9, -C(=O)R9,
-alkylR9, -C(=O)A, -C(=O)NH2, -C(=O)NHA, -C(=O)NA2 or -C(=O)OA; or a
pharmaceutically acceptable salt of said compound
The term "hydrocarbyl" refers to any structure comprising only carbon and
hydrogen
atoms up to 14 carbon atoms.
The term "alkyl" used alone or as a suffix or prefix, refers to straight or
branched
chain hydrocarbyl radicals comprising 1 to about 12 carbon atoms.
The term "alkenyl" refers to straight or branched chain hydrocarbyl radicals
having at
least one carbon-carbon double bond and comprising at least 2 up to about 12
carbon atoms.
The term "alkynyl" refers to straight or branched chain hydrocarbyl radicals
having at
least one carbon-carbon triple bond and comprising at least 2 up to about 12
carbon atoms.
The term "cycloalkyl" refers to ring-containing hydrocarbyl radicals
comprising at
least 3 up to about 12 carbon atoms.
The term "cycloalkenyl" refers to ring-containing hydrocarbyl radicals having
at least
one carbon-carbon double bond and comprising at least 3 up to about 12 carbon
atoms.
The term "cycloalkynyl" refers to ring-containing hydrocarbyl radicals having
at least
one carbon-carbon triple bond and comprising about 7 up to about 12 carbon
atoms.
The term "aromatic" refers to hydrocarbyl radicals having one or more
polyunsaturated carbon rings having aromatic character, (e.g., 4n + 2
delocalized electrons)
and comprising 6 up to about 14 carbon atoms.
The term "aryl" refers to aromatic radicals including both monocyclic aromatic
radicals comprising 6 carbon atoms and polycyclic aromatic radicals comprising
up to about
14 carbon atoms.
The term "alkylene" refers to divalent alkyl moieties, wherein said moiety
serves to
link two structures together.
The term "heterocycle" or "heterocyclic" or "heterocyclic moiety" refers to
ring-
containing monovalent and divalent radicals having one or more heteroatoms,
independently
selected from N, O and S, as part of the ring structure and comprising at
least 3 and up to
about 20 atoms in the rings, preferably 5 and 6 membered rings Heterocyclic
moieties may be
saturated or unsaturated, containing one or more double bonds, and
heterocyclic moieties may
contain more than one ring.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-4-
The term "heteroaryl" refers to heterocyclic monovalent and divalent radicals
having
aromatic character. .
Heterocyclic moieties include for example monocyclic moieties such as:
aziridine,
oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline,
imidazolidine,
pyrazolidine, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran
tetrahydrofuran,
thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine,
thiomorpholine,
pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-
dioxane, 1,3-
dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1H azepine
homopiperazine, 1,3-
dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide. In addition
heterocyclic
moieties include heteroaryl rings such as: pyridyl, pyrazinyl, pyrimidinyl,
pyridazinyl,
thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl,
isothiazolyl, isoxazolyl,
1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-
triazolyl, 1,2,4-
thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and -
1,3,4 oxadiazolyl.
Additionally, heterocyclic moieties encompass polycyclic moieties such as:
indole, indoline,
quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-
benzodioxan,
coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, 1,2-
benzisoxazole,
benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole,
thioxanthine;
carbazole, carboline, acridine, pyrolizidine, and quinolizidine. '
In addition to the polycyclic heterocycles described above, heterocyclic
moieties
include polycyclic heterocyclic moieties wherein the ring fusion between two
or more rings
comprises more than one bond common to both rings and more than two atoms
common to
both rings. Examples of such bridged heterocycles include quinuclidine,
diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.
The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine
radicals.
The term "alkoxy" refers to radicals of the general formula -O-R, wherein R is
selected from a hydrocarbyl radical. Alkoxy moieties include methoxy, ethoxy,
propoXy,
isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and
propargyloxy.
The term amine or amino refers to radicals of the general formula NRR',
wherein R
and R' are independently selected from hydrogen or a hydrocarby radical.
Detailed Description of the Invention
In a further aspect of the invention, A, Rl and R3, each independently, as an
alkyl,
alkenyl, alkynyl and as a cycloalkyl, may optionally be substituted with
halogen, nitro, cyano,

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-5-
hydroxy, trifluoromethyl, amino, carboxy, carboxamido, amidino, carbamoyl,
mercapto,
sulfamoyl, Cz~ alkyl, C2~ alkenyl, C2~ alkynyl, C3_6 cycloalkyl, C3_6
cycloalkenyl, C1~
alkoxy, C1~. alkanoyl, C1~ alkanoyloxy, NH(Cl~ alkyl), N(C1~ alkyl)2, C1~
alkanoylamino,
(C1_4 alkanoyl)Zamino, N(C1~ alkyl)carbamoyl, N,N-(C1_4 alkyl)ZCarbamoyl,
(C1_4)S, (Cr_4
allcyl)S(O), (C1_4alkyl)S(O)2, (C1~) alkoxycarbonyl, N-(C1~ alkyl)sulfamoyl,
N,N-CI~
alkyl)sulfamoyl, C1~ alkylsolfonylamino, and heterocyclic.
Examples of optional substituents for aryl and heterocyclic groups, when not
otherwise defined, are halogen, nitro, cyano, hydroxy, trifluoromethyl, amino,
carboxy,
carboxamido, amidino, carbamoyl, mercapto, sulfamoyl, CI_4 alkyl, C2~ alkenyl,
Ca_4 alkynyl,
C3_6 cycloalkyl, C3_6 cycloalkenyl, C1~ alkoxy, C1_4 alkanoyl, C1~
alkanoyloxy, N-(C1~ alkyl),
N(C1,~ alkyl)2, C1_4 alkanoylarnino, (C1_4 alkanoyl)Zamino, N-(C1~
alkyl)carbamoyl, N;N-(C1_4
alkyl)2carbamoyl, (CI~)S, (C1_4 alkyl)S(O), (C1_4alkyl)S(O)a, (C1~)
alkoxycarbonyl, N-(C1~
alkyl)sulfamoyl, N,N-C1~ alkyl)sulfamoyl, C1~ alkylsolfonylamino, and
heterocyclic.
A, Rl and R3 each independently as an alkyl, alkenyl or alkynyl may be
straight or
branched, preferably having 1-6 carbon atoms. A, Rl and R3 preferably have 3-6
atoms when
each are independently a cyclic alkyl. Other preferable values for A, RI and
R3 when each
are an alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
tent-butyl,
cyclopentyl, neopentyl and cyclohexyl. Preferable values for Rl when Rl is a
halogen are
fluorine, chlorine, and bromine. Other preferable values for R' when Rl is at
position 6 on the
bicyclic ring are methyl, ethyl, ethoxy and methoxy. Preferable values for Rl
when R1 is at
position 5 on the bicyclic ring are -H, methyl, ethyl and methoxy. When Rl is
at position S-
on the bicyclic ring, Rl is more preferably -H. When Rl is at position 7- on
the bicyclic ring,
Rl is preferably -H.
R2 is preferably represented by Formula i. Preferably Ra is represented by
formula i,~
wherein n equals 2. Most preferably RZ is represented by N-methyl piperazinyl.
R3 is preferably represented by hydrogen, methyl, ethyl, n-propyl, isopropyl,
n-butyl,
isobutyl, and tent-butyl. R3 is most preferably represented by methyl.
R4 is preferably represented by hydrogen, methyl, ethyl, n-propyl, isopropyl
and
trimethylsilanyl-ethoxymethoxy. Rø is most preferably represented by methyl.
R6 is preferably represented by H.
Y represents a linking group. Y is preferably -C(=O)N(CH3)-, when Y is

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
_g_
-C(=O)N(A)-. .Y may also be -C(=O)-piperazine. When Y represents a five-
membered
heterocyclic ring, Y may be represented by, for example, pyrrole, thiophene,
furan, imidazole,
thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, 1,2,3-
thiadiazole, 1,2,3-
oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-
triazole, 1,3,4-thiadiazole
or 1,3,4-oxadiazole.
More preferably, Y is -C(=O)NH-.
Examples of R7 that represent monocyclic or bicyclic aromatic ring or a
heterocycle
include, but are not limited to, phenyl; 1- and 2-naphthyl; 2-, 3- and 4-
pyridyl; 2- and 3-
thienyl; 2- and 3-furyl; 1-, 2- and 3-pyrrolyl; imidazolyl; thiazolyl;
oxazolyl;pyrazolyl;
isothiazolyl; isoxazolyl; 1,2,3-triazolyl; 1,2,3-thiadiazolyl; 1,2,3-
oxadiazolyl; 1,2,4-triazolyl;
1,2,4-thiadiazolyl; 1,2;4-oxadiazolyl; 1,3,4-triazolyl; 1,3,4-thiadiazolyl;
1,3,4 oxadiazolyl;
quinolyl; isoquiriolyl; indolyl; benzothienyl; benzofuryl; benzimidazolyl;
benzthiazolyl;
benzoxazolyl; or triazinyl.
R7 may also be represented by the Formula (v):
(v)
i
Rlo
R' may further be represented by the Formula (vi):
.I R8-R9 (vi)
When the values for R' are as set forth above, R$ may be a single bond as
tether, -C(=O)-,
-CHa-, -C(=O)-, -S02-, -S(=O)-, -S-, -O-, -C(=O)NH-, -SOZNH-, or a five
membered
heterocycle connected to.R7 by a single bond or by ring fusion; and R9 may
represent an aryl,
heterocyclic or heteroaryl each independently optionally substituted with
halogen, nitro,
cyano, hydroxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto,
sulfamoyl, C1~ alkyl,
CZ_4alkenyl, Cap alkynyl,.C3_6 cycloalkyl, C3_6 cycloalkenyl, C1~ alkoxy, Cr~
alkanoyl, C1_4
alkanoyloxy, N-(C1~ alkyl), N(C1~ alkyl)Z, C1~ alkanoylamino, (C1_4
alkanoyl)Zamino, N-(C1_
4alkyl)carbamoyl, N,N-(C1~)2carbamoyl, C1~)S, C1_4S(O), (Cl~alkyl)S(=O)2,
(C1~)
alkoxycarbonyl, N-(C1_4 alkyl)sulfamoyl, N,N-CI~ alkyl)sulfamoyl, C1~,
alkylsolfonylamino,
or heterocyclic. Preferably R9 is an optionally substituted heterocyclic
moiety.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
_7_
More preferably R9 represents piperazine, thiomorpholine or morpholine each
independently optionally substituted on carbon with at least one substituent
selected from A.
R8 may be ~a five membered heterocycle, incorporating at least one heteroatom
selected from
N, O, or S and it may be connected to R7 by a ring fusion, preferably when R7
is phenyl.
When Rg is a single bond as tether, R9 is preferably methoxy, cyano, a five-
membered
heterocycle optionally substituted with at least one substituent represented
by A or Rl1 for
example compounds represented by the Formulas (vii), (viii) and (ix):
11
N N-R ~ (vii)
11
N O R (viii)
11
N S R (ix)
When R8 is represented by a 5-membered heterocyclic comprising N and further
when it is
connected to R7 by a ring fusion, R9 is preferably -C(=O)A attached at the
nitrogen atom, R9
is most preferably -C(=O)CH2CH3 .
When R' is phenyl or a 6-membered heterocyclic ring, R9, is attached via the
Rg tether
at the 2-, 3- or 4-position of the phenyl or a 6-membered heterocyclic ring.
Preferably, R9 is
attached via, the R8 tether at the 3- or 4-position of the phenyl or a 6-
mernbered heterocyclic
ring. More preferably, R9 is attached via the R$ tether at the 4 position of
the phenyl or a 6-
membered heterocyclic ring.
Rl° may be represented by alkyl or cycloalkyl each independently
optionally
substituted with halogen, vitro, cyano, hydroxy, trifluoromethyl, amino,
carboxy, carbamoyl,

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
_g_
mercapto, sulfamoyl, C1~ alkyl, C2_4alkenyl, CZ_4 alkynyl, C3_~ cycloalkyl,
C3_6 cycloalkenyl,
C 1 ~ alkoxy, C 1 ~ alkano y1, C 1 ~ alkanoyloxy, N-(C 1 _4 alkyl), N(C 1 _4
alkyl)2, C 1 ~.
alkanoylamino, (CI_d allcanoyl)2amino, N-(Cl~alkyl)carbamoyl, N,N-
(Ci~.)2carbamoyl, CI~)S,
C1_4S(O), (C1_4alkyl)S(O)2, (C1~) alkoxycarbonyl, N-(Cl~ alkyl)sulfamoyl, N,N-
C1_4
alkyl)sulfamoyl, CI~ alkylsulfonylamino, or heterocyclic. R1° is
preferably a halogen,
preferably chlorine or fluorine, cyano, or -OCH3. When Rl° is a
halogemit is preferably
chlorine or fluorine. When R7 is a phenyl or 6-membered heteroaromatic ring,
Rl° is
attached at the 2-, 3- or 4-position of the phenyl or a 6-membered
heterocyclic ring.
Preferably, Rl° is attached at the 2- or 3-position of the phenyl or a
6-membered heterocyclic
ring when R9 is attached via the R$ tether at the 4-position of the phenyl or
a 6-membered
heterocyclic ring. More preferably, R~° is attached at the 3-position
of the phenyl or a 6-
membered heterocyclic ring when R9 is attached via the R8 tether at the 4-
position of the
phenyl or a 6-membered heterocyclic ring.
When R8 is represented by a single bond as tether, R9 is preferably
represented by an
optionally substituted heterocyclic, optionally substituted on carbon with at
least one
substituent selected from A and further substituted on a heteroatom opposite
to the heteroatom
attached to the tether, with a substituent represented by Rl l (see e.g.,
Formulas (vii), (viii) and
(ix)). The preferred heterocyclic compounds for R8 are piperazine, morpholine,
or
thiomorpholine
. When Rl l represents SOZA it is preferably represented by an alkylsufonyl,
more
preferably -S02CH3, -SOZCH2CH3, SOZ-n-C3H7, SOz-i-C3H7, S02-n-C4Hlo, -S02-i-
C4Hlo, or -S02-t-C4Hlo. When R11 represent C(=O)A, it is preferably
represented by an
alkylcarbonyl more preferably-C(=O)CH3, -C(=O)CH2CH3, C(=O)-n-C4H1°, -
C(=O)-i-
CøHlo, -C(=O)-t-C4Hlo, or -C(=O)C3H7.- When Rl I is represented by C(=O)NHA or
C(=O)NA2 it is preferably an alkyl or dialkyl carbamoyl more preferably
C(=O)NCHZCH3,
C(=O)NH-cycloC6H12, or C(=O)NH-cycloCSHlo,. When R11 is represented by C(=O)R9
it is
preferably -C(=O)-pyrrolidine, or -C(=O)-morpholine. When Rl 1 is represented
by
S02NA2 it is preferably SOZN(CH3)2, . When Rl1 is represented by AOH, it is
preferably
represented by, CH2CH20H or -C(=O)CHZCHZOH. R' 1 may also be represented by -
.
C(=O)OC4Hlo.
In preferred embodiments, when Y is represented by -C(=O)NH:

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-9-
(a) R1 is halogen or methoxy, most preferably fluorine, at the 6th position of
the
bicyclic ring, and is preferably hydrogen, methyl, ethyl or methoxy at the 5th
position of the bicyclic ring, and is hydrogen at the 7th position on the
bicyclic
ring;
(b) RZ is methyl piperazine;
(c) R6 is hydrogen;
(d) R7 is phenyl substituted with R8-R9
(e) R8 is a single bond as tether;
(f) R9 is a heterocyclic moiety, preferably morpholine or piperazine attached
to R$ by
nitrogen and optionally substituted on the other nitrogen (for~piperazine)
with Rl1
or optionally substituted on the oxygen with Rr 1 when R9 is morpholine;
Ri 1 is AOH or -SOaA wherein A is represented by methyl or ethyl. The
compounds
provided herein are useful in the form as a free base, but may also be
provided in 'the form of
a pharmaceutically acceptable salt,. and/or in the form of a pharmaceutically
acceptable
hydrate. For example pharmaceutically acceptable salts of.compounds of Formula
I include
those derived from mineral acids such as for example: hydrochloric acid,
nitric acid,
phosphoric acid, sulfuric acid, hydxobromic acid, hydroiodic acid, nitrous
acid, and
phosphorous acid. Pharmaceutically acceptable salts may also be developed with
organic
acids including aliphatic mono and dicarboxylates and aromatic acids. Other
pharmaceutically-acceptable salts of compounds of the present invention
include for example
hydrochloride, sulfate, pyrosulfate, bisulfate, bisulfate, nitrate, and
phosphate.
Processes for the manufacture of the compounds of Formula I are provided as
further
features of the invention. Many of the Compounds described herein can be made
by processes
known in the chemical arts for the production of structurally analogous
compounds.
Accordingly, the compounds of this invention may be prepared by employing
procedures
known in the literature starting from known compounds or readily prepared
intermediates.
For example, the core bicyclic, heterocyclic structure may be made by first
preparing a
chromone, quinolone or quinoline.
For compounds of the present invention that have Y as an amide linker, the
compounds are preferably made by the general procedure for amide coupling,
that is by
coupling an anime with an acid hydrochloride. The amines used in the current
invention if not
commercially available may be made.by known techniques. For example as a first
step in the

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-10-
process of making compound of Formula I, a vitro compound may be reduced to an
amine.
The vitro compound may be a nitrophenyl compound. The resulting amines may be
reacted
with an acid hydrochloride.
Provided herein is a process for preparation of a precursor compound or use in
practicing aspects of the present invention by reacting a compound of Formula
(VIa):
R~ i ~
I
~XH
Halogen
Vla
(R1, RZ, R3, and R7 are as defined for Formula I unless otherwise specified
and X is
represented by O), with for example a compound represented by::
R'O C CO R' .
2 2 , wherein R' is represented by alkyl, preferably lower alkyl (e.g.,
C1-Cg) most preferably methyl or ethyl, to form a precursor compound of
Formula (VIb):
C02R'
R1
~X 02R,
Halogen
Vlb
R1 is preferably fluorine, chlorine, methyl, methoxy, ethoxy or hydrogen. The
Halogen is
preferably Chlorine or Bromine. The reaction may be carned out in the presence
of a catalyst
such as tetrabultyammonium fluoride in THF. The reaction may be stirred for
example at
room temperature and refluxed with heat.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-11-
Further provided herein is a process for the preparation of a precursor
compound
comprising hydrolyzing the esters of compound (VIb) to form intermediate
(VIc):
C02H
1
R1 . ~ ~ X C02H
Halogen
Vic
This reaction may be carried our for example by reacting a compound of Formula
(VIb) with
a base such as sodium hydroxide (aqueous). Also provided here is a process for
the
preparation of an intermediate by the cyclization of compound (VIc) to form
intermediate
(VId)
R1 ~~ / OR'.
~X
Halogen O
Vld
Intermediate compound (VId) may be formed by refluxing a compound of Formula
(VIc) with a strong acid (e.g., HaSO) and further refluxed with heat and an
alkyl alcohol for
example R"OH wherein R" is C1-C4 alkyl, preferably ethyl.
In an additional aspect of the invention, a process is provided for the
preparation of an
intermediate by reacting a compound of Formula (VId) with an amine of R2 in
the presence of
a catalyst and a base to form intermediate Formula (VIe): .

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-12-
R~--
O R"
Vle
In a further embodiment of the invention, a compound of Formula (VId) is
reacted with a
catalyst selected from the group consisting of nickel and palladium.
Preferably the palladium
is provided in the presence of a phosphine ligand for example 2,2'-
bis(diphenylphosphino)-
1,1'-binapthyl. The palladium may be provided as tris(dibenzylideneacetone)
dipalladium.
The base is preferably selected from the group consisting of potassium
carbonate, sodium
carbonate, cesium carbonate and triethylamine and mixtures thereof.
Further provided herein is an acid hydrochloride of a compound of Formula
(VIe)
which is intermediate Formula (VIf):
R~--
H
HCI
Vif

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-13-
The intermediate Formula (VIfj may be formed for example by heating a compound
of
Formula (VIe) in the presence of an acid and water (e.g., HCL/H20).
In another aspect of the invention provided is intermediate Formula (VIg):
R~
L
HCI
Vlg
Thus, in another aspect of the invention, a leaving group is added to the
carboxylate of a
compound of Formula (VIfJ. L is a leaving group. This intermediate is useful
in that the
acid is activated to provide an electrophile. L is preferably represented by
chlorine in
I S intermediate Formula (VIg) which is prepared by reacting a compound of
Formula (VIf~ with
thionyl chloride (SOC12).
Provided herein is a compound of Formula (VIh):

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-.14-
R~- H
N\R~
Vlh
S Methods for reacting amines with acid chlorides may be used to prepare
compounds of
formula I such as a compound of Formula (VIh) For example, a method for the
preparation
of (VIh) may include reacting a compound of Formula (VIg) with HZN-R7 in the
presence of
DIPEA.
Alternatively, compounds of Formula (VIh) may also be prepared by reacting a
compound of Formula (VIf) with H2N-R7 in the presence for example 1-
hydroxybenzotriazole (HOBT), O-(1H-Benzotriazol-1-yl)-N,N,N'N'-pentamethylene-
uronium tetrafluorborate (TBTU), and (dimethylamino)pyridine, preferably in
that order.
Compounds of Formulas (VIe), (VIf), and (VIg), and (VIh) may also comprise a
pharmaceutically acceptable salt of said compounds.
1 S The compounds and processes above may also be used to prepare the chroman
derivatives of Formula (I) via the saturation of the double bond (4H-chromene)
in the bicyclic
compound. Depending on the reduction conditions, the 4-oxo derivative may or.
may not be
obtained.
A method for preparing the acid hydrochlorides useful in synthesis of a
chromone is
set forth in Scheme 1 below:.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-15-
R1 I \ . ~C02R' ~ C02R'
/ OH Br . . R~ i /
Hal°9en R' -- CH C H ~O 02R'
3' 2 5 Hal°9en
Halogen = CI, Br
(R~)q = -OCH3, F, CH3. CI, OEt, H. Vlb
Vla NaOH
COZH
R 1. H2SO4
Et ~ R ~ / Cp2H
2. EtOH, reflux O
Hal°gen
Vld H
N~ Vlc
(CH2)n ~ Or precursor amines for (ii) or (iii)1
N structural variations of R J2
3
R
Pd catalyst
phosphine ligand
cesium carbonate
R HCI/H~O R~
OEt
Vle Vlf
Scheme 1: Preparation of chromone-2-carboxylic acids as intermediates in the
synthesis of
compounds of the present invention.
Alternatively, the chromone-2-carboxylic acid may be converted to the acid
chloride
and reacted immediately with an appropriate amine, as depicted in Scheme 2,
below:
b
(CH2)n
N HCI
3
R

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-16-
R~ SOCI2 R
OH
Vlh
Vlg ~ ~ R$R9 DIPEA I \ R8R9
H2N . H2N
TBTU, HOBT
DMF, DIPEA
R H
N
~I R$R9
Scheme 2. Amide synthesis via acid chloride intermediate.
Additional functional group manipulations include, but are not limited to, O-
dealkylation and N-dealkylation (Scheme 3).

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-17-
0
0
HaC/ ~ ~
BBr
O
85%
N O
N
N Example 31 O
CHa
1-chloroethyl chloroformate
64%
O
O
"3C/
~ o N w
N O
~ ~ N~
Example 85 ~O
N
H
Scheme 3: Functional group manipulation with compounds of the present
invention includes, but is not limited
to, N- and O- dealkylation
Quinoline and quinolone compounds of the present invention are prepared and
derivatized via synthetic routes similar to those employed for synthesis of
the chromone-2-
carboxamides described above and in Schemes 1-3. These synthetic routes to
quinoline and
quinolone compounds of the present invention are depicted in Scheme 4, znfra.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-18-
Me0 O O
methanol H
R~ \ ~ ~ reflux \ I home
/ NH ~ / N OMe
Br z Me0 O Br H O
R~ = OCH3 or F ~ 230°C
O~O~SI(CH3)3 O
~ \ \ ~ -~ R~ \ I
R / home 2-(nimethylsilyl)ethoxy- / N OMe
N methyl chloride H
Br ~ O , Br O
amine, Pd
O~O~Si(CH3)3 R1 O - ' Ri O -
\ \ _ I \ I amine I \ I
R / home ~ / N~OH ~ N~NHAr
LiO I IH
Rz N O THF/MeOH/H20 Rz H O Rz H O
OMe
R~ OMe 1 OMe
R~ ~ \ \ \ E R \ \ ~ ~ CH3I
I / ~OH ~~-- . I
N LiOH ~ . N~OMe amine, Pd I / i OMe
Rz O THF/MeOH/H20 Rz O ~N
Br
amihe
TBTU LiOH
HOBt CI O THF/MeOH/HZO
OMe R~
\ \ R~ \ \ I \ I
R~ ~ / ~'_ .f-
/ ~ NHAr NCI oxalyl chloride / N~OH -
Rz N O Br O Br H IIO
1 ) amine
CI RvN.R4 RvN.R4
/ \ ~ R~ / I \ amine t / \
R \ I N~NHAr amine \ N NHAr , R \ I N~NHAr
D, 60 psi
Br O Br 0 Rz O
amine
TBTU
O R' O~O~SI(CH3)3 ~ O HOBt
R~ \ I \ \ NaH R \
l v II
I'/ ~NHAr~ I / N~NHAr
z H~NHAr amine, Pd N [J 2-(trimethylsil 1 ethoxy [~-
R 0 - Br O methyl chloride ) Br H 0

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-19-
It will be appreciated by those skilled in the art that certain compounds of
the present
invention contain for example asymmetrically substituted carbon and/or sulfur
atoms; and
accordingly may exist in and be isolated in, optically=active and racemic
forms. Some
compounds may exhibit polymorphism, thus it is to be understood that the
present invention
encompasses racemic, optically-active, polymorphic or stereoisomeric forms, or
mixtures
thereof, which forms possess properties useful in the treatment of the
disorders set forth
below. Preparation of optically active forms is well known in the art how (for
example by
resolution of racemic forms by recrystallization techniques, synthesis from
optically-active
starting materials, chiral synthesis, or by chromatographic separation using a
chiral stationary
phase) and how to determine efficacy for the treatment of the disorder
described above.
Compounds of Formula I have been found by the inventors to be useful as S-HTIB
and
SHTID antagonists. The compounds of Formula I, and their pharmaceutically
acceptable salts,
may also ~be used in a method for the treatment of depression, generalized
anxiety, eating
disorders, dementia, panic disorder, sleep disorders, gastrointestinal
disorders, motor disorders,
endocrine disorders, vasospasm and sexual dysfunction. The treatment of these
disorders
comprises administering to a warm-blooded animal, preferably a mammal, more
preferably a
human, in need of such treatment, an effective amount of a compound of Formula
I, or a
pharmaceutically acceptable salt of said compound.
Further provided herein are compounds of Formula I, and their pharmaceutically
acceptablesalts, for use in the treatment of depression, generalized anxiety,
eating disorders,
dementia, panic disorder, sleep disorders, gastrointestinal disorders, motor,
disorders,
endocrine disorders, vasospasm and sexual dysfunction of a warm-blooded
animal, preferably
a mammal, more preferably a human, in need of such therapy.
Further provided herein is a method of treatment of a warm-blooded animal,
preferably a mammal, more preferably a human, suffering from disorders such as
depression,
generalized anxiety, eating disorders, dementia; panic disorder, sleep
disorders,
gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm
and sexual
dysfunction comprising administering to such animal an effective amount of a
compound of
Formula I, or a pharmaceutically acceptable salt of the compound.
Further provided is the use of a compound of Formula I in the preparation of a
medicament for the treatment of a disorder such as depression, generalized
anxiety, eating
disorders, dementia, panic disorder, sleep disorders, gastrointestinal
disorders, motor

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-20-
disorders, endocrine disorders, vasospasm and sexual dysfunction in a warm-
blooded animal,
preferably a mammal, more preferably a human, suffering from such disorder.
The invention further provides a pharmaceutical composition suitable for the
treatment
of the above describe disorders comprising administering to a warm-blooded
animal having
S such disorder an effective amount of a pharmaceutical composition of a
compound of
Formula I, or a pharmaceutically acceptable salt. '
The invention also provides a pharmaceutical composition comprising a compound
of
Formula I, as defined herein, or a pharmaceutically acceptable salt, in
combination with a
pharmaceutically acceptable carrier. Preferred compounds of Formula I, for use
in the
compositions of the invention are as described above.
All compounds described herein demonstrate binding affinities (observed Ki
values),
in an assay described below, of less than about 10~,M. Further, compounds of
the present
invention not only demonstrate SHTIB antagonist activity by reversing SHT1B~
agonist-induced
hypothermia in the guinea pig, these compounds are considered to be orally
active, and hence,
1S they are the preferred compounds. Examples 1, 10, 11, 31, 32, 34, 44, SS,
S6, S7, 71 and 72,
infra, demontrate SHT1B antagonist activity in a dosage range of 0.006-S.S
mg/kg. In
addition, compounds described herein demonstrate activity in the learned
helplessness assay
for antidepressant/antianxiety activity. Examples 31, 44, 71 and 72, infra,
demonstrate
activity in the learned helplessness assay. In addition, compounds were tested
for maximal
intrinsic activity (IA), and were found to have measured IA's of negative SO%
to positive
1 SO% in the GTPyS assay described below, thus demonstrating a range of
response from
agonism (low percentages) to antagonism (high percentages).
The compounds described herein may be provided or delivered in a form suitable
for
oral use, for example in a tablet, lozenge, hard and soft capsule, aqueous
solution, oily
2S solution, emulsion, and suspension. The compounds may be also be provided
for topical
administration, for example, as a cream, ointment, gel, spray, or aqueous
solutions, oily
solutions, emulsions or suspensions. The compounds described herein may also
be provided
in a form suitable for nasal administration for example, as a nasal spray,
nasal drops, or dry
powder. The compositions may also be administered to the vagina or rectum in
the form of a
suppository. The compounds described herein may also be administered
parentally, for
example by intravenous, intravesicular, subcutaneous, or intramuscular
injection or infusion.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-21-
The compounds may be administered by insufflation (for example as a finely
divided
powder). The compounds may also be administered transdermally or sublingually.
The compositions of the invention may accordingly be obtained by conventional
procedures using conventional pharmaceutical excipients, well known in the
art. Thus,
compositions intended for oral use may contain, for example, one or more
coloring,
sweetening, flavoring andlor preservative agents.
The amount of active ingredient that is combined with one or more excipients
to
produce a single dosage form will necessarily vary depending upon the host
treated and the
particular route of administration. The size of the dose for therapeutic or
prophylactic
purposes of a compound of the Formula I, will naturally vary according to the
nature and
severity of the conditions, the age and sex of the animal or patient and the
route of
administration, according to well known principles of medicine. Various assays
and in vivo
tests are known for determining the utility of the compounds in the disorders
noted above and
specifically as agonists and antagonists of SHTiB and SHTiD
The utility of the compounds for example to treat depression may be shown via
a
learned helplessness test in guinea pigs, which is used extensively as
correlative to
antidepressant activity in humans. The learned helplessness test may be
carried out as follows:
Seventy male Hartley guinea pigs, each weighing about 350-425 gm are fed ad
lib, and are
housed under a 12-hour light/dark.cycle. The procedure consists of two phases:
The induction
phase and the avoidance training phase. In the induction phase, subjects are
placed into
standard shuttle cages (20 L X 16 W.X 21 centimeters H ) which are fitted with
a grid floor.
Electrical stimulation (1.25 mA, 10 sec duration) is delivered to the floor of
the cage every
90-sec during 1 hour daily sessions. Subjects have no opportunity to escape or
to avoid
shocks. Induction is conducted for 2 consecutive days.
In avoidance training, testing is also conducted in the shuttle cages, except
that the
subj ects are not returned to the same chamber in which induction had
occurred. Additionally,
all cages are fitted with a partition with an arch in the center of the cage,
through which
animals can pass between the left and right halves of the cage. The procedure
employed is a
standard shuttle avoidance procedure in which a compound, conditioned stimulus
(a 10-sec
presentation of a tone and turning on of a lamp on the side of the cage that
the guinea pig was
occupying) serves to indicate presentation of electrical current to the floor
of the cage. Shock
is presented for a 5 sec period, 5 sec after initiation of the conditioned
stimulus. Entry into

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-22-
the opposite side of the shuttle cage via the arched partition prior to shock
onset results in the
end of the trial (avoidance response). If shock is delivered, entry into the
opposite side of the
cage results in termination of the shock and CS (escape)., Reversal of learned
helplessness in
the induction subjects correlates to antidepressant activity of the test
compound.
Avoidance training, 45-min in duration, is conducted on 2 consecutive days,
beginning
48 hr after the final induction session. Seventy subjects are assigned to 1 of
6 groups of 11-12
animals. The groups are as follows:
1) No induction group. The subjects are placed into the shuttle cages but are
not given
inescapable shock, the animals are subsequently trained in the avoidance
procedure and the
vehicle is administered;
2) Induction vehicle control group;
3) Imipramine 17.8 mg/kg;
4) 0.3 mg/kg compounds;
5) 1 mg/kg compounds; and
6) 5 mg/kg compounds.
Groups 2-6 are given induction and avoidance training sessions. Injections are
administered immediately following induction sessions and 1 hour prior to
avoidance training
sessions. A second injection is administered 7-8 hours following the first
injection, for a total
of 9 injections administered over 5 days. No injections are administered
following the final
avoidance training session.
Compounds of the present invention may be administered in a volume of lmLlkg
bwt.
Imipramine is dissolved in DI water. The compounds are dissolved in DI water,
~to which was
added a few drops of lactic acid (pH 5.5). The vehicle control is DI water
prepared with.lactic
acid to the same pH as the-treated. groups.
The primary dependent variable is escape failure during avoidance training. 2-
way
analysis of variance (ANOVA) is used to assess overall treatment effect, with
Dunn's post
hoc analysis used to compare the vehicle-treated group with the drug-treated
groups. The no-
induction group is used to gauge whether learned helplessness is established,
by comparison
to the vehicle treated group.
An alternative method for determining the utility of the compounds of the
present
invention is to investigate the in vivo activity of the compounds using a
guinea pig hypothermia
test (J. Med. Chem., 41: 1218-1235 (1998)). Compounds that bind to 5-HT1B
receptors are

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 23 -
known to be useful in treating disorders described above (e.g., depression,
generalized anxiety,
eating disorders, dementia, panic disorder, sleep disorders, gastrointestinal
disorders, motor
disorders, endocrine disorders, vasospasm and sexual dysfunction. While not
wishing to be
bound to any theory, it is believed that 5-HT1B receptors on nerve terminals
control the amount
of release of s5-ht into the synapse. Thus, it can be shown that compounds of
Formula I, and
their pharmaceutically acceptable salts, are able to act as 5-HT1B
antagonists~and block the
agonist-induced effect of hypothermia (a drop in body temperature of about
2°C observed
within 0.5-1.5 hours following administration of a 5-HT1B agonist) as a method
for assessing
whether the novel compounds are effective as antagonists at the 5-HT1B
receptor.
The hypothermia test is conducted as follows: A tele-thermometer fitted with a
flexible probe will be used. The tip of the probe is immersed in a test tube
containing a
lubrication agent between usage. Core temperature is measured by inserting the
probe into
the rectum and by waiting for the temperature to stabilize, which occurs
within the 20 - 60
seconds. Core temperature is measured once (pretest) prior to administration
of the test
substance in order to establish a baseline temperature for all animals. Guinea
pigs are then
dosed with the test substance (candidate 5-htlb antagonist) either
subcutaneously or
intraperitoneally. In general, 30 min following dosing with antagonist,
agonist is administered
subcutaneously. The temperature is then recorded 30-, 60, 90- min following
agonist. In
some studies, in order to record time course of antagonist activity, up ~to 12
hours may be
allowed to elapse between administration of antagonist and agonist. The drugs
may either be
injected subcutaneously, intraperitoneally or orally (using a flexible plastic
gavage tube, or a
stainless 'steel gavage tube). In addition, animals may be observed on the
days following drug
administration in order to monitor for unexpected toxicity. The body
temperature of the
guinea pigs is recorded separately for each guinea pig at each test time
point, and submitted to
a ANOVA with one between subjects~factor: dose, and one within subject factor:
time.
Following a significant two-way interaction (p<0.05), Dunnett's t-test is
performed to
compare the drug treatment with either the saline or the effects of treatment
with the
hypothermic agent.
Male Guinea Pig (Dunkin-Hartley), maximum 3 animals per cage, are used. The
animals may be grouped in sets of 5 during testing. The animals will not be
deprived of food
or water during their time in the laboratory. The routes of administration
are: S.C., LP., P.O.
The maximum dose (volume) is 2m1/kg s.c. or i.p., Sml/kg P.O. three times
daily.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-24-
This method may function as a primary ih vivo screen for compounds having an
affinity for 5-htlb receptors as a determination of antagonist activity. Each
experiment may
consist of separate groups of 5 subjects per treatment level. One group is
given vehicle prior
to agonist administration and may serve as the control group, i.e.,
hypothermia will be
unaltered by introduction of an antagonist. The other groups are administered
different doses
of antagonist prior to agonist administration, but no more than 5 groups are
tested at a time. In
order to determine full dose effect functions for compounds (to determine drug
potency) 4-6
doses of each compound are evaluated. That results in about 25-35 animals per
drug to be
evaluated. Dose-response curves are generated and ED50 values are determined.
ED50
values for compounds of the present invention range from 0.006-5.5 mg/kg.
Other assays that may be used to measure for example affinity of compounds of
the
present invention for SHT1B and SHT1D receptors are described in J. Med. Chem
41:1218-
1235, 1228 (1998) and J. Med. Chem 42:4981-5001, (1999) and incorporated by
reference
herein. These assays may be used with some modifications: Frozen membrane
preparations
of a stably transfected Chinese hamster ovary (CHO) cell line expressing 5-
HT1B receptors and
5-HT1D receptors are thawed rapidly, briefly vortexed, and diluted in assay
buffer (AB)
containing 50 mM Tris-HCI, 4 mM MgCl2, 4mM CaClz, 1 mM EDTA, and adjusted to
pH 7.4
with NaOH. Final protein concentrations are - 0.185~mg/ml for 5-HT1B, and 0.4
mg/ml for 5-
HT1D membranes. Test compounds are evaluated in competition assays using [3H]-
GR125.743
(Amersham). The ligand concentration in both assays was 0.27nM. Kd for [3H]-
GR125743
may vary from 0.15 nM to 0.25 nM. The 5-HT1B and 5-HT1D assays are performed
simultaneously on one 96-well assay plate, one drug/compound per plate. Ten
serial dilutions
(1 uM to 4 pM, final concentration) of compound are prepared in DMSO from 10
mM stock
solutions. Incubation mixtures are prepared in quadruplicate in 96-deep well
assay plates
(Matrix 1 ml). Final assay volumes per well are 10 ~,1 compoundlnonspecific;
100 ~.1
membranes; 100 ~.1 [3H]-GR125743; and 790 ~,1 AB. Specific binding is defined
by using 10
uM Methiothepine. The assay plates are shaken for 5 min., and then incubated
for an
additional 55 min. Then the assay plates are filtered through Beckman GFB
filters (soaked >
2 hrs. in PEI) using a Packard Filtermate 196. Filters are washed 2x with 1 ml
ice-cold wash
buffer (5 mM Tris-HCl - pH7.4 with NaOH): After the filters are dried, 35 ~,1
of Microscint20
is added to each well. The plates are then counted on a Packard TopCount to
determine
CPM's per well. Ki values are determined for each test compound utilizing the
graphic and

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-25-
analytical software package, GraphPad Prism. Compounds are then ranked in
order of
potency, and selectivity for 5-HT1B over 5-HTID receptors.
A method that~may be used to determine a compound's affinity for 5-HT1B and
SHT1D
receptors~is a guinea pig cortical test. This assay is described in detail by
Roberts, et al, Br. J.
Pharmacol., 1996, 117, 384-388, which is incorporated by reference herein. The
test is
earned out as follows: Guinea pigs are decapitated and the cortici is
dissected out, weighed
and homogenized in 50 mM Tris-HCI, pH ~7.7 with an Ultra-Turrax followed by
centrifugation for 10 min at 48000 x g and 5°C. The pellet is
resuspended and recentrifuged.
The final pellet is suspended in 0.32 M sucrose buffer to a concentration of
O.Sg original wet
weight per mL and stored frozen at -70°C. The radioligand binding assay
is carried out as
follows: [3H]GR125743 saturation studies are tested in duplicate with 3-4 mg
w.w. per tube
in 5 mL buffer (50 mM Tris, 4 mM CaCl2, 4 mM MgCl2 and 1 mlVl EDTA at pH 7.7),
and a
concentration range of 0.012 - 2 nM (10-l2~concentrations) for the
radioligand. Non-specific
binding is determined in the presence of 10 mM methiotliepin. In competition
experiments 4-
8 mg w.w. per tube and a radioligand concentration of 0.2 nM are used with 10 -
12
concentrations of the competing drug. The assays are run for 2_4 hours at
30°C and terminated
by rapid filtration through Whatman GFB filters (pretreated with 0.1 %
polyethyleneimine)
using a Brandel cell harvester. Bovine serum albumin (0.1%) is added to the
washing buffer
to reduce non-specific binding. Data from the experiments may be analyzed
using the
iterative non-linear curve-fitting program LIGAND. The Kd values' obtained
from the
saturation studies are used in the calculation of the Ki values by the LIGAND
program. The
Kd value of [3H]GR125743 may result in a measurement of 46 ~ 4 pM and the Bm~
in a
measurement of 4.9 ~ 0.2 pmollg w.w:
A GTPyS binding assay may used to determine whether a compound is a SHTIB or
SHTID agonist or antagonist. One assay available measures agonist stimulated
GTP binding
for example as set forth by Lazareno, S. (1999) Methods in Molecular Biology
106: 231-245.
Membrane preparations of a stably transfected CHO cell line expressing human 5-
HT1B
receptors are purchased for example from Unisyn, Hopkinton, MA. Frozen
membranes are
thawed, briefly sonicated, and diluted to 167~,g/ml protein in assay buffer
containing 20 mM
HEPES, 100 mM NaCI, 1mM MgCL2 and l~,M GDP, pH adjusted to 7_4 W ith NaOH.
Diluted membranes are briefly homogenized with a Polytron and allowed to
equilibrate at
room temperature for at least 15 minutes before use. Serial dilutions (10 ~,M
to 1 pM, final

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-26-
concentration) of test compounds are prepared in buffer with and without 100
nM 5-HT (final
concentration) from 10 mM DMSO stock solutions. Incubation mixtures are
prepared in
quadruplicate in 96-well, deep-well plates and consisted of 180 ~,L of
membranes (30 ~.g
protein) and 40 ~,L of compound with or without 5-HT. After an incubation
period of 15
minutes at room temperature, 20 ~,L of [35S]GTP~yS (NEN; 100 pM final
concentration) is
added to begin the assay. Mixtures are shaken for 2 minutes and incubated at
room
temperature for an additional 28 minutes. The reaction is stopped by rapid
filtration through
Beckman GF/B glass fiber filters using a 96-well Packard cell harvester.
Filters are washed
four times with 1 mL ice-cold water. The filter plates are nominally dried and
30 ~,L of
scintillation cocktail (MicroScint 40, Packard) is added to each well. CPMs
for each well is .
determined using a TopCount~Scintillation Counter (Packard). Maximum
stimulation of
[ssS]GTP~yS binding is defined in the presence of 100nM 5-HT. Basal
[35S]GTP~yS binding is
defined in buffer alone. IC50 values are defined as the concentration of
compound at which
50% of the 100nM 5-HT response [was] obtained. Maximal intrinsic activity (IA)
of a
compound is defined as the percent maximal 5-HT-induced stimulation by 10 ~.M
compound
in the absence of 5-HT. As an inter-assay standard, a concentration response
curve of 5-HT
(1 ~,M to 1pM final) in the absence of compounds was included in each assay
and an ECso
was determined.
Preferred compounds of the present invention include, but are not limited to,
the
following compounds listed in Table 1 on the following pages.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-27-
Table 1: Compounds.
' Example..: ' St=iiatlira~ . N'ariie , ..,:
# '" : y . '. " :. '. °.-'-: , , _: ' ~. .; . . : , ;: ''
0 8-(4-methyl-1-piperazinyl)-N [4-(4-
morpholinyl)phenyl]-4-oxo-4H
~ , o~N chromene-2-carboxamide
N o
CND
0
a o i 2-{ 1-[4-(2-Methoxy-phenyl)-
piperazin-1-yl]-methanoyl }-8-(4-
~ N
methyl-piperazin-1-yl)-chromen-4-
o~N~ ~° one
~N~ ° 1
o i ~ 2-{ 1-[4-(1-Acetyl-2,3-dihydro-1H-
N indol-6-yl)-piperazin-1-yl]-
~N ~o methanoyl}-8-(4-methyl-piperazin-
o~ 1-yl)-chromen-4-one
CN\ O . ,
° ~ ~c~ 2-Chloro-5-(4-{ 1-[8-(4-methyl-
piperazin-1-yl)-4-oxo-4H-chromen-
w
~N cN 2-yl]-methanoyl}-piperazm-1-yl)-
~ o~N~ benzonitrile
°
NJ
o , o~ 2-{ 1-[4-(4-Methoxy-phenyl)-
piperazin-1-yl]-methanoyl}-8-(4-
N methyl-piperazin-1-yl)-chromen-4-
o~ ~ one
CNJ o
N
.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-28-
EXampIe° Structure :: - ~ Name
,,,..',.. _'=: '. , : p; .. .. , ,.:.
8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid (5-
~ , ~N o furan-2-yl-1H-pyrazol-3-yl)-amide
o' ~ \
N O N~N \
cN~
0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid (4-
~ o~N . imidazol-1-yl-phenyl)-amide -
N o I i
C ~ ~ ~ ~~ - .
N
0 , s-N~ 8-(4-Methyl-piperazin-1-yl)-4-oxo
w N 4H-chromene-2-carboxylic acid (4
w
[ 1,2,3]thiadiazol-5-yl-phenyl)-
o N ~ amide
~N~
N
0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid 4
~ ~ ~N ~ ~ s [1,2,3]thiadiazol-5-yl-benzylamide
o ~
N. O NN
CN~ .
0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid [4-
~ ~ o~N \ (4-acetyl-piperazin-1-yl)-phenyl]-
amide
N o ~
. C ~ ~N
0
11 , o . 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid [4-
~N (4-methanesulfonyl-piperazin-1-yl)-
o ~ phenyl]-amide
N o ~ i
C ~ ~N. .

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-29-
Examplev ~~ Structure , ~ .. , ... '.- '.., .Name
,., ,.,~ ,,. ,: . ~ ,,,.: ° , ,...;.; ., ;,' . ...,. ; ... ,_ >., ; ..
; -r _,._. ..w'.
12 0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
o~ 4H-chromene-2-carboxylic acid (2-
~ , ~N ~ methoxy-4-morpholin-4-yl-phenyl)-
o ~ amide
N o
~ ~ N~o
N
.
13 0 ~ 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid (3-
~N ~~ chloro-4-morpholin-4-yl-phenyl)-
o ~ amide
N o
0
N
14 0 ' 8-(4-Methyl-piperazin-1-yl)-4-oxo
4H-chromene-2-carboxylic acid (4
~N thiomorpholin-4-yl-phenyl)-amide
0
N o
c
N
15 0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid
i .~N o (2,5-diethoxy-4-morpholin-4-yl-
o ~ ~ phenyl)-amide
N O O . ~ ~ N
CND ~ ~ - ~~
16 0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid (4-
~N cyanomethyl-phenyl)-amide
0
N o ~ i
~N~ ~N
0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid
~N (1H-indol-5-yl)-amide .
0
N O I / N
CND

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-30-
LXampIe Structure ;Name
'''. #. .:~, .... ' ..:.: , : °~.'.' ~ n ... , ...; ,.. ,. .. .>, ' ; .
.... , . .. ,:,y. :. :,
,.. .
1 g o 8-(4-Methyl-piperazin-1-yl)-4-oxo
4H-chromene-2-carboxylic acid [4
N ( 1-morpholin-4-yl-methanoyl)
o~ ~ ~o phenyl]-amide
N 0 I / NJ .
cN~ ° _
19 0 8-(4-Methyl-piperazin-1-yl)-4-oxo
4H-chromene-2-carboxylic acid [4
/ ~N (2,6-dimethyl-morpholin-4-yl)
o ~ - phenyl]-amide
N o
c ~ N~
N O
I.
20 0 8-(4-Methyl-piperazin-1-yl)-4-oxo
4H-chromene-2-carboxylic acid [4
/ ~N F (4-fluoro-phenoxy)-phenyl]-amide
o [~ ~ /
N o ~ / w
CND o
.
21 0 _ 8-(4-Methyl-piperazin-1-yl)-2-(6-
N ~ ~ o morpholin-4-yl-benzooxazol-2-yl)-
I . ~--~ chromen-4-one
o Il o
CND o
N
22 0 8-(4-Methyl-piperazin-1-yl)-4-oxo
4H-chromene-2-carboxylic acid (2
/ ~N hydroxy-4-morpholin-4-yl-phenyl)
o ~ amide
N O I / N
CND ~o
23 0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
~ 4H-chromene-2-carboxylic acid (5-
/ o~N~s ethoxy-benzothiazol-2-yl)-amide
N O N
CND _ °
. ~ --

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-31-
Example' S.tiizcture ; - Name
~. . ;; :::,e.. ~ ' .' ;,';.... ~ ,.. ..'_..,....'a, '..
24 0 - 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid (4-
~N bromo-phenyl)-amide
0
N o
0
N
25 0 8-(4-Methylpiperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid
I ~ I N methyl-(4-morpholin-4-yl-
° I ~ phenyl)amide
N O
C~
26 0 8-(4-Methyl-piperazin-1-yl)-4-oxo
0 4H-chromene-2-carboxylic acid (3
( i ~N N J morpholin-4-yl-phenyl)-amide
0
N o I ~
CND
2~ 0 8-(4-Methyl-piperazin-1-yl)-4-oxo
4H-chromene-2-carboxylic acid (3
I i ~N CN cyano-4-morpholin-4-yl-phenyl)
o ~ amide
N o
0
N
2 s o 8-(4-Methyl-pip erazin-1-yl)-4-oxo
~ 4H-chromene-2-carboxylic acid (3
I i ~N F fluoro-4-morpholin-4-yl-phenyl)
o ~ amide
N o I i . .
C~
N
29 0 4-[4-( f 1-[8-(4-Methyl-piperazin-1-
~ yl)-4-oxo-4H-chromen-2-yl]-
I , ~N methanoyl}-amino)-phenyl]-
o ~ piperazine-1-carboxylic acid tent-
N o I ~ but 1 ester
N ~N~O
c ~ N~ y
O

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 32 -
~:~xample:: Structure , Name .
# ° , ~:. ;°, "= ~ , ' ' =: .. . w . , . :-'';: - ,._' ,.
30 0 . 8-(4-Methyl-piperazin-1-yl)-4-oxo-
4H-chromene-2-carboxylic acid (4-
~ ~ ~N piperazin-1-yl-phenyl)-amide
o ~
N o
C~ N
~NH
N
31 0 6-Methoxy-8-(4-methyl-piperazin-'
i° ~ _ 1-yl)-4-oxo-4H-chromene-2-
~N carboxylic acid (4-morpholin-4-yl-
~ phenyl)-amide .
N o ~ i
~o
N
3~ 0 6-Methoxy-8-(4-methyl-piperazin-
o ~ 1-yl)-4-oxo-4H-chromene-2-
~ N carboxylic acid [4-(4-
°~ ~ methanesulfonyl- i erazin-1-yl
N o ~ , pp )
N~ , phenyl]-amide
N ~N.S/
,,
O~ O
33 0 6-Methoxy-8-(4-Methyl-piperazin-
1-yl)-4-oxo-4H-chromene-2-
~ ~ ~N o~ carboxylic acid (3-chloro-4-
o ~ morpholin-4-yl-phenyl)-amide
N o
c~ ~ .
.N
.
34 0 6-Methoxy-8-(4-methyl-piperazin-
io ( ~ ~ 1-yl)-4-oxo-4H-chromene-2-
o~N \ F carboxylic acid (3-fluoro-4-
morpholin-4-yl-phenyl)-amide
N o ~ ~
c~ w
N
35 0 6-Methoxy-8-(4-methyl-piperazin-
io ~ o~ 1-yl)-4-oxo-4H-chromene-2-
N carboxylic acid (2-methoxy-4
o ~ morpholin-4-yl-phenyl)-amide
N O ~ / N
CND
.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 33 -
Example- '8triactura Name
p ~ d
36 , o ~ 6-Methoxy-8-(4-methyl-piperazin-
io ~ 1-yl)-4-oxo-4H-chromene-2-
I / ~N carboxylic acid (4-thiomorpholin-4-
o ~ yl-phenyl)-amide
N o I /
C~
N
.
3~ 0 6-Methoxy-8-(4-methyl-piperazin-
io ~ 1-yl)-4-oxo-4H-chromene-2-
carboxylic acid [4-(2,6-dimethyl-
/ o~N ~ morpholin-4-yl)-phenyl]-amide
N O I /
c ~ N~
0
N .
3$ ~ 0 6-Methoxy-8-(4-methyl-piperazin-
o ~ ~0 1-yl)-4-oxo-4H-chromene-2-
I / I N ~N J carboxylic acid (3-morpholin-4-yl-
o ~ phenyl)-amide
N o I / . .
~N~
39 ° 6-Methoxy-8-(4-methyl-piperazin- .
i° ~ 1-yl)-4-oxo-4H-chromene-2
~N ~ carboxylic acid f 4-[4-(2-hydroxy-
N °' ~° I ~ ethyl)-piperazin-1-yl]-phenyl~-
N~ amide
i N~oFi
40 ~ 0 6-Methoxy-8-(4-methyl-piperazin-
o ~ 1-yl)-4-oxo-4H-chromene-2-
I / o~N \ ~ o carboxylic acid [4-(1-rnorpholin-4-
yl-methanoyl)-phenyl]-amide
N O ~ / NJ
CND o
41 0 6-Methoxy-8-(4-methyl-piperazin-
io ~ 1-yl)-4-oxo-4H-chromene-2-
I / o~N carboxylic acid (3-cyano-4-
morpholin-4-yl-phenyl)-amide
N o I / N
CN~ CN ~O

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 34 -
Exam 1e.. ', , :. .. Structure , . : , :, a., , . ..:. . Name , , : .
# ~ ,. :, , , , ..
42 0 4-[4-( { l -[6-Methoxy-8-(4-methyl-
io ~ piperazin-1-yl)-4-oxo-4H-chromen-
~N ~ 2-yl]-methanoyl}-amino)-phenyl]-
o ~ piperazine-1-carboxylic acid te~t-
N o I i butyl ester
~°
i ~
°
43 0 6-Methoxy-8-(4-methyl-piperazin-
1-yl)-4-oxo-4H-chromene-2-
N carboxylic acid (4-piperazin-1-yl-
phenyl)-amide
N O ~ ~ N
CN/ .. ~NH
44 0 6-Methoxy-8-(4-methyl-piperazin-
1-yl)-4-oxo-4H-chromene-2-
~N carboxylic acid [4-(4-propionyl-
N o ~o( I , - piperazin-1-yl)-phenyl]-amide
CN, ~N
45 0 6-Methoxy-8-(4-methyl-piperazin-
~ ~ 1-yl)-4-oxo-4H-chromene-2-
I , o N ~ carboxylic acid [4-(4-ethane
N o ( , sulfonyl-piperazin-1-yl)-phenyl]-
~N amide
CND ~ ,
00
46 ° 6-Methoxy-8-(4-methyl-piperazin-
o ~ 1-yl)-4-oxo-4H-chromene-2-
~N carboxylic acid [4-(4-dimethyl
o ~ sulfamoyl-piperazin-1-yl)-phenyl]-
N o I i amide
N
~N~ ~N, ,N
I O g0 \
4~ 0 4-[4-( { 1-[6-Methoxy-8-(4-methyl-
io ~ piperazin-1-yl)-4-oxo-4H-chromen-
~N 2-yl]-methanoyl }-amino)-phenyl]-
o ~ piperazine-1-carboxylic acid
N o ~ i dimeth lamide
~N , y .
~N\
O

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-35-
Example.. 5trixctvre ' ' Name
. # . 3.. ;. , , . ', '.l , .,. _. ''. ' . ~ , ; : .. . " , x :
0 4-[4-({ 1-[6-Methoxy-8-(4-methyl-
io ~ piperazin-I-yl)-4-oxo-4H-chromen-
N 2-yl]-methanoyl }-amino)-phenyl]-
N ° o ~ ~ piperazine-1-carboxylic acid
ethylamide
N~
~N~
49 ° 4-[4-({ 1-[6-Methoxy-8-(4-methyl-
pip erazin-1-yl)-4-oxo-4H-chromen-
~N 2-yl]-methanoyl}-amino)-phenyl]-
N °' ~o ~ ~ piperazine-1-carboxylic acid
cyclohexylamide
N N
O
50 0 4-[4-({ 1-[6-Methoxy-8-(4-methyl-
io ~ piperazin-1-yl)-4-oxo-4H-chromen-
~ ~ ~N 2-yl]-methanoyl}-amino)-phenyl]
o ~ piperazine-1-carboxylic acid
N o ~ i c clo ent lamide
y .p y
N N
O
51 0 6-Methoxy-8-(4-methyl-piperazin-
io ~ . 1-yl)-4-oxo-4H-chromene-2-
~N carboxylic acid {4-[4-(1-pyrrolidin-
~ 1-yl-methanoyl)-piperazin-1-yl]-
N o I i hen 1 -amide
C ~ ~N p Y }
i ?~N~
°
52 ° 6-Methoxy-8-(4-methyl-piperazin-
1-yl)-4-oxo-4H-chromene-2-
~ ~ ~N carboxylic acid {4-[4-(propane-2-
o ~ sulfonyl)-piperazin-1-yl]-phenyl}-
N o ~ i amide
C~
,S,
°°
53 . 0 6-Methoxy-8-(4-methyl-piperazin-
1-yl)-4-oxo-4H-chromene-2-
~N carboxylic acid {4-[4-(2-methyl-
o ~ propanoyl)-piperazin-1-yl]-phenyl}-
N o ~ i amide
C ~ . N~N
N
0

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 36 -
Example;. ,, - Structure ; :..:. .. : , : Name z,, ' . ... . ... . ':,.
,; : . ''' .
:, . , ;
, .. ,. >: ,.
54 ~ 0 6-Methoxy-8-(4-methyl-piperazin-
o ~ . 1-yl)-4-oxo-4H-chromene-2-
~ o~N \ ~ carboxylic acid {4-[4-(1-morpholin-
4-yl-methanoyl)-piperazin-1-yl]-
o ~ i N~ phenyl}-amide
~N~
0
55 0 6-Fluoro-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
N carboxylic acid (4-morpholin-4-yl-
. ~ phenyl)-amide
N O
C ~ ~o
N
56 0 6-Fluoro-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
carboxylic acid [4-(4-
o~N ~ methanesulfonyl-piperazin-1-yl)-
N o I i phenyl]-amide
C ~ ~N. ;
i o s~ o
5~ o , 6-Fluoro-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
carboxylic acid [4-(4-acetyl-
o~N I ~ piperazin-1-yl)-phenyl]-amide
N O
C ~ ~N
0
g o 6-Fluoro-8-(4-methyl-pip erazin-1-
yl)-4-oxo-4H-chromene-2-
N ~~ . carboxylic acid (3-chloro-4-
o~ ~ morpholin-4-yl-phenyl)-amide
N o ~ i
0
N
59 0 6-Fluoro-8-(4-methyl-pip erazin-1-
yl)-4-oxo-4H-chromene-2-
N \ F carboxylic acid (3-fluoro-4-
morpholin-4-yl-phenyl)-amide
N o
0
N

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-37-
Example' Structure' r - Narne
'~~' -:. ". ~ ~;° .: ~-.' ..-= , -.~.... ~.. ~ , ~ '.~' x. ~ :.
.,,;,.:: , H .'.;.: '~ '
60 0 6-Fluoro-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
i ~N CN carboxylic acid (3-cyano-4-
~ ~ morpholin-4-yl-phenyl)-amide
N O
e. ~
N
61 0 6-Fluoro-8-(4-methyl-piperaziri-1-
yl)-4-oxo-4H-chromene-2-
~ N carboxylic acid [4-(1-morpholin-4-
o I ~ ~o yl-methanoyl)-phenylJ-amide
N O / NJ
.. CND . o
0 6-Methyl-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
~N carboxylic acid (4-morpholin-4-yl-
o ~ phenyl)-amide
N o ~ ~
~ ~ ~°
N
63 0 6-Methyl-8-(4-methyl-piperazin-1-
H3~ ~ yl)-4-oxo-4H-chromene-2-
N carboxylic acid [4-(1-morpholin-4-
o~ ~ ~o y1-methanoyl)-phenyl]-amide
N O I / NJ
. CND °
64 0 6-Methyl-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
o~N \ F carboxylic acid (3-fluoro-4-
morpholin-4-yl-phenyl)-amide
N o ~ i
N
65 . 0 6-Chloro-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
o~N carboxylic acid (4-morpholin-4-yl-
phenyl)-amide
N o ~ ~
N

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 38 -
Example: ' Structure ,; ;.. Nape
y;. ,.#.., . ;.. ' .; '' .~.'. ' ., . -',,:' :. ;. . .. _. ''' ,'; w: ' ' ,'.
..,, ..:
66 cH3 0 5-Methyl-8-(4-methyl-piperazin-1-
y1)-4-oxo-4H-chromene-2-
~ N carboxylic acid (4-morpholin-4-yl-
o ~ phenyl)-amide
N o
0
.
0 5-Methoxy-8-(4-methyl-piperazin-
1-yl)-4-oxo-4H-chromene-2-
carboxylic acid (4-morpholin-4-yl-
N w phenyl)-amide
N °
~ ~ ~°
N
0 6-Methoxy-8-(4-methyl-piperazin-
o ~ 1-yl)-4-oxo-4H-chromene-2-
N carboxylic acid {4-[4-(3-hydroxy-
propanoyl)-piperazin-1-yl]-phenyl}-
N o ~ i amide
OH
C~ N
0
69 0 4-[4-({ 1-[6-Fluoro-8-(4-methyl
F ~ piperazin-1-yl)-4-oxo-4H-chromen-
N 2-yl]-methanoyl}-amino)-phenyl]-
piperazine-1-carboxylic acid te~t-
N o ~ i but 1 ester
N ~N~O
C ~ N~ y .
O
70 0 4-[4-({ 1-[6-Fluoro-8-(4-methyl-
piperazin-1-yl)-4-oxo-4H-
~N chromene-2-carboxylic acid (4-
o ~ piperazin-1-yl-phenyl)-amide
N o
C~ N
~NH
N
0 6-Fluoro-8-(4-methyl-piperazin-1- ,
yl)-4-oxo-4H-chromene-2-
~ . N carboxylic acid [4-(4-ethane
sulfonyl-piperazin-1-yl)-phenyl]-
N o ~ amide
C~ ~N,~ .
o' o

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-39-
"Example ' Structure '. ,NaWa
"~ ;; '. ..,, . ,., .;° ~.. ... . ,,, ,
6-Fluoro-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
~N carboxylic acid [4-(4-propionyl-.
N o o ~ ~ piperazin-1-yl)-phenyl]-amide
~N~
N\
'O
. 73 ° . 6-Fluoro-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H-chromene-2-
~N carboxylic acid {4-[4-(3-hydroxy-
o ~ propanoyl)-piperazin-1-yl]-phenyl}-
N o ~ ~ amide
~N OH
c~ N
r
O
~4 0 ~ N-[8-(4-Methyl-piperazin-1-yl)-4-
0 oxo-4H_chromen-2-yl]-4-
morpholin-4-yl-benzamide
O N
N ~ ~
c ~ ~°
N
w 8-(4-Methyl-piperazin-1-yl)-
N chroman-2-carboxylic acid
o ~ (4-morpholin-4-yl-phenyl)-amide
N o ~ ~
N
racemic
76 ~ (+)-8-(4-Methyl-piperazin-1-yl)-
chroman-2-carboxylic acid (4-
/ O N I ~ morpholin-4-yl-phenyl)-amide
N O / N
C~ o
N
(-)-8-(4-Methyl-piperazin-1-yl)-
( chroman-2-carboxylic acid (4-
/ O N I ~ morpholin-4-yl-phenyl)-amide
N O / N
0
N

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-40-
Example : St~cictutre : ' Name
W# .. , . . ~. . :''..'. ,>.. .'° ..' ,.'. . : ° ;,: ~;;.:,
.=
racemic-8-(4-methyl-pip erazin-1-
yl)-4-oxo-chroman-2-carboxylic
acid (4-morpholin-4-yl-phenyl)-
/ o N amide
N O I ~ N
C ~ '~
~o
N
0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
chroman-2-carboxylic acid (4-
~N ~ morpholin-4-yl-phenyl)-amide
o ~ (faster running isomer)
N o
C ~ ~°
N
80 0 8-(4-Methyl-piperazin-1-yl)-4-oxo-
chroman-2-carboxylic acid (4-
~N morpholin-4-yl-phenyl)-amide
o ~ (slower running isomer).
N o ~ i
c ~ ~°
N
$1 0 4-[4-({ 1-[6-Fluoro-8-(4-methyl-
piperazin-1-yl)-4-oxo-4H-chromen-
~N 2-yl]-methanoyl}-amino)-phenyl]-
o ~ piperazine-1-carboxylic acid
N o ~ ~ i ethylamide .
C~ N .
~N O
82 0 6-Methoxy-8-(4-methyl-
[ 1,4] diazepan-1-yl)-4-oxo-4H
chromene-2-carboxylic acid (4-
o~N ~ morpholin-4-yl-phenyl)-amide
N o ~ i
N

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-41-
Example: ' Stn~cture ' Name
".#~. . ..~ ~ "- , . r' :;, - ., : ...; ... . , . '' , .. .;~ , , ',, ;' ," ,--
.,.. , '-:. . ..t;' '
0 6-Ethoxy-8-(4-methyl-piperazin-1-
yl)-4-oxo-4H chromene-2-
( / ~N carboxylic acid (4-morpholin-4-yl-
o ~ phenyl)-amide
N o ~ / .
N
0 6-Ethoxy-8-(4-methyl-piperazin-1-
~ yl)-4-oxo-4H chromene-2-
/ ~ N carboxylic acid [4-(4-propionyl-
o~ ~ piperaain-1-yl)-phenyl]-amide
N o
c~
°
85 0 - 6-Methoxy-4-oxo-8-piperazin-1-yl-
io ~ 4H chromene-2-carboxylic acid (4-
/ ~N morpholin-4-yl-phenyl)-amide
o w
N o ~ /
N
86 . 0 6-Hydroxy-8-(4-methyl-piperazin-
o ~ 1-yl)-4-oxo-4H chromene-2-
~N 1 carboxylic acid (4-morpholin-4-yl-
o ~ phenyl)-amide
N O ~ /
C ~ ~°
N
0 6-Methoxy-8-(4-methyl-
[ 1,4] diazepan-1-yl)-4-oxo-1,4-
/ ~ ~ dihydro-quinoline-2-carboxylic acid
N H N \ (4-morpholin-4-yl-phenyl)-amide
o ~ /
N
g g o 6-Methoxy-8-(4-methyl-piperazin-
1-yl)-4-oxo-1,4-dihydro-quinoline-
/ ~ H 2-carboxylic acid (4-morpholin-4-
N 1- hen 1 -amide
N H ~ \ y p y)
N
c~ ° / ~
N ~°

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-42-
Example ' Sttti.cture ' v ; ' ._Narit~
. - # ~ , ';, ~ -:. ; ' ~ ,. . °.. '~., ,w ,,,
6-Methoxy-8-(4-methyl-piperazin-
I -yl)-4-oxo-1,4-dihydro-quinoline
2-carboxylic acid [4-(4-propionyl
N
N H \ piperazin-1-yl)-phenyl]-amide
° ~ /
~N~ N
~N O
90 ~ 6-Fluoro-8-(4-methyl-piperazin-1
yl)-4-oxo-1,4-dihydro-quinoline-2
( . carboxylic acid (4-morpholin-4-yl
N N I ~ phenyl)-amide
N O \~~/
c~
N
91 ° 6-Fluoro-8-(4-methyl-piperazin-1-
w yI)-4-oxo- I ,4-dihydro-quinoline-2-
N carboxylic acid [4-(4-propionyl-
N~ ~ i erazin-1- 1 - hen 1 -amide
N ° ~ , pp Y)p Y]
CND
8-[(2-Dimethylamino-ethyl)-
methyl-amino]-6-methoxy-4-oxo-
1,4-dihydro-quinoline-2-carboxylic
N ~ acid (4-morpholin-4-yl-phenyl)-
/N H ° ~ , amide
~N O
° ~ 8-[(3-Dimethylamino-propyl)-
methyl-amino]-6-methoxy-4-oxo-
1,4-dihydro-quinoline-2-carboxylic
N ~ acid (4-morpholin-4-yl-phenyl)-
,N H ° I ,~ amide
. , ~ ~° .
N
94 ° 8-((3R)-(+)-3-Dimethylamino-
~o
w H pyrrolidin -1-yl)-6-methoxy-4-oxo
1,4-dihydro-quinoline-2-carboxylic
N H N \ acid (4-morpholin-4-yl-phenyl)
° I i amide
-N

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 43 -
Example Stnieture ' Narrie
.. . ~ ' °, ~ :~ ; , ..: . :' ' >,
~, ' :~ . ;.. ' . '. ;
0 8-((3 S)-(-)-3-Dimethylamino-
w pyrrolidin -I-yl)-6-methoxy-4-oxo
~ / ~ H 1,4-dihydro-quinoline-2-carboxylic
N
N H \ acid (4-morpholin-4-yl-phenyl)-
o ~ / amide
~o
-N
96 0 _ 6-Methoxy-8-[methyl-(I-methyl-
~° ~ pyrrolidin-3-yl)-amino]-4-oxo-1,4-
dihydro-quinoline-2-carboxylic acid
N ~ (4-morpholin-4-yl-phenyl)-amide
/N H O I /
N O
0 8-[Ethyl-(1-ethyl-pyrrolidin-3-yl)-
amino]-6-methoxy-4-oxo-1,4-
dihydro-quinoline-2-carboxylic acid
N 4-mo holin-4- 1- hen 1 -amide
( ~ Y p Y)
~N H O / N~
~lO
~ N ~ 4-dimethylamino-6-methoxy-8-(4
~o methyl-piperazin-1-yl)-quinoline-2-
carboxylic acid (4-morpholin-4-yl-
/ N N ~ ~ phenyl)-amide
N o ~ /
CND
0
99 H.N i 6-methoxy-4-methylamino-8-(4-
methyl-piperazin-1-yl)-quinoline-2-
carboxylic acid (4-morpholin-4-yl-
/ N N ~ phenyl)-amide
N o ~ /
cN~
0

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-44-
Exarriple Struotiire ° .. .:. , , ;Name ,
: :: , . y ;;. .. . ~' .. .. : r . ,... ..; . . . w ~ 3 - , .:,, ' : » .
:°x
100 0~ 6-fluoro-4-methoxy-8-(4-methyl-
piperazin-1-yl)-quinoline-2-
carboxylic acid (4-morpholin-4-yl-
/ N' N w phenyl)-amide
N O ~ /
c~ ~ ..
N
I
1 o 1 0 6-Fluoro-4-oxo-8-piperazin-1-yl-
4H chromene-2-carboxylic acid (4-
I i o~N ~ morpholin-4-yl-phenyl)-amide °
N j0[ I ~
~N~
0
Also provided herein are the pharmaceutically acceptable salts of the
compounds set
forth in Table 1.
The following reference examples illustrate the making of intermediates in the
synthesis of the compounds of the present invention, and are not intend to
limit the invention
m any manner.
Reference Example 1
Preparation of Reference Example 1: 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-
2-carboxylic acid hydrochloride.
Reference Example la: (E,Z)-2-(2-Bromo-phenoxy)-but-2-enedioic acid diethyl
ester.
Diethyl acetylenedicarboxylate (20 ml, 0.162 mol) was added to 2-bromophenol
(28 g,
0.162 mol), in anhydrous 2-propanol (60 ml) followed by the addition of a
catalytic amount of
tetrabutylammonium fluoride (0.5 ml, 1.0 M in THF). The solution was stirred
at room
temperature four hours and was then heated to reflux for one hour. The mixture
was cooled to
room temperature, then concentrated under vacuum to an oil (51 g = 91 %).
Reference Example 1b: (E,Z)-2-(2-Bromo-phenoxy)-but-2-enedioic acid.
(E,Z)-2-(2-Bromo-phenoxy)-but-2-enedioic acid diethyl ester (51 g, 148 mmol)
as
prepared in Reference Example 1 a was suspended in ethanol (95 ml) and a
solution of sodium
hydroxide ( 12.9 g, 0.323 mol) in water (95 ml) was added. The solution was
refluxed for 1 h
to give a clear orange solution. The mixture was cooled to room temperature
and acidified
with 6 M HCl (50 ml). The mixture was then concentrated under vacuum and the
residue

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-45-
azeotroped (4x) with ethanol. The solid was filtered, washed with water and
dried to give
(2Z)-2-(2-bromo-4-methoxyphenoxy)-2-butenedioic acid as a light orange solid
(24.3 g, 88
yield). This crude product was used without further purification.
Reference Example lc: Ethyl-8-Bromo-4-oxo-4H-chromene-2-carboxylate.
Sulfuric acid (95mL) was added to crude (E,Z)-2-(2-Bromo-phenoxy)-but-2-
enedioic
acid as prepared in Reference Example 1b. After heating the mixture with a
heat gun for 45
min an orange milky solution was obtained. This solution was slowly added to
refluxing
absolute ethanol (500 mL). After the addition, the reaction was refluxed for
30 min then
allowed to cool. Crystals started to form after 20 min and the reaction was
put in the
refrigerator overnight. The solid was filtered, washed with cold ethanol/
water 9:1 and dried
to~give ethyl 8-bromo-4-oxo-4H-chromene-2-carboxylate as an off white solid
(11.7 g, 24
yield, mp 124-126 °C).
Reference Example 1d: Ethyl-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromenec-2-
carboxylic acid.
Ethyl 8-bromo-4-oxo-4H-chromene-2-carboxylate as prepared in Reference Example
1 c (Davies, Stephen et al., J. Chem. Soc. Perkin Trans I p 2597, 1987) (3.0
g, 10.1 mmol) was
azeotroped with anhydrous toluene then the white solid was dissolved in 100 mL
anhydrous
toluene and transferred to the reaction vessel. The mixture was subjected to
vacuum / argon
(x2) and the following were added in order- (positive argon pressure): N-
methylpiperazine ( 1.3
ml, 11.1 mmol), 2,2'-bis (diphenylphosphino)-1,1'-binaphthyl (0.75 g, 1.2
mmol,), .
tris(dibenzylideneacetone) dipalladium (0) (0.48 g, 0.5 mmol) then cesium
carbonate (4.6 g,
14.1 mmol).The mixture was again subjected to vacuum / argon and was heated at
80 °C
overnight. ~ _ .
The cooled reaction mixture was filtered through diatomaceous earth and the
toluene
solution was applied directly to a 600 ml filter funnel (silica 230 - 400 mesh
ASTM packed in
ethyl acetate) and then washed with ethyl acetate (21). The product was eluted
with 5-8
methanol / chloroform and the desired was collected to give 2.5 g of a
slightly impure orange
yellow solid (mp 120-123 °C). The impure product was chromatographed on
a Waters Delta
Prep 4000 using 1 PrepPak cartridge (Porasil 37-SS~,m 125A.) eluting with 3-5
% methanol /
chloroform. The product was collected and dried to give ethyl 8-(4-methyl-1-
piperazinyl)-4-
oxo-4H chromene-2-carboxylate as a yellow solid (2.25 g, 70 % yield mp 124-125
°C).
GC/MS (EI, M+) m/z 316.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-46-
Reference Example 1e: 8-(4-methyl-1-piperazinyl)-4-oxo-4H chromene-2-
carboxylic acid
hydrochloride.
Ethyl 8-(4-methyl-1-piperazinyl)-4-oxo-4H chromene-2-carboxylate as prepared
in
Reference Example 1d (1.01 g. 3.19 mmol) was suspended in 6 M HCl (60 ml) and
to reflux
S for 1.S h (after 20 min a clear solution was obtained).
The reaction was allowed to cool. The solution was concentrated in vacuo and
anhydrous
toluene was added (x3) and the solution was again concentrated in vacuo to
give 8-(4-methyl-
1-piperazinyl)-4-oxo-4H chromene-2-carboxylic acid hydrochloride as a yellow
powder (1.02
g, quantitative yield). LC/MS (M+1) m /z 289.
Reference Example 2
CH3 O .
O
O ~ OH
N- . O
Hci
Preparation of 6-Methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic
acid hydrochloride.
Reference Example 2a: Diethyl (2Z)-2-(2-bromo-4-methoxyphenoxy)-2-
butenedioate.
1 S Ethyl acetylenedicarboxylate (17.8 ml, 0.145 mol) was added to 2-bromo-4-
methoxyphenol (Synlett p1241, 1997) (27.3 g, 0.134 mol), in anhydrous 2-
propanol (SS ml)
followed by the addition of a catalytic amount of tetrabutylammonium fluoride
(0.4 ml, 1.0 M
in THF). The solution was stirred at room temperature overnight and was then
heated to
reflux for 30 min. Upon cooling a precipitate formed. The solution was cooled
and filtered to
give diethyl (2Z)-2-(2-bromo-4-methoxyphenoxy)-2-butenedioate as a yellow
solid (29.9 g,
62 % yield). Note: the solid contains 10 % of diethyl (2E)-2-(2-bromo-4-
methoxyphenoxy)-2-
butenedioate. GC/MS (EI, M+) m/z 344 and 346.
Reference Example 2b: (2Z)-2-(2-bromo-4-methoxyphenoxy)-2-butenedioic acid.
Diethyl (2Z)-2-(2-bromo-4-methoxyphenoxy)-2-butenedioate (29.9 g, 86.6 mmol)
as
2S prepared in Reference Example 2a was suspended in ethanol (SS ml) and a
solution of sodium
hydroxide ( 7.0 g, 0.175 mol) in water (SS ml) was added: The solution was
refluxed for 1 h to
give a clear orange solution. Most of the ethanol was removed in vacuo then 6
M HCl (SO

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-47-
ml) was added. The solid was filtered, washed with water and dried to give
(2Z)-2-(2-bromo-
4-methoxyphenoxy)-2-butenedioic acid as a light orange solid (24.3 g, 88 %
yield).
Reference Example 2c: Ethyl-6-methoxy-8-bromo-4-oxo-4H-chromene-2-carboxylate.
Sulfuric acid (SOmI) was added to (2Z)-2-(2-brbmo-4-methoxyphenoxy)-2-
butenedioic
acid (24.38, 86.6 mmol; as prepared in Reference Example 2b above). After
heating the mixture
with a heat gun for 5-10 min a clear deep brown solution was obtained. This
solution was
slowly added to refluxing absolute ethanol (250 ml). After the addition the
reaction was
refluxed for 30 min then allowed to cool. Crystals started to form after 20
min and the reaction
was put in the refrigerator overnight. The solid was filtered, washed with
cold ethanol/ water
9:1 and dried to give ethyl 8-bromo-6-methoxy-4-oxo-4H-chromene-2-carboxylate
as an off
white solid (12.3 g, 50 % yield, mp 159-161 °C).
Reference Example 2d: Ethyl-6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-
2-carboxylat~.
Ethyl 8-bromo-4-oxo-4H-chromene-2-carboxylate (9.2 g, 28.1 mmol), as prepared
in
Example 2c above, was azeotroped with anhydrous toluene then the white solid
was dissolved
in 300 ml anhydrous toluene in a 500 mL single-neck round bottom flask.. The
mixture was
degassed by alternating argon sparge and vacuum (3x), and the following were
added in
order: N-methylpiperazine (4.0 ml, 35.1 mmol), 2,2'-bis (diphenylphosphino)-
1,1'-binaphthyl
(1.05 g, 1.69 mmol,), tris(dibenzylideneacetone) dipalladium (0) (0.50 g, 0.56
mmol) then
cesium carbonate (12.8 g, 39.3 mmol).The mixture was again degassed via
alternating argon
sparge and vacuum and was heated at 80 °.C for 17 h. Additional
tris(dibenzylideneacetone)
dipalladium (0) (0.10 g, 0.11 mmol) and 2,2'-bis (diphenylphosphino)-1,1'-
binaphthyl (0.20
g, 0.32 mmol,) was added and the reaction was stirred at 80 °C for
another 55 h at which time
the conversion was essentially complete.
The cooled reaction mixture was diluted with tetrahydrofuran (250 mL),
filtered and
concentrated under vacuum. The residue was purified by chromatography on a
silica column
eluted with 2-5 % methanol / chloroform and the desired fractions were
collected and
concentrated under vacuum and the residue triturated with methylene chloride
to give 7.4 g
(76%) of a yellow powder.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 48 -
Reference Example 2e: 6-Methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-
carboxylic acid.
Ethyl-6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene -2-carboxylate
(1.0 g.
2.89 mmol), as prepared in Reference Example 2d above, was suspended in 6 M
HCl (60 ml)
and methanol (10 mL) and warmed to reflux for 3.0 h. The reaction was allowed
to cool. The
solution was concentrated i~z vacuo and anhydrous toluene was added (x3) and
the solution
was again concentrated in vacuo. The residue was dried under vacuum (17 h) to
yield 6-
methoxy-8-(4-methyl-1-piperazinyl)-4-oxo-4H chromene-2-carboxylic acid
hydrochloride as
a yellow powder (1.0 g, quantitative yield).
Reference Example 3
F
OH
N O
HCI
N
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid
hydrochloride.
Reference Example 3a: Diethyl (EZ)-2-(2-bromo-4-fluorophenoxy)-2-butenedioate.
This compound was synthesized from 2-bromo-4-fluorophenol and
diethylacetylenedicarboxylate, using the same synthetic procedures and the
same
stoichiometry as demonstrated in Reference Example la above.
Reference Example 3b: (EZ)-2-(2-Bromo-4-fluorophenoxy)-2-butenedioic acid.
This compound was synthesized from diethyl (EZ)-2-(2-bromo-4-fluorophenoxy)-2-
butenedioate, as prepared in Reference Example 3a above, using the same
synthetic
procedures and the same stoichiometry as demonstrated in Reference Example 1b
above.
Reference Example 3c: Ethyl-6-fluoro-8-bromo-4-oxo-4H-chromene-2-carboxylate.
This compound was synthesized from (EZ)-2-(2-bromo-4-fluorophenoxy)-2-
butenedioic acid, as prepared in Reference Example 3b above, using the same
synthetic
procedures and the same stoichiometry as demonstrated in Reference Example 1 c
above.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-49-
Reference Example 3d: Ethyl-6-fluoro-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-
carboxylate.
This compound was synthesized from ethyl-6-fluoro-8-bromo-4-oxo-4H-chromene-2-
carboxylate, as prepared in Reference Example 3c above, using the same
synthetic
procedures and the same stoichiometry.as demonstrated in Reference Example 1d
above.
Reference Example 3e: 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic acid hydrochloride.
This compound was synthesized starting from ethyl-6-methoxy-8-(4-Methyl-
piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylate, as prepared in Example 3d,
using the
same synthetic procedures and the same stoichiometry as demonstrated in
Reference Example
1 a above.
Reference Example 4
H3C
OH
N O
HCI
N
Preparation 6-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic acid
1 S hydrochloride.
Reference Example 4a: Diethyl (E,Z)-2-.(2-bromo-4-methylphenoxy)-2-
butenedioate.
2-Bromo-4-methyl phenol (10 mL, 83mmo1) was dissolved in diethyl ether (90
mL). To this
was added dropwise triethyl amine (13.7 mL, 98mmol) followed by dimethyl
acetylene
dicarboxylate (11.2 mL, 9lmmol). The resulting mixture was stirred overnight
at room
temperature. The reaction was worked up by adding diethyl ether (200 mL) and
tetrahydrofuran (50 mL) and washing the resulting mixture with 1N HCl (200
mL), water
(200 mL) and brine (100 mL). The organic phase was then dried (NaaS04),
filtered and
concentrated to a red-brown oil which was used without further purification.
Reference 4b: (2E,Z)-2-(2-Brorrio-4-fluorophenoxy)-2-butenedioic acid.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-SU-
This compound was synthesized from diethyl (E,Z)-2-(2-bromo-4-methylphenoxy)-2-
butenedioate, as prepared in Reference Example 4a above, using the same
synthetic
procedures and the same stoichiometry as demonstrated in Example 1b above.
Reference Example 4c: Ethyl-6-methyl-8-bromo-4-oxo-4H-chromene-2-carboxylate.
S This compound was synthesized from (2Z)-2-(2-brorno-4-methylphenoxy)-2-
butenedioic acid, as prepared in Reference Example 4b above, and using the
same synthetic
procedures and the same stoichiometry as demonstrated in Reference Example lc
above.
Reference Example 4d: Ethyl-6-methyl-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-
carboxylate.
This compound was synthesized from ethyl-6-methyl-8-bromo-4-oxo-4H-chromene-2-
carboxylate, as prepared in Reference Example 4c above, using the same
synthetic procedures
and the same stoichiometry as demonstrated in Reference Example 1 d above.
Reference Example 4e: 6-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic acid hydrochloride.
' This compound was synthesized starting with ethyl-6-methyl-8-(4-Methyl-
piperazin-'
1-yl)-4-oxo-4H-chromene-2-carboxylate, as prepared in Reference Example 4d,
using the
same synthetic procedures and the same stoichiometry as demonstrated in
Reference Example
1 a above. .
Reference Example 5
CI
OH
HCI
N
Preparation of 6-Chloro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic
acid hydrochloride.
Reference Example 5a: Diethyl (E,Z)-2-(2-bromo-4-chlorophenoxy)-2-
butenedioate.
This compound.was prepared from 2-bromo-4-chloro phenol and dimethyl
acetylenedicarboxylate by the same synthetic procedures and in the same
stoichiometry as the
preparation described in Reference Example 4a.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-51-
Reference Example Sb: (2E,Z)-2-(2-Bromo-4-chlorophenoxy)-2-butenedioic acid.
This compound was synthesized from diethyl (E,Z)-2-(2-bromo-4-chlorophenoxy)-2-
butenedioate, as prepared in Reference Example Sa above, as using the same
synthetic
procedures and the same stoichiometry as demonstrated in Reference Example 1b
above.
Reference Example 5c: Ethyl-6-chloro-8-bromo-4-oxo-4H-chromene-2-carboxylate.
This compound was synthesized from (2E,Z)-2-(2-bromo-4-chlorophenoxy)-2-
butenedioic acid, as prepared in Reference Example Sb above, using the same
synthetic
procedures and the same stoichiometry as demonstrated in Example 1 c above.
Reference Example Sd: Ethyl-6-chloro-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-
carboxylate.
This compound was synthesized from ethyl-6-chloro-8-bromo-4-oxo-4H-chromene-2-
carboxylate, as prepared in Reference Example Sc above, using the same
synthetic procedures
and the same stoichiometry as demonstrated in Example 1d above.
Reference Example Se: 6-Chloro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic acid hydrochloride.
This compound was synthesized starting with ethyl-6-chloro-8-(4-methyl-
piperaziri-1-
yl)-4-oxo-4H-chromene-2-carboxylate, prepared in Reference Example Sd above,
using the
same synthetic procedures and the same stoichiometry as demonstrated in
Reference Example
1e above.
Reference Example 6 .
H3
~O
N O
HCI
N
Preparation of 5-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic
acid hydrochloride
Reference Example 6a: Diethyl (E,Z)-2-(2-chloro-5-methylphenoxy)-2-
butenedioate.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-52-
This compound was prepared from 2-chloro-5-methylphenol and dimethyl
acetylenedicarboxylate by the same synthetic procedures and in the same
stoichiometry as the
preparation described in Reference Example la.
Reference Example 6b: (2E,Z)-2-(2-chloro-5-methylphenoxy)-2-butenedioic acid.
This compound. was synthesized from diethyl (E,Z)-2-(2-chloro-5-methylphenoxy)-
2-
butenedioate, as prepared in Reference Example 6a above, using the same
synthetic
procedures and the same stoichiometry as demonstrated in Reference Example 1b
above.
Reference Example 6c: Ethyl-5-methyl-8-chloro-4-oxo-4H-chromene-2-carboxylate.
This compound was synthesized from (2Z)-2-(2-chloro-S-methylphenoxy)-2-
butenedioic acid,
as prepared in Reference example 6b, using the same synthetic procedures and
the same
stoichiometry as demonstrated in Reference Example lc above.
Reference Example 6d: Ethyl-5-methyl-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-
carboxylate.
Ethyl 5-methyl-8-chloro-4-oxo-4H-chromene-2-carboxylate (1.0 g, 3.6 mmol) as
prepared in Reference Example 6c above, was azeotroped with anhydrous toluene
then the
white solid was dissolved in 100 ml anhydrous toluene in a 250 mL single-neck
round bottom.
flask.. The mixture was degassed by alternating argon sparge and vacuum (3x),
and the
following were added in order: N-methylpiperazine (0.6 ml, 5.37 mmol), (2'-
dicyclohexylphosphanyl-biphenyl-2-yl)-dimethyl-amine (JACS 1998, 120, p9722)
(40 mg,
0.1 mmol,), tris(dibenzylideneacetone) dipalladium (0) (66 mg, 0.072 mmol)
then cesium
carbonate (1.6 g, 5.37 mmol).The mixture was again degassed via alternating
argon sparge
and vacuum and was heated at 80 °C for 17 h. Additional
tris(dibenzylideneacetone)
dipalladium (0) (66 mg, 0.072 mmol) and (2'-dicyclopentylphosphanyl-biphenyl-2-
yl)-
dimethyl-amine (40 g, 0.1 mmol,) were added and the reaction was stirred at 80
°C for
another four days at which time the conversion was still only about 50%
complete by HPLC.
Tetrahydrofuran (100 mL) was added, and the combined mixture was filtered,
concentrated
under vacuum and purified by chromatography on silica eluted with 2.5%
methanol in
chloroform. The desired fractions were concentrated under vacuum to yield a
yellow powder
(250 mg = 21%).
Reference Example 6e: 5-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic acid hydrochloride.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 53 -
This compound was synthesized starting with ethyl-5-methyl-8-(4-methyl-
piperazin-1-
yl)-4-oxo-4H-chromene-2-carboxylate, as prepared in Reference Example 6d, and
using the
same synthetic procedures and the same stoichiometry as demonstrated in
Example 1e above.
Reference Example 7
H3C
OH
N O
HCI
N
I.
Preparation of 5-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-
carboxylic
acid hydrochloride.
Reference Example 7a: (E,Z)-2-(2-Bromo-5-methoxyphenoxy)-2-butenedioate.
This compound was prepared from 2-bromo-5-methoxyphenol and dimethyl
acetylenedicarboxylate by the same synthetic procedures and in the same
stoichiometry as the
preparation described in Reference Example 1 a.
Reference Example 7b: (E,Z)-2-(2-Bromo-5-methoxyphenoxy)-2-butenedioic acid.
This compound was synthesized from diethyl (E,Z)-2-(2-bromo-5-methoxyphenoxy)-
2-butenedioate, as prepared in Reference Example 7a, using the same synthetic
procedures
and the same stoichiometry as demonstrated in Reference Example 1b above.
Reference Example 7c: Ethyl-5-methoxy-8-bromo-4-oxo-4H-chromene-2-carboxylate.
This compound was synthesized from (E,Z)-2-(2-bromo-5-methoxyphenoxy)-2-
butenedioic
acid, as prepared in Reference Example 7b above, using the same synthetic
procedures and
the same stoichiometry as demonstrated in Reference Example lc above.
Reference Example 7d: Ethyl-5-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-
2-carboxylate.
This compound was synthesized from ethyl-5-methoxy-8-bromo-4-oxo-4H-chromene-
2-carboxylate, as prepared in Reference Example 7c above, using the same
synthetic
procedures and the same stoichiometry as demonstrated in Reference Example 1d
above.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-54-
Reference Example 7e: S-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-
carboxylic acid hydrochloride.
This compound was prepared from ethyl-S-methoxy-8-(4-Methyl-piperazin-1-yl)-4-
oxo-4H-chromene-2-carboxylate, as prepared in Reference Example 7d above,
using the same
S method as the preparation in 1e.
Reference Example 8
~~CH3
N
N 1H
U
Preparation of 1-(6-Piperazin-1-yl-2,3-dihydro-indol-1-yl)-ethanone
Reference Example 8a: 1-[S-(4-Benzyl-piperazin-1-yl)-2,3-dihydro-indol-1-yl]-
ethanone.
1-acetyl-S-bromoiridoline (3.0 g, l2.Smmo1) was dissolved in toluene (60 mL).
To
this was added, sodium t-butoxide (1.68 g, l7.Smmo1), N-benzylpiperazine (2.4
mL,
13.8mmol), S-BINAP (0.93 g, l.Smmo1) and Pd2(dba)3 (0.46 g, O.Smmol). The
mixture
was degassed via three cycles of vacuum and nitrogen sparge and then stirred
at 9S°C until
GC analysis confirmed that the reaction was complete (1 h). The mixture was
diluted with
1 S ethyl acetate (1 SO mL), washed with water and extracted with 2N HCl (2 x
100 mL). The
combined aqueous extract was basified with concentrated ammonium hydroxide and
extracted
with ethyl acetate (2 x 100 mL). The combined organic extract was dried
(MgS04) and
concentrated to yield a solid (2.7 g) which was purified by chromatography to
yield a white
solid (1.81 g, 43%). Mp = 1SO.S-152.8°C.,
20. Reference Example 8b: 1-(6-Piperazin-1-y1-2,3-dihydro-indol-1-yl)-
ethanone.
1-[S-(4-Benzyl-piperaziri-1-yl)-2,3-dihydro-indol-1-yl]-ethanone (0.37 g,
l.lmmol), as
prepared in Reference Example 8a above, was dissolved in methanol (S mL). Pd/C
(90 mg,
10%) and ammonium formate (0.9 g, l4mmol) was added and the resulting mixture
was
heated to 6S°C for two hours. The mixture was filtered and the filter
cake washed with hot
2S methanol. The combined filtrate was concentrated to yield the desired
product (0.26 g, 90%).
Reference Example 9
NC
CI ~ ~ N VH

CA 02433950 2003-07-08
WO 02/055013 ~ PCT/SE02/00069
-55-
Preparation of 2-chloro-5-piperazin-1-yl benzonitrile.
Reference Example 9a: 3-Cyano-4-chloroaniline.
2-Chloro-5-nitrobenzonitrile (25 g, 137mmo1) was dissolved in ethanol (275
mL).
Stannous chloride dihydrate (154.5 g, .685 M) was added and the mixture
stirred at 70°C for
30 min. The mixture was then cooled to room temperature and poured into
crushed ice. The
mixture was made basic with solid sodium hydroxide. This mixture was extracted
with ethyl
acetate (3 x 100 mL). The extracts were combined, washed with brine, dried
(MgS04),
concentrated and the residue dried under vacuum and recrystallized from
ethanol to yield light
brown needles ( 10.6 ~ g, 51 %).
Reference Example 9b: 2-chloro-5-piperazin-1-yl benzonitrile.
3-Cyano-4-chloroaniline (10.1 g, 66mmol), as prepared in Reference Example 9a,
was
dissolved in n-butanol (300 mL) bis-(2-chloroethyl)amine hydrochloride (23.2
g, 130mrno1)
and potassium iodide (50 mg, catalytic) were added. The mixture was heated at
reflux for
three days, then cooled in a refrigerator overnight. A solid precipitate was
collected by
filtration, washed with cold n-butanol and dried. The crude product was
distributed between
methylene chloride and ZN ammonium hydroxide. The organic layer was separated,
dried
(Na2S04) and concentrated to yield a light yellow solid (9.1 g, 59%) which
gave a single peak
by GC and TLC analysis.
Reference Examule 10
H2N / \ ~ N
S' .
Preparation of 4-[1,2,3]thiadiazol-5-yl-phenylamine.
SnCl2 ' H20 (3.21 g, 5 e~ was added to a slurry of (5-(4-Nitrophenyl)-1,2,3-
thiadiazole (Lancaster Synthesis) (0.59 g, 2.8 mmol) in absolute EtOH (50 mL)
and the
reaction heated to 70° C for 2 h. The reaction was allowed to cool to
room temperature and
pour into saturated NaHC03 and ice. The product was extracted with EtOAc (2X)
the
solution dried (MgS04) and evaporated to dryness in vacuo to yield 0.47 g of a
light yellow
solid mp 126-128° C.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-56-
Reference Example 11
H2N /
O
CH3
Preparation of 1-[4-(4-Amino-phenyl)-piperazin-1-yl]-ethanone.
Reference Example 11a: 4-(4-Nitrophenyl)-1-acetylpiperazine.
1-(4-Nitrophenyl)piperazine (2.5 g, 12.1 mmol) was dissolved in
dichloromethane
(100 ml). Triethylamine (2.0 ml, 14.5 mmol) was added and the reaction was
cooled to 0 °C.
Acetic anhydride (1:25 ml, 13.3 mmol) was added dropwise and the reaction was
stirred at 0
°C for 1 h. Saturated sodium bicarbonate was added and the reaction was
extracted (x3) with
dichloromethane, dried (MgS04), filtered and concentrated in vacuo to give 4-
(4-
nitrophenyl)-1-acetylpiperazine as a yellow solid (3.01 g,).GC/MS (EI, M+) m/z
= 249.
Reference Example 11b: 1-[4-(4-Amino-phenyl)-piperazin-1-yl]-ethanone.
4-(4-Nitrophenyl)-1-acetylpiperazine (3.0 g, 12.0 mmol), as prepared in
Reference Example
1 la above, was mixed in methanol (100 ml) and 2 M ammonia in methanol (50 ml)
and 10
palladium on carbon (300 mg) was added. The mixture was hydrogenated on a Paar
apparatus
(50 psi) for 1.5 h.
The reaction was allowed to cool, the catalyst was filtered and the solution
was
concentrated ih vacuo.. The crude solid was recrystallized from ethyl acetate
to give 4-(4-
acetyl-1-piperazinyl)benzenamine as a light purple solid (1.86 g, 70 % yield,
mp 149.5-150.5
°C). GCIMS (EI, M+) m/z = 219
Reference Example 12
HZN ~ ~ N-O~O
CH3
Preparation of 4-(4-methanesulfonyl-piperazin-1-yl)-phenylamine
Reference 12a: 4-(4-Nitrophenyl)-1-methylsulfonylpiperazine.
1-(4-Nitropherlyl)piperazine (2.79 g, 13.5 mmol) was dissolved in
dichloromethane
(100 ml). Triethylamine (2.25 ml, 16.2 mmol) was added and the reaction was
cooled to 0 °C. .
Methanesulfonyl chloride ( 1.15 ml, 14.9 mmol) was added dropwise and the
reaction was
stirred at 0 °C for-1 h. Saturated sodium bicarbonate was added and the
reaction was
extracted (x3) with dichloromethane, dried (MgS04), filtered and concentrated
in vacuo to

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-57-
give 4-(4-nitrophenyl)-1-methylsulfonylpiperazine as a yellow solid (3.83 g,
quantitative
yield). GC/MS (EI, M+) m/z = 285.
Reference Example 12b: 4-(4-methanesulfonyl-piperazin-1-yl)-phenylamine.
4-(4-Nitrophenyl)-1-methylsulfonylpiperazine (3.83 g, 13.4 mmol), as prepared
in
Reference Example 12a above, was mixed in methanol (100 ml) and 2 M ammonia in
methanol (50 ml) and 10 % palladium on carbon (400 mg) was added. The mixture
was
hydrogenated on a Paar apparatus (50 psi) for 3 h.
The reaction was allowed to cool, the catalyst was filtered, washed with
methanol then
washed with chloroform. The chloroform portion contained~a minor amount of the
desired but
looked purer. The chloroform portion was concentrated in vacuo and was
recrystallized ethyl
acetate to give 4-[4-(methylsulfonyl)-1-piperazinyl]benzenamine as a shiny
brown solid (0.94
g, 27 % yield, mp 192-193 °C). GC/MS (EI, M+) mlz = 255.
Reference Example 13
H2N ~ ~ S
U
Preparation of 4-Thiomorpholin-4-yl-phenylamine:
Reference Example 13a: 4-(4-Nitro-phenyl)-thiomorpholine.
4-Fluoronitrobenzene (3.0 g, 21.3 mmol) was dissolved in toluene (25 mL).
Thiomorpholine
(2.4 mL, 23.4 mmol) was added and the mixture stirred overnight at 100
°C. At 17 h, the
mixture was distributed between ethyl acetate (100 mL) and saturated sodium
bicarbonate (50
mL). The organic layer was separated, dried (Na2S04), filtered and
concentrated under
vacuum. The residue was triturated with hexane to yield a bright yellow solid.
Reference Example 13b: 4-Thiomorpholin-4-yl-phenylamine.
4-(4-Nitro-phenyl)-thiomorpholine(3.Og, 13.4 mmol), as prepared in Reference
Example 13a above, was dissolved in ethanol (250 mL) and 10% palladium on
carbon (250
mg) was added. This mixture was shaken on a Parr hydrogenator for 3 h. The
reaction
mixture was then filtered through diatomaceous earth and concentrated under
vacuum. The
residue was triturated with hexane to yield an gray solid (2.1 g). .

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-58-
Reference Example 14
HzN ~ ~ ~O
NJ
O
Preparation of 1-(4-Amino-phenyl)-1-morpholin-4-yl-methanone.
Reference Example 14a: 1-Morpholin-4-yl-1-(4-vitro-phenyl)-methanone:
4-Nitrobenzoyl chloride (5 g, 27 mmol) in tetrahydrofuran (10 mL) was added
slowly
to a solution of morpholine (5g, 88 mmol) and triethylamine (2.7 g, 27 mmol)
in _
tetrahydrofuran (50 mL), and stirred at room temperature for four hours. Ethyl
acetate (200
mL) was added to the mixture and the combined mixture was washed with water
(25 mL), 1N
HCl (25 mL), water (25 mL), saturated sodium bicarbonate (25 mL), water (25
mL) and brine
(25 mL). The mixture was dried (Na2S04), filtered and concentrated under
vacuum and the
residue used without further purification.
Reference Example 14b: 1-(4-Amino-phenyl)-1-morpholin-4-yl-methanone.
This compound was prepared from 1-morpholin-4-yl-1-(4-vitro-phenyl)-methanone
as
prepared in Reference Example 13b.
Reference Example 15
CN
HzN ~ ~ O
U
Preparation of 5-Amino-2-niorpholin-4-yl-benzonitrile
Reference Example 15a: 2-Morpholin-4-yl-5-vitro-benzonitrile.
3-Cyano-4-fluoronitrobenzene (3.3 g, 19.9 mmol) was dissolved in ethyl acetate
(10
mL). Morpholine (2.2 mL, 25 mmol), and N,N-diisopropylethylamine (3.5 mL, 20
mmol)
were added and the mixture stirred overnight at room temperature. At 17 h,
additional ethyl
acetate (150 mL) was added and the combined mixture was washed with water (50
mL) and
brine (50 mL), dried (NaZS04), filtered and concentrated under vacuum. The
residue was
used without further purification.
Reference Example 15b: 5-Amino-2-morpholin-4-yl-benzonitrile
This compound was prepared from 2-Morpholin-4-yl-5-vitro-benzonitrile (as
prepared
in Reference Example 15a above), as prepared in Reference Example 13b.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-59-
Reference Example 16
F
HZN ~ ~ p
U
Preparation of 3-Fluoro-4-morpholin-4-yl-phenylamine
Reference Example 16a: 4-(2-Fluoro-4-nitro-phenyl)-morpholine.
3,4-Difluoronitrobenzene (3.7 g, 23.2 mmol) was dissolved in ethyl acetate (10
mL).
Morpholine (2.2 mL, 25 mmol), and N,N-diisopropylethylamine (4 mL, 23 mmol)
were added
and the mixture stirred overnight at room temperature. At 17 h, additional
ethyl acetate (150
mL) was added and the combined mixture was washed with water (50 mL) and brine
(50 mL),
dried (NazS04), filtered and concentrated under vacuum. The residue was used
without
further purification.
Reference Example 16b: 3-Fluoro-4-morpholin-4-yl-phenylamine.
This compound was prepared from 4-(2-Fluoro-4-nitro-phenyl)-morpholine, (as
prepared in
Reference Example 16a above) as prepared in Reference Example 13b. .
Reference Example 17
O
HEN ~ ~ N~ CH3
~ \O~ ~ . _
H3C CH3
Preparation of 4-(4-Amino-phenyl)-piperazine-1-carboxylic acid tart-butyl
ester:
Reference Example 17a: 4-(4-Nitro-phenyl)-piperazine-1-carboxylic acid tart-
butyl ester.
4-Fluoronitrobenzene (4.8 g, 34 mmol) was dissolved in ethyl acetate (25 mL).
Piperazine-1-
carboxylic acid tart-butyl ester (6.7 g, 36 mmol) and N,N-
diisopropylethylamine (6.3 mL, 36
mmol) were added and the mixture was stirred at 65 °C for five days and
cooled to room
temperature. Ether (100 mL) was added and the combined mixture was washed with
water
(25 mL) and brine (25 mL), dried (Na2S04), filtered and concentrated under
vacuum. The
residue was triturated with hexane to yield a bright yellow solid (8 g, 77%).
Reference Example 17b: 4-(4-Amino-phenyl)-piperazine-1-carboxylic acid tent-
butyl ester.
4-(4-Amino-phenyl)-piperazine-1-carboxylic acid tent-butyl ester was prepared
from
4-(4-Nitro-phenyl)-piperazine-1-carboxylic acid tent-butyl ester, (as prepared
in Reference
Example 17a) as prepared in Reference Example 13b.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-60-
Reference Example 18
~O
H2N / NJ
Preparation of 3-Morpholin-4-yl-phenylamine
Reference Example 18a: 4-(3-Nitro-phenyl)-morpholine.
3-Fluoronitrobenzene (10 g, 71 mmol) was dissolved in acetonitrile (100 mL).
Morpholine (30 mL, 350 mmol) was added and the mixture was reacted 18 h at 150
°C/80psi
in a pressure reactor. The reaction was cooled to room temperature,
concentrated under
vacuum and Sg of the total mixture was purified by column chromatography on
silica eluted
with CHaCl2. . The product (3.6 g) was isolated as a bright yellow oil.
Reference Example 18b: 3-Morpholin-4-yl-phenylamine
3-Morpholin-4-yl-phenylamine was prepared from 4-(3-Nitro-phenyl)-morpholine,
(as
prepared in Reference Example 18a), as prepared in Reference Example 13b.
Reference Example 19
OH
H2N
U
Preparation of 2-[4-(4-amino-phenyl)-piperazin-1-yl)-ethanol.
Reference Example 19a: 2[4-(4-nitrophenyl)piperazine-1-yl]-ethanol.
2 [4-(4-nitrophenyl)piperazine I 1-yl]-ethanol is prepared from commercially
available
4-fluoronitrobenzene (Aldrich) and commercially available N-(2-
hydroxyethyl)piperazine
(Aldrich) via the same procedure as described in Reference Example 13a above.
Reference Example 19b: 2-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanol.
2-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanol is prepared by catalytic
hydrogenation a
of 2[4-(4-nitrophenyl)piperazine-1-yl]-ethanol (prepared as in Reference
Example 19a) as
described in Reference Example 13b
Reference Example 20
HZN. ~ ~ O
Preparation of 4-Morpholin-4-yl-phenylamine.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-61-
4-(4-Nitrophenyl)morpholine (10.3 g, 49.5 mmol;) (Lancaster Synthesis) was
suspended in methanol (130 ml) and 2 M ammonia in methanol (70 mL) and S %
palladium
on carbon (100 mg) was added. The mixture was hydrogenated on a Paar apparatus
(SO psi)
for 1 h. The reaction was allowed to cool, the catalyst was filtered and the
solution was
S concentrated in vacuo. The crude solid was recrystallized from ethyl acetate
l hexane to give
4-(4-morpholinyl)aniline as a light purple solid (6.2 g, 70 % yield, mp 132-
133 °C).
GC/MS (EI, M+) m/z = 178.
Reference Example 21
HO
H2N ~ \ O
U
Preparation of 4-Amino-3-hydroxyphenylmorpholine
4-Nitro-3- hydroxyphenylmorpholine (Maybridge Chemical) (3.34 g, 14.9mmo1) was
dissolved in S9 ml of ethanol at 30°C. The mixture was stirred at
2S°C and treated with tin
(II) chloride dihydrate (16.8 grams, 74.Smmo1) with~stirring. The yellow
suspension Was
heated to reflux over a 30 minute period. TLC showed reaction progress over
several hours.
1 S The mixture was refluxed for 18 hours, cooled to room temperature, and
concentrated to
remove most of the ethanol to give a yellow slurry. The mixture was treated
with saturated
aqueous sodium bicarbonate until it was basic. The mixture was extracted with
ethyl acetate,
filtered, and the organic layer was separated. The aqueous layer was extracted
twice more
with ethyl acetate. The extracts were combined, dried over magnesium sulfate,
filtered, and
concentrated to give 1.02 grams of a purple solid. Proton NMR and CI mass
spectral analyses
were consistent for the desired product (m/z = 19S base peak by positive ion
CI and m/z =193
base peak by negative ion CI). ,
Reference Example 22
O
O
~)

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-62-
Preparation of fi-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-oxo-4H chromene-2-
carboxylic acid
Reference Example 22a: 6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-oxo-4H
chromene-2-
carboxylic acid ethyl ester.
S Into a 2S0 mL 3 neck round bottom flask equipped with a reflux condenser,
nitrogen.
inlet and magnetic stirrer is placed 1.S g (4.59 nunol, 1.0 equiv.) of 8-Bromo-
6-methoxy-4-
oxo-4H chromene-2-carboxylic. acid ethyl ester (Reference Example 2c), 84 mg
(0.092 mmol,
0.02 equiv.) of tris dibenzylidineacetone dipalladium, 342 mg (O.SS mmol, 0.12
equiv.) of
racemic 2,2'-bis(diphenylphosphino)-1,1'-binapthyl and 2 g of 4 A molecular
sieves. .To this
suspension is added 1 SO mL of dry toluene. To the stirred suspension is then
added 628 mg,
684 ~,L, (S.SO mmol, 1.2 equiv.) of 1-methylhomopiperazine, followed by 2.0S g
(6.3 mmol,
1.4 equiv.) of cesium carbonate. The mixture is then heated to 80 °C
for 3 days. At the end of
this time completion was monitored by LC/MS analysis of an aliquot. When the
reaction was
determined to be complete it was cooled to room temperature then filtered
through a plug of
1 S diatomaceous earth with toluene washing to remove solid by products.
Purification by flash
chromatography, using a gradient of S to 20% methanol in methylene chloride as
eluent,
yielded 1.0 g, (60%) of the desired product.
Mass Spec.: calc. for [C19Hz4NaOs+H]+ Theor. mlz = 361; Obs. = 361
Reference Example 22b: 6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-oxo-4H
chromene-
2-carboxylic acid.
Into a 12S mL erlenmeyer equipped with a magnetic stirrer is placed 319 mg
(0.89
mmol, 1.0 equiv.) of 6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-oxo-4H
chromene-2-
carboxylic acid ethyl ester. This material is dissolved in 30 mL of THF, then
30 mL of
methanol are added. To this stirring solution is added 30 mL of a water
containing 41 mg
2S (0.97 mmol, 1.1 equiv.) of lithium hydroxide. This mixture is stirred at
room temperature for
2 hr. Completion of the reaction is monitored by LC/MS, then I O mL of 2N HCl
is added.
This mixture is then concentrated, dried and triturated with ether to give the
product as the
hydrochloride salt in quantitative yield.
Mass Spec.: calc. for [C17H2oNZO5+H]+ Theor. m/z = 333; Obs. = 333

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-63-
Reference Example 23
N
Preparation of 6-Ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-2-
carbonyl
chloride
Reference Example 23a: 8-Bromo-6-hydroxy-4-oxo-4H chromene-2-carboxylic acid
ethyl
ester:
The hydroxy compound, 8-Bromo-6-hydroxy-4-oxo-4H chromene-2-carboxylic acid
ethyl ester, is formed as a side product during the synthesis of 8-Bromo-6-
methoxy-4-oxo-4H
chromene-2-carboxylic acid ethyl ester. It can be separated from the crude
methoxy
compound by flash chromatography using a step gradient of 20% ethyl acetate in
methylene
chloride to the same solvent containing 2% methanol. , The hydroxy compound,
which elutes
last, is concentrated to give the pure compound. Mass Spec.: calc. for
[C~aH9Br05+H]+
Theor. m/z = 313, 315; Obs. = 313, 315
Reference Example 23b: 8-Bromo-6-ethoxy-4-oxo-4H chromene-2-carboxylic acid
ethyl
ester:
Into a 100 mL 3 neck round bottom flask equipped with a reflux condenser,
nitrogen
inlet and magnetic stirrer is added 700 mg (2.24 mg, 1.0 equiv.) of 8-Bromo-6-
hydroxy-4-
oxo-4H chromene-2-carboxylic acid ethyl ester (Reference Example 23a). This
material is
dissolved in 50 mL of toluene, then 689 mg, 586 ~,L (4.47 mmol, 2.O.equiv.) of
diethyl sulfate
and 309 mg (2.24 mmol, 1.0 equiv.) of KzC03 were added. The reaction was then
heated to
reflux for 24 hr. At the end of this time, monitoring by LC/MS reveals that
the reaction is
>than 95% complete. The reaction is then cooled, 100 mL of ethyl acetate is
added and the
organic layer is washed with O.SN HCl solution, dried over Na2S04, filtered
and concentrated.
The residues were subjected to flash chromatography, using 40% ethyl acetate
in hexane as
eluent. The purified fractions were concentrated to yield 500 mg (65%) of a
colorless solid.
Mass Spec.: calc. for [C1øH13Br05+H]+ Theor. m/z = 341, 343; Obs. = 341, 343

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-64-
Reference Example 23c: 6-Ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-
2-
carboxylic acid ethyl ester:
Into a 100mL, 3 neck round bottom flask equipped with a reflux condenser,
magnetic
stirrer and nitrogen inlet is added 350 mg (1.03 mmol, 1.0 equiv.) of 8-Bromo-
6-ethoxy-4-
oxo-4H chromene-2-carboxylic acid ethyl ester (Reference Example 23b), 18.9 mg
(0.02
mmol, 0.02 equiv.) of tris dibenzylidineacetone dipalladium, 77 mg (0.123
mmol, 0.12 equiv.)
of racemic 2,2'-bis(diphenylphosphino)-1,1'-binapthyl and 1g of 4 A molecular
sieves and 60
mL of dry toluene. To the stirred suspension is then added 113 mg, 1255 ~,L,
(1.13 mmol, 1:1
equiv.) of 1-methylpiperazine, followed by 470 mg (1.44 mmol, 1.4 equiv.) of
cesium
carbonate. The mixture is then heated to 80 °C for 3 days. At the end
of this time completion
was monitored by LC/MS analysis of an aliquot. When the reaction was
determined to be
complete it was cooled to room temperature then filtered through a plug of
diatomaceous
earth, with toluene washing to remove solid by products. Purification by flash
chromatography, using a gradient of 5 to 40% methanol in methylene chloride as
eluent,
yielded 350 mg (75%) of the desired product as a yellow solid. Mass Spec.:
calc. for
[C19H24N2O5+H]+ Theor. m/z = 361; Obs. = 361 '
Reference Example 23d: 6-Ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-
2-
carboxylic acid:
Into a 125 mL Erlenmeyer equipped with a magnetic stirrer is placed 500 mg
(1.39
mmol, 1.0 equiv.) of 6-Ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-2-
carboxylic
acid ethyl ester (Reference Example 23c). This material is dissolved in 30 mL
of THF, then
rriL of methanol are added. To this stirnng solution is added 30 mL of a water
containing
64.2 mg (1.53 mmol, 1.1 equiv.) of lithium hydroxide. This mixture is stirred
at room
temperature for 2 hr. Completion of the reaction is monitored by LC/MS, .then
~10 mL of 2N
25 HCl is added. This mixture is then concentrated, dried and triturated with
ether to give the
product as the hydrochloride salt in quantitative yield.
Mass Spec.: calc. for [Cl7HaoN205+H]+ Theor. m/z = 333; Obs. = 333
Reference Example 23e: 6-Ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-
2-
carbonyl chloride:
30 Into a 100 mL round bottom flask equipped with a reflux condenser, nitrogen
inlet and
magnetic stirrer is placed 250 mg (0.68. mmol, 1.0 equiv.) of 6-Ethoxy-8-(4-
methyl-piperazin-
1-yl)-4-oxo-4H chromene-2-carboxylic acid hydrochloride salt (Reference
Example 23d) and

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-65-
20 mL of methylene chloride. To the stirring suspension is then added 129.5
mg, 164
L(1.02 mmol, 1.5 equiv.) of oxalyl chloride followed by addition of one drop
of DMF from
a 50 microliter syringe to act as catalyst. The mixture is stirred for 2
hours, then concentrated
to dryness on a rotary evaporator under a nitrogen atmosphere, followed by
drying under high
vacuum. The completeness of the reaction was ascertained by analysis of an
aliquot, which
was quenched with a THF solution of methylamine, by LClMS. The crude material
was used
as obtained in the subsequent amidation reaction.
Reference Example 24
~SI-
O
Preparation of 8-Bromo-6-methoxy-4-(2-trimethylsilanyl-ethoxymethoxy)-
quinoline-2-
carboxylic acid methyl ester.
Reference Example 24a: 2-(2-Bromo-4-methoxy-phenylamino)-but-2-enedioic acid
dimethyl ester.
A solution of 2-bromo-4-methoxy aniline (6.02 g, 29.8 mmol) in 125 mL
anhydrous
methanol was treated with dimethyl acetylenedicarboxylate (3.70 mL, 30.2 mmol)
and the
solution was heated at reflux under nitrogen for 8 hours. The reaction mixture
was cooled,
concentrated, and redissolved in hot methanol. Yellow crystals were obtained
by filtration
(6.93 g, 68%). A second crop of crystals was obtained from ethanol (0.942 g,
9%). The
filtrates were combined and purified by flash chromatography on silica gel
using 4:1
hexanes:ethyl acetate to afford an additional 1.63 g (16%) for a total yield
of 93%. 1HNMR
(300 MHz, DMSO, d6) b 9.60 (s, 1 H, N~, 7.26 (d, 1 H, Jm 2.7 Hz, ArH ), 6.93
(dd, 1 H,
Jo 8.7, Jm 2.7 Hz, ArH ), 6.87 (d, 1 H, Jo 8.7 Hz, ArH6), 5.34 (s, 1 H, C=Cue,
3.76 (s, 3
H, OCH ), 3.68 (s, 3 H, CHC02CH ), 3.66 (s, 3 H, CNCOZCH ); Mass Spec.: calc.
for
[C13Hi4BrN05+H]+ Theor. m/z = 344, 346; Obs. 344, 346.
Reference Example 24b: 8-Bromo-6-methoxy-4-oxo-1,4-dihydro-quinoline-2-
carboxylic
acid methyl ester.
Dow-Therm (175 mL) was heated to 244 °C and the 2-(2-bromo-4-
methoxy
phenylamino)-but-2-enedioic acid dimethyl ester (9.50 g, 27.6 mmol) was added
as a solid in

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-66-
portions over 7 minutes while maintaining a temperature of 230-240 °C.
The brown reaction
mixture was heated at 240-245 °C for 45 minutes and then cooled to room
temperature. A
yellow precipitate formed upon cooling. Approximately 100 mL of hexanes were
added to
the mixture and the solids were isolated by filtration, washed with additional
hexanes, and
dried under high vacuum to afford the product as a yellow solid (6.73 g,
78%).'H NMR (300
MHz, DMSO; d6) 8 12.01 (s, 1 H, NHS, 7.86 (d, 1 H, Jm 2.7 Hz, ArH ), 7.52 (s,
1 H, C=CH),
7.48 (d, 1 H, Jm 2.7 Hz, ArH7), 3.93 (s, 6 H, OCH and C02CH ); Mass Spec.:
calc. for
[CizHioBrN04+H]+ Theor. m/z = 312, 314; Obs. 312, 314.
Reference Example 24c: 8-Bromo-6-methoxy-4-(2-trimethylsilanyl-ethoxymethoxy)-
quinoline-2-carboxylic acid methyl ester.
A brown solution of 8-bromo-6-methoxy-4-oxo-1,4-dihydro-quinoline-2- .
carboxylic acid methyl ester ( 6.73 g, 21.6 mmol) in 100 mL N-methyl
pyrolidinone was
treated with sodium hydride (60% dispersion in oil, 1.028 g, 25.7 mmol). Gas
evolution and
warming were observed. The reaction was stirred for 10 minutes at room
temperature under
nitrogen. Addition of 2-(trimethylsilyl)ethoxymethyl chloride (5.00 mL, 28.3
mmol) resulted
in a slightly cloudy, light brown solution. After 2.5 hours at room
temperature, the reaction
mixture was poured into 800 mL water and stirred for 15 minutes. The resulting
cream
colored precipitate was isolated by filtration, washed with water, and dried
under high
vacuum to afford the product as a cream colored solid (9.70 g, quantitative
yield): 1H NMR
(300 MHz, DMSO, d6) 8 7.976 (d, 1 H, Jm 2.7 Hz, ArH7), 7.79 (s, 1 H, C=CH),
7.53 (d, 1 H,
Jm 2.7 Hz, ArH ), 5.70 (s, 2 H, OCH O), 3.99 (s, 6 H, OCH and COzCH ), 3.88
(t, 2 H, J
8.0 Hz, OCH CHZSi), 0.97 (t, 2 H, J-- 8.0 Hz, OCH2CH Si), ), -0.04 (s, 9 H,
Si(C H3) 3; Mass
Spec.: calc. for [C18Ha4BrNO5Si+H]+ Theor. mlz = 442, 444; Obs. 442, 444.
Reference Example 25
,O
~H

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-67-
Preparation of 6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-oxo-1,4-dihydro-
quinoline-
2-carboxylic acid.
Reference Example 25a: 6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-(2-
trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester.
To a clear, light brown solution of 2-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (1.01 g, 2.28 mmol), N-
methylhomopiperazine (0.32 mL, 2.57 mmol), and 41~ sieves in 30 mL anhydrous
toluene
was added Pda (dba) a (43.8 mg, 0.048 mmol) and BINAP (159.8 mg, 0.27 mmol).
The
resulting wine colored solution was treated with cesium carbonate (1.124 g,
3.45 mmol). The
reaction mixture was heated at reflux under nitrogen for 21 hours. The pea
green reaction
mixture was cooled to room temperature and concentrated. The crude mixture was
purified
by flash chromatography on silica gel using a gradient of 95:5 to 40:60
methylene chloride:
methanol to afford the desired product as a yellow foam (1.004 g, 92%). 1H NMR
(300 MHz,
DMSO, d6) S 7.67 (s, 1 H, ArH ), 6.94 (d, 1 H, Jm 2.4 Hz, ArH ), 6.66 (d, 1 H,
Jm 2.4 Hz,
ArH7), 5.60 (s, 2 H, OCH O), 3.94 (s, 3 H, C02CH ), 3.88 (s, 3 H, OCH ), 3.82
(t, 2 H, J-- 8.0
Hz, OCH CH2Si), 3.75 (bs, 4 H, ArNCH CH2CH2NCH3 & ArNCH CH2N-CH3), 3.45 (bs, 2
H, ArNCH2CH NCH3), 3.31 (bs, 2 H, ArNCH2CHzCH NCH3), 2.83 (s, 3 H, NCH ), 2.28
(bs, 2 H ArNCH2CH CH2NCH3), 0.92 (t, 2 H, J-- 8.0 Hz, OCH2CH Si), -0.04 (s, 9
H, Si(C
H ) 3; Mass Spec.: calc. for [Ca4H37N305Si+H]+ Theor. m/z = 476; Obs. 476.
Reference Example 25b: 6-Methoxy-8-(4-methyl-[1,4]diazepan-I-yl)-4-oxo-1,4-
dihydro-
quinoline-2-carboxylic acid.
To a light brown solution of 6-methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-(2-
trimethylsilanyl-ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (1.00
g, 2.10
mmol) in 18 mL 3:1:1 tetrahydrofuran:methanol:water was added lithium
hydroxide'
monohydrate (0.267 g, 6.35 mmol). The reaction mixture was stirred at room
temperature for
5 hours, acidified to pH 4 with 1 N HCI, and stirred an additional 20 minutes.
The reaction
mixture was concentrated and dried under high vacuum to afford an orange foam.
'H NMR
(300 MHz, DMSO, d6) 811.06 (s, I H, N~, 7.53 (s, 1 H, C=Cue, 7.00 (d, 1 H, Jm=
2.4 Hz,
ArHs), 6.70 (d, f H, Jm 2.4 Hz, ArH7), 4.05-3.99 (m, 2 H, ArNCH CHaCH2NCH3),
3.87 (s,
3 H, OCH ), 3.68-3.60 (m, 2 H, ArNCH CH2NCH3), 3.54-3.47 (m, 2 H, ArNCH2CH
NCH3),
3.41-3.26 (m, 2 H, ArNCHaCH2CH NCH3), 2.82 (d, 3 H, J 4.8 Hz, NCH ), 2.46-2.41
(m, 1

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-68-
H ArNCHZCH CH2I~CH3), 2.30-2.25 (m, 1 H ArNCH2CH CH2NCH3); Mass Spec.: calc.
for
[Ci7HziN304+H]+ Theor. mlz = 332; Obs. 332.
Reference Example 26
F
i
Preparation of 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-
quinoline-2-
carboxylic acid.
This compound was prepared via the same procedure described for preparation of
Reference
Example 25.
Reference Example 27
~Si~
O
~O
\ \ H
/ N . N
N
N O /
N ~O
~
Preparation of 6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
Reference Example 27a: 8-Bromo-6-methoxy-4-oxo-1,4-dihydro-quinoline-2-
carboxylic
acid.
To a light brown solution of 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example
24c) (4.98 g,
11.3 mmol) in 75 mL 3:1:1 tetrahydrofuran:methanol:water was added lithium
hydroxide

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-69-
monohydrate (1.367 g, 32.6 mmol). The reaction was stirred at room temperature
for 5 hours.
The reaction mixture was concentrated and then poured into water. The solution
was
acidified to pH 2 with 1 N HCl and the resulting solids were isolated by
filtration. The solids
were then suspended in methanol and filtered to afford the desired product
(2.6732 g, 80%).
An additional 0.5768 g (17%) of product was obtained from the methanol
filtrates. 'H NMR
(300 MHz, DMSO, d6, TFA Shake) 8 7.86 (d, 1 H, Jm 2.7 Hz, ArH ), 7.55 (d, 1 H,
Jm= 2.7
Hz, ArH7), 7.32 (s, 1 H, C=CH , 3.94 (s, 3 H, OCH ); Mass Spec.: talc. for
[C~ 1H$BrN04+H]+ Theor. mlz = 298, 300; Obs. = 298, 300.
Reference Example 27b: 8-Bromo-6-methoxy-4-oxo-1,4-dihydro-quinoline-2-
carboxylic
acid (4-morpholin-4-yl-phenyl)-amide.
To a yellow suspension of 8-brbrno-6-methoxy-4-oxo-1,4-dihydro-quinoline-
2-carboxylic acid (Reference Example 27a) (3.446g, 11.56 mmol), TBTU (9.039 g,
28.15
mmol), and HOBt ( 3.757 g, 27.8 mmol) in 100 mL dimethylformamide was added 4-
morpholinoaniline ( 2.733 g, 15.3 mmol) and diisopropylethyl amine (8.2 mL,
50.2 mmol).
The resulting marroon solution was stirred at room temperature under nitrogen
for 16 hours
during which time the reaction became greenish brown and formed a large amount
of
precipitate. The reaction mixture was filtered and the solids washed with
dimethylformamide,
water, and methanol: Drying under high vacuum afforded the desired product as
a yellow
solid (3.09 g, 58%). 1H NMR (300 MHz, DMSO, d6) 8 12.13 (s, 1 H, NHJ, 10.18
(s, 1 H,
C(O)NHJ, 7.90 (d, 1 H, Jm 2.7 Hz, ArH~, 7.68 (d, 2 H, Jo 9.0 Hz, ArH ~& H6~),
7.63 (s, 1,
H, C=CH), 7.51 (d, 1 H, Jm 2.7 Hz, ArH7), 7.00 (d, 2 H, Jo 9.0 Hz, ArH ~&y),
3.94 (s, 3
H, OCH ), 3.75 (t, 4 H, J-- 4.8 Hz, OCH CH2N), 3.10 (t, 4 H, J-- 4:8 Hz,
OCH2CH N); Mass
Spec.: talc. for [C21H2oBrN304+H]+ Theor. m/z = 458, 460; Obs. = 458, 460.
Reference Example 27c: 8-Bromo-6-methoxy-4-(2-trimethylsilanyl-ethoxymethoxy)-
quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
A yellow suspension of 8-bromo-6-methoxy-4-oxo-1,4-dihydro-quinoline-2-
carboxylic acid (4-morpholin-4-yl-phenyl)-amide (Reference Example 27b) (3.092
g, 6.75
mmol) in 40 mL N-methylpyrolidinone was treated with sodium hydride (60%
dispersion in
oil, 0.410 g, 10.24 mmol). Gas evolution and warming were, observed and the
suspension
became light brown and almost clear. The reaction was stirred for 10 minutes
at room
temperature under nitrogen. Addition of the 2-(trimethylsilyl)ethoxymethyl
chloride (1.6 mL,
9.1 mmol) resulted in a slightly cloudy, lighter brown solution. After 4.5
hours at room

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 70 -
temperature, the reaction mixture was poured into 300 mL water, stirred for 15
minutes and
then stored at 0 °C overnight. The solids were isolated by filtration,
suspended in methanol,
filtered again, and dried under high vacuum to afford the product as a yellow
solid (3.190 g,
80%). 1H NMR (300 MHz, DMSO, d6) 8 10.18 (s, 1 H, C(O)NS, 7.95 (d, 1 H, Jm 2.4
Hz,
ArH,, 7.83 (s, 1 H, ArH ), 7.69 (d, 2. H, Jo 9.0 Hz, ArH2~& H6~), 7.51 (d, 1
H, Jm 2.7 Hz,
ArHs), 7.00 (d, 2 H, Jo 9.0 Hz, ArH ~& H5~), 5.69 (s, 2 H, OCHaO), 3.95 (s, 3
H, OCH3), 3.85
(t, 2 H, J-- 8.0 Hz, OCH CHZSi), 3.75 (t, 4 H, J-- 4.7 Hz, OCH CHZN), 3.10 (t,
4 H, J-- 4.7
Hz, OCHZCH N), 0.94 (t, 2 H, J-- 8.0 Hz, OCH2CH Si),.-0.04 (s, 9 H, Si(C'H )
3; Mass Spec.:
calc. for [C27Hs4BrN305Si+H]+ Theor. m/z = 588, 590; Obs. = 588, 590.
Reference Example 27d: 6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-(2-
trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
To a yellow-green suspension of 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid (Reference Example 27c) (4-
morpholin-4-yl-
phenyl)-amide (1.155 g, 1.96 mmol), N-methyl homopiperazine (0.39 mL, 3.14
mmol), and 4
1~ sieves in 30 mL anhydrous toluene was added Pd2 (dba) 2 (90.0 mg, 0.098
mmol) and
BINAP (0.358 g, 0.58 mmol). The resulting reddish brown mixture became lighter
in color
upon treatment with cesium carbonate (2.544 g, 7.81 mmol). The reaction
mixture was
heated at reflux under nitrogen fox 17 hours. The clear brown solution was
cooled to room
temperature, concentrated, and then purified by flash chromatography on silica
gel using a
slow gradient of 9f:5 to 50:50 methylene chloride:rnethanol to afford the
desired product
(0.989 g, 81 %). lI-I NMR (300 MHz, DMSO, dg) 8 9.88 (s, 1 H, N~, 7.73 (s, 1
H, ArH ),
7.68 (d, 2 H, Jo 8.9 Hz, ArH >& H6~), 7.00 (d, 2 H, Jo 8.9 Hz, ArH ~& H5~),
6.94 (d, 1 H,
Jm 2.7 Hz, ArH ), 6.66 (d, 1 H, Jm 2.7 Hz, ArH7), 5.62 (s, 2 H, OCH20), 3.87
(s, 3 'H,
OCH ), 3.80(t, 2 H, J-- 8.0 Hz, OCH CH2Si), 3.73 (t, 4 H, J-- 4.7 Hz, OCH
CHZN), 3.63 .(t, 2
H, J-- 5.9 Hz, ArNCH CHaCH2NCH3), 3.33 (bs, 2 H, ArNCH CHZNCH3), 3.09~(t, 4 H,
J--
4.7 Hz, OCHZCH N), 2.97 (bs, 2 H, ArNCHZCH NCH3), 2.69 (bs, 2 H,
ArNCHZCH2CH NCH3), 2.35 (s, 3 H, NCH ), 2.09 (bs, 2 H ArNCH2CH CH2NCH3), 0.94
(t,
2 H, J-- 8.0 Hz, OCHZCH Si), -0.03 (s, 9 H, Si(C H3) 3; Mass Spec.: calc. for
(C33H47NsOsSi+H)+ Theor. m/z = 622; Obs. = 622.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-71-
Reference Example 28
\../
/O
\ \ .
H
/ _ i N
N ~ i\
0
N
~O
Preparation of 8-Bromo-4-dimethylamino-6-methoxy-quinoline-2-carboxylic acid
(4-
morpholin-4-yl-phenyl)-amide.
Reference Example 28a: 8-Bromo-4-chloro-6-methoxy-quinoline-2-carboxylic acid
(4-
morpholin-4-yl-phenyl)-amide.
A suspension of 8-bromo-6-methoxy-4-oxo-1,4-dihydro-quinoline-2-carboxylic
acid
(Reference Example 27b) (1.75 mmol) in 20 mL methylene chloride was treated
with oxalyl
chloride (1.5 mL, 17.2 mmol) and catalytic dimethylformamide (3 drops). The
reaction
mixture bubbled vigorously and became clearer. The reaction was heated at
reflux for 2
hours, cooled to room temperature, and concentrated to a pale yellow solid
(kept under
nitrogen).
To a yellow solution of the acid chloride in 20 mL methylene chloride was
added 4-
morpholinoaniline (0.347 g, 1.94 mmol) and diisopropylethyl amine (1.0 mL, 6.1
mmol). The
solution became orange and gas evolution was observed. Within 30 minutes,
solids began to
precipitate from the solution. The reaction was stirred at room temperature
for 1 hour. The
solids were isolated by filtration and dried under high vacuum to afford the
desired product
(0.406 g, 49%). 1H NMR (300 MHz, DMSO, d6) b 10.15 (s, 1 H, C(O)NS, 8.33 (s, 1
H,
ArH ), 8.10 (d, 1 H, Jm 2.7 Hz, ArH,,, 7.70 (d, 2 H, Jo 9.0 Hz, ArH ~& H6.),
7.56 (d, 1 H,
Jm 2.7 Hz, ArH ), 7.01 (d, 2 H, Jo 9.0 Hz, ArH >& H5.), 4.06 (s, 3 H, OCH ),
3.75 (t, 4 H, J--
4.8 Hz, OCH CHZN), 3.11 (t, 4 H, J 4.8 Hz, OCHaCH N); Mass Spec.: calc. for
[CaiHi9BrC1N303+H]+ Theor. m/z = 476, 478; Obs. = 476, 478.
Reference Example 28b: 8-Bromo-4-dimethylamino-6-methoxy-quinoline-2-
carboxylic
acid (4-morpholin-4-yl-phenyl)-amide.
A solution of 8-bromo-4-chloro-6-methoxy-quinoline-2-carboxylic acid (4-
morpholin-4-yl-phenyl)-amide (Reference Example 28a) (0.1512 g, 0.317 mmol) in
100 mL

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-72-
2.0 M dimethyl amine in tetrahydrofuran was heated at 100 °C in a Parr
bomb. The initial
pressure was 75-80 psi and then remained at approximately 60 psi. After 18
hours, the
reaction was cooled to room temperature, concentrated and dried to afford the
crude product
as a brown solid. Purification on silica gel using a gradient of 100:0 to 95:5
methylene
chloride:methanol afforded the clean product (0.142 g, 92%). IH NMR (300 MHz,
DMSO,
d6) 810.20 (s, 1 H, C(O)NS, 7.90 (d, 1 H, Jm 2.7 Hz~ ArH~, 7.69 (d, 2 H, Jo
9.0 Hz,
ArH ~& H6~), 7.60 (s, 1 H, ArH ), 7.41 (d, 1 H, Jm 2.7 Hz, ArH7), 7.01 (d, 2
H, Jo 9.0 Hz,
ArH ~& H5~), 3.96 (s, 3 H, OCH ), 3.75 (t, 4 H, J 4.8 Hz, OCH CH2N), 3.10 (t,
4 H, J-- 4.8
Hz, OCHZCH N), 3.08 (s, 6 H, N(CH ) 2); Mass Spec.: calc. for
[C21H~9BTC1N3O3+H]+ Theor.
m/z = 485, 487; Obs. = 485, 487
Reference Example 29
i
C")
Preparation of 6-Fluoro-4-methoxy-8-(4-methyl-piperazin-1-yl)-quinoline-2-
carboxylic
acid
Reference Example 29a: .8-Bromo-6-fluoro-4-methoxy-quinoline-2-carboxylic acid
methyl
ester
Into a 150 mL 3 neck round bottom flask equipped with a reflux condenser,
magnetic
stirrer and nitrogen inlet is placed 2.0 g (6.76 mmol, 1.0 equiv.) of 8-Bromo-
6-fluoro-4-oxo-
1,4-dihydro-quinoline-2-carboxylic acid methyl ester. This material is then
dissolved in 50
mL of NMP. Then 300 mg (7.44 mmol, 1.1 equiv.) of a 60% dispersion of sodium
hydride in
oil is cautiously added portion-wise to the solution at room temperature. A
yellow color then
develops, indicating that formation of the anion has occurred, with hydrogen
evolution.
Stirnng of the anion solution is continued for one hour, then 1.14 g, 500 ~,L
(8.04 mmol, 1.2
equiv.) of iodomethane is added via syringe. The mixture is allowed to react
for two hours
additional, then is cautiously quenched with 20 mL of water. The solids, which
precipitate
upon dilution in 1L of water, are collected by filtration, then washed with
water to give the
pure O methylated material as 2.1 g (98%) of a colorless solid.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 73 -
Mass Spec.: calc. for [C12H9BrFN03+H]+,Theor. m/z = 314, 316; Obs. = 314, 316
Alternatively, into a 100 mL 3 neck round bottom flask equipped with a reflux
condenser, nitrogen inlet and magnetic stirrer is placed 350 mg (1.17 mmol,
1.0 equiv.) of 8-
Bromo-6-fluoro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid methyl ester and
242 mg
(1.75 mmol, 1.5 equiv.) of K2C03. This material is suspended in 20 mL of DMSO
then
heated to 70 °C for 1 hr. The anion formation of the anion is apparent
when the mixture
becomes cloudy. The mixture is allowed to cool to 35 °C then 331 mg,
145 ~.L (2.33 mmol,
2.0 equiv.) of methyl iodide are added and stirring is continued for 2 hr. At
the end of this
time it is determined if the reaction is complete by LC/MS. Upon completion
the mixture is
poured into 200 mL of water and the solids which form are collected by
filtration and washed
with water to give 340 mg (93%) of the O-methylated product after drying.
Reference Example 29b: 6-Fluoro-4-methoxy-8-(4-methyl-piperazin-1-yl)-
quinoline-2-
carboxylic acid methyl ester
Into a 250mL, 3 neck round bottom flask equipped with a reflux condenser,
magnetic
stirrer and nitrogen inlet is added 2.1 g (6.68 mmol, 1.0 equiv.) of 8-Bromo-6-
fluoro-4-
methoxy-quinoline-2-carboxylic acid methyl ester (Reference Example 29a) (122
mg, 0.134
mmol, 0.02, equiv.) of tris dibenzylidineacetone dipalladium, 499 mg (0.802
mmol, 0.12
equiv.) ~of racemic 2,2'-bis(diphenylphosphino)-l,l'-binapthyl and 1g of 4 A
molecular sieves
and 80 mL of dry toluene. To the stirred suspension is then added 736 mg, 815
~,L, (7.35
mmol, 1.1 eq'uiv.) of 1-methylpiperazine, followed by 3.05 g (9.35 mmol, 1.4
equiv.) of
cesium carbonate. The~mixture is then heated to 80 °C for 36 hr. At the
end of this time
completion was monitored by LC/MS analysis of an aliquot. When the reaction
was
determined to be complete it was cooled to room temperature then filtered
through a plug of
celite, with toluene washing to remove solid by products. Purification by
flash
chromatography using a gradient of 5 to 20% methanol in methylene chloride as
eluent
yielded 2.0 g, (90%) of the desired product. Mass Spec.: calc. for
[Cl7Ha°FN303+H]+ Theor.
m/z = 334; Obs. = 334
Reference Example 29c: 6-Fluoro-4-methoxy-8-(4-methyl-piperazin-1-yl)-
quinoline-2-
carboxylic acid
Into a 125 mL erlenmeyer flask containing 30 mL of THF and 30 mL of methanol
is
placed 2.1 g (6.3 mmol) of 6-Fluoro-4-methoxy-8-(4-methyl-piperazin-1-yl)-
quinoline-2-
carboxylic acid methyl ester (Reference Example 29b). To this solution is
added with stirring

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-74-
30 mL of water in which is dissolved 291 mg (6.9 mmol, 1.1 equiv.) of lithium
hydroxide
monohydrate. This solution is allowed to react for 1 hr then is quenched with
10 mL of 2N
HCl solution. The solution is then filtered and the solids washed with 10 mL
of 0.5 N HCl
solution. The combined filtrates are then concentrated to give 2.15 g, (95%)
of the solid
. yellow product as the hydrochloride salt. Mass Spec.: calc. for
[C16H~$FN303+H]~ Theor. m/z
= 320; Obs. = 320

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-75-
Example 1
N
N O ~ /
N
N ~O
8-(4-methyl-1-piperazinyl)-N [4-(4-morpholinyl)phenyl]-4-oxo-4H chromene-2-
carboxamide.
8-(4-methyl-1-piperazinyl)-4-oxo-4H chromene-2-carboxylic acid hydrochloride .
(Reference Example 1) (400 mg, 1.23 mmol) was suspended in anhydrous N,N
dimethylformamide (20 ml) and triethylamine (0.69 ml, 4.92 mrnol) was added to
give a clear
solution. The following were added in order: 1-hydroxybenzotriazole (HOBt (205
mg, mol)),
O-(1H-Benzotriazol-1-yl)-N,N,N',N'-pentamethylene-uronium tetrafluoroborate
(TBTU (435
mg, 3.1 mmol)) then 4-(dimethylamino)pyridine (25 mg). After stirring for 5
min at room
temperature, 4-(4-morpholinyl)aniline (Reference Example 21) (220 mg, mmol).
The
reaction stirred overnight at room temperature. The~solution was concentrated
ih vacuo, the
remains were partitioned between chloroform / saturated sodium bicarbonate,
extracted (x3)
with chloroform, dried (MgS04) and concentrated in vacuo to give the crude
product.
Chromatography on silica (230 - 400 mesh ASTM) and eluting ethyl acetate
followed
by 2.5-5% methanol / chloroform gave 190 mg ( % yield) of 8-(4-methyl-1-
piperazinyl)-N
[4-(4-morpholinyl)phenyl]-4-oxo-4H benzochromene=2-carboxamide as a yellow
solid (mp
217-218° decomposition and melt 244-247C). LC/MS (M+1) m/z = 449.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-76-
Examule 2
p ~I
I \ I hN \
NJ /p
i
N O
N
2-{ 1-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-methanoyl }-8-(4-methyl-piperazin-
1-yI)-
chromen-4-one.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 1-(2-
Methoxy-phenyl)-piperazine (Aldrich) via the same procedure used in example l,
yielding a
yellow solid. MS (M+H) m/z = 463.
Example 3
O ~I
\ ~N \ . N
~ C N\/' / O
_O
N O
2- f 1-[4-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-piperazin-1-yl]-methanoyl}-8-(4-
methyl-
piperazin-1-yl)-chromen-4-one.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 1-(6-Piperazin-1-yl-
2,3-dihydro-
indol-1-yl)-ethanone (Reference Example 8) as prepared in Example l, yielding
a yellow
solid. MS (M+H) m/z = 516.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-77-
Example 4
O / CI
I ~N CN
/ O NJ
I
N O
N
I
2-Chloro-5-(4-{ 1-[8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-
methanoyl}-
piperazin-1-yl)-benzonitrile. .
S This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 2-chloro-5-piperazin-
1-yl
benzonitrile (Reference Example 9) as prepared in Example 1, yielding a yellow
solid. MS
(M+H) m/z = 493.
Example 5
/. I Ow
I~ I ~N
/ O NJ
N O
N
2-{ 1-[4-(4-Methoxy-phenyl)-piperazin-1-yl]-methanoyl}-8-(4-methyl-piperazin-1-
yl)-
chromen-4-one.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available (Aldrich)
1-(4-Methoxy-phenyl)-piperazine as prepared in example l, yielding a yellow
solid. MS
(M+H) m/z = 463.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
_~8_
Example 6
~HJ
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (5-furan-2-yl-
1H-pyrazol-
3-yl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-
carboxylic acid hydrochloride (Reference Example 1) and commercially available
5-furan-2-
yl-1H-pyrazol-3-ylamine (Maybridge) as prepared in example 1, yielding a
yellow solid. MS
(M+H) m/z = 420.
Example 7
0
~ i o~
N o I,
C~
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-imidazol-1-
yl-phenyl)-
amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 4-
imidazol-1-yl-phenylamine (Aldrich) as prepared in Example l, yielding a
yellow solid. MS
(M+H)m/z = 430.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 79 -
Example 8
O S~N~
N
\ \
/ O ~ N I /
N O
c~
'N
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
[1,2,3]thiadiazol-5-yl-
phenyl)-amide. .
. This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 4-[1,2,3]thiadiazol-
5-yl-
phenylamine (Reference Example 10) as prepared in Example 1, yielding a yellow
solid. MS
(M+H)m/z = 448.
Example 9
O
\ \
~, o~ N ~, S,
N O I NN
C~
N
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid 4-
[1,2,3]thiadiazol-5-yl-
benzylamide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available
(Maybridge) 4-[1,2,3]thiadiazol-5-yl-benzylamine as prepared in Example 1,
yielding a
yellow solid. MS (M+H) mlz = 462.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
._$~_
Example 10
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-acetyl-
piperazin-1-
yl)-phenyl]-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 1-[4-(4-amino-
phenyl)-piperazin-
1-yl]-ethanone (Reference Example 11) as prepared in Example l, yielding a
yellow solid.
MS (M+H) m/z = 499.
Example 11
O
N \
N O. ~ ~ N
N ~N\S/
i, y
O O
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-
methanesulfonyl-
piperazin-1-yl)-phenyl]-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 4-(4-methanesulfonyl-
piperazin-
1-yl)-phenylamine (Reference Example 12) as prepared in Example 1, yielding a
yellow solid.
MS (M+H) m/z = 526.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-81-
Example 12
O
/ O II N \
N O ~ / N
~O
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (2-methoxy-4-
morpholin-
4-yl-phenyl)-amide.
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride
(Reference Example 1) (0.10 g, 0.35mmo1), HOBt (0.10 g, 0.7mmol), TBTU (0.225
g,
0.7mrno1), 4-(dimethylamino) pyridine (0.01 g, catalytic amount),
triethylamine (0.15 mL,
1.04mmol), and commercially available 2-methoxy-4-morpholin-4-yl-phenylamine
(SALOR)
(0.08 g, 0.38mmo1) were dissolved in dimethylformamide (2.5 mL) and stirred at
room
temperature overnight. Ethyl acetate (150 mL) was added and the resulting
mixture was
washed with water (3 x SO.mL), dried (Na2S04), filtered, concentrated under
vacuum and
triturated with ether to yield a yellow solid (85 mg, 54%). LCMS: mlz = 480.3
Example 13
O
/ ~ N \ CI
O
N ~ ~ / N
N ~O
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-chloro-4-
morpholin-4-
yl-phenyl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 3-chloro-
4-morpholin-4-yl-phenylamine (Maybridge) as prepared in Example 12, yielding a
yellow
solid. (110 mg = 73%), LCMS - m/z = 483.5

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-82-
Example 14
O
O ~ N \
N O ~ ~ N
N ~ ~S
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
thiomorpholin-4-yl-
phenyl)-amide;
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 4-thiomorpholin-4-yl-
phenylamine (Reference Example 13) as prepared in Example 12, yielding a
yellow solid. (55
mg = 38%), LCMS - m/z -- 465.5
Example 15
O
~ O ~ N \
N O O ( ~ N
N ~ ~O
.
8-(4-Methyl-piperazin 1-yl)-4-oxo-4H-chromene-2-carboxylic acid (2,5-diethoxy-
4-
morpholin-4-yl-phenyl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 2,5-
diethoxy-4-morpholin-4-yl-phenylamine (Aldrich) as prepared in Example 12,
yielding a
yellow solid. (80 mg = 50%), LCMS - m/z = 537.6

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-83-
Example 16
N
N
8-(4-Methyl-piperazin-I-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-cyanomethyl-
phenyl)-
amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available (4-
amino-phenyl)-acetonitrile (Aldrich) as prepared in Example 12, yielding a
yellow solid. (65
mg = 54%), LCMS - m/z = 403.5
Example 17
~NJ
8-(4-Methyl-piperazin-I-yI)-4-oxo-4H-chromene-2-carboxylic acid (1H-indol-5-
yl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 1H-
indol-5-ylamine (Aldrich) as prepared in Example 12, yielding a yellow solid.
(35 mg =
29%), LCMS - m/z = 401.6
Example 18
0
~ a~. N ~ o
N o
C~
N O

CA 02433950 2003-07-08
WO 02/055013 . PCT/SE02/00069
-84-
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(1-
morpholin-4-yl-
methanoyl)-phenyl]-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 1-(4-amino-phenyl)-1-
morpholin-4-yl-methanone (Reference Example 14) as prepared in Example 12,
yielding a
yellow solid. (21 mg = 15%), LCMS - m/z = 477.6
Examine 19
~J
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(2,6-
dimethyl-
morpholin-4-yl)-phenyl]-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 4-(2,6-
dimethyl-morpholin-4-yl)-phenylamine (Maybridge) as prepared in Example 12,
yielding a
yellow solid. (60 mg = 42%), LCMS - mlz = 477.6
Example 20
~O~N ~ \ / ~ F
N O / \
O
N
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-fluoro-
phenoxy)-
phenyl]-amide
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 4-(4-

CA 02433950 2003-07-08
WO 02/055013 . PCT/SE02/00069
-85-
fluoro-phenoxy)-phenylamine (Maybridge) as prepared in Example 12, yielding a
yellow
solid. (110 mg = 77%), LCMS - m/z = 475.6
Example 21
O
0 0
N O
N
8-(4-Methyl-piperazin-1-yl)-2-(6-morpholin-4-yl-benzooxazol-2-yl)-chromen-4-
one.
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride
(Reference Example 1) (0.532 g, 1.85mmol) was placed in a 25 mL 3-neck flask
under
nitrogen and treated with PPA (6 g). The mixture was then treated with the
prepared
intermediate 4-amino-3-hydroxyphenylmorpholine (0.43 g of ~85% pure, ~2mmo1).
The
mixture was stirred and heated in an oil bath to 205°C for 3 hours to
give a dark liquid. The
mixture was cooled to room temperature and treated with 10 mL of water to give
a dark
solution. The solution was slowly neutralized with 1N aqueous sodium hydroxide
to pH~7 as
a solid formed. The solid was collected, washed several times with water, air
dried, and
vacuum dried at room temperature to give 0.65 g of a black solid. TLC (10%MeOH
in CHCl3
on Si02) showed 2 major components at R~0.5 and several lower Rfminor
components. The
solid was triturated with°saturated aqueous sodium bicarbonate at room
temperature. It was
filtered off, washed several times with water, and air dried to give 0.65 g of
a dark gray solid.
TLC showed the same components seen previously. Mass spectral analysis showed
m/e = 447
by positive ion CI and m/e = 446 by negative ion CI. The solid was dissolved
in 2% methanol
in chloroform and it was chromatographed on a Megabond Elute silica gel column
(10 g of
Si02) using 2% methanol in chloroform. The slightly faster Rf yellow component
was
concentrated to give 0.0188 g of a yellow solid. CI mass spectral analysis
showed m/e = 447
as the base peak by positive ion CI. The solid was recrystallized in methanol
to give 0.0178 g
of a yellow solid with a melting point of 158.1-158.8°C. Proton NMR
(CDCl3) and CI mass
spectral analyses were consistent for the desired product (mlz = 447 base peak
by positive ion
CI and mlz = 446 base peak by negative ion CI).

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-86-
ExamuTe 22
IY
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (2-hydroxy-4-
morpholin-
4-yl-phenyl)-amide.
S 8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid
hydrochloride
(Reference Example 1) (0.3768 g, 1.16 mmol) was placed in a 100 mL 3-neck
flask under
nitrogen and it was dissolved in 20 mL of DMF. The solution was treated with
triethylamine
(0.49mL, 3.Smmol) followed by HOBT hydrate (0.36g, 2.3mmo1) followed by TBTU
(0.74 g,
2.3mmol) and then followed by DMAP (0.020 g). The mixture was sfirred for 10
minutes and
then it was treated with 4-amino-3-hydroxyphenylmorpholine (Reference example
21) (0.228
g, 1. I7 mmol). The mixture was stirred for 1 S minutes and then it was
treated with
triethylamine (0.17 mL, 1.2 mmol). The mixture was stirred at room temperature
for 42
hours and then it was added to a solution of SO mL of saturated aqueous sodium
bicarbonate
. and SO mL of water. The mixture was extracted 4 times with ethyl acetate,
dried over
1 S magnesium.sulfate, filtered, and concentrated to give 0.834 gram of a
purple oil. The oil was
dissolved in 2 percent methanol in chloroform and it was placed on a silica
gel column (S.S
cm diameter by 10.5 cm long) and eluted with 2 percent methanol in chloroform
followed by
S percent methanol in chloroform. The yellow fraction was concentrated to give
0.2031 gram
of an orange-yellow solid. The solid was dissolved in methanol, filtered
through a medium
sintered glass funnel, and concentrated to a few ml volume as a solid formed.
The solid was
filtered off, washed with methanol, and air dried to give 0.1613 gram of a tan
solid with MP
of 248.4 - 249.6°C. Proton COSY NMR and CI mass spectral analyses were
consistent for
the desired product (m/z = 46S by positive ion CT and m/z = 463 by negative
ion CI).

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
_8~_
Example 23
O
i o~ N s
~~ / v
C~
;.
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (5-ethoxy-
benzothiazol-2-
yl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 5-ethoxy-
benzothiazol-2-ylamine (SALOR) as prepared in Example 12, yielding a yellow
solid. (55 mg
= 39%), LCMS - m/z = 465.3
Example 24
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-bromo-
phenyl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and commercially
available 4-bromo-
phenylamine (Aldrich) as prepared in Example 12, yielding a yellow solid. (1.0
g = 75%),
LCMS - rn/z = 442.4

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
_$$_
Example 25
8-(4-Methylpiperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid methyl-(4-
morpholin-4-yl-
phenyl)amide.
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-morpholin-4-
yl-phenyl)-amide (Example 1) (0.1046 g, 0.2332 mmol) was placed in a 10 mL
single neck
round flask under nitrogen. The solid was dissolved in 2.8 mL of anhydrous
DMF. The
yellow solution was stirred at room temperature and treated with one portion
of sodium
hydride (0.011 g of 95%, 0.44 mmol). The mixture evolved gas and became a red
solution. It
was stirred under nitrogen for 20 minutes and then it was treated with
iodomethane (0.015
mL, 0.033 g, 0.233 mmol). The mixture was sealed and stirred at room
temperature for 18
hours.
The reaction mixture was concentrated to remove most of the DMF (35 C bath @
0.5
mm) to give a dark semisolid. It was treated with a few drops of water
followed by 10 mL of
ethyl acetate. The mixture was dried over magnesium sulfate, filtered, and
concentrated to
give 0.0564 gram of a yellow glass. The glass was' triturated with diethyl
ether, filtered off,
and dried under high vacuum to give 0.0302 g of a tan solid with MP of 245.0 -
246.8 C.
Proton NMR and CI mass spectral analyses were consistent for the desired
product (m/z =
463 by positive ion CI).
Example 26
O
0
/ O N \ NJ
N O ~ /
N

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-89-
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-morpholin-4-
yl-
phenyl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example l) and 3-morpholiri-4-yl-
phenylamine
(Reference Example 18) as prepared in Example 12, yielding a yellow solid.
(120 mg = 86%),
LCMS - m/z = 449.5
Example 27
CN
~~J L
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-cyano-4-
morpholin-4-
yl-phenyl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 5-amino-2-morpholin-
4-yl-
benzonitrile (Reference Example 15) as prepared in Example 12, yielding a
yellow solid. (120
mg = 82%), LCMS - m/z = 474.5
Example 28
IV
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-fluoro-4-
morpholin-4-
yl-phenyl)-amide.
This compound was prepared from 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 3-fluoro-4-mozpholin-
4-yl-
phenylamine (Reference Example 16) as prepared in example 12, yielding a
yellow solid.
(120 mg = 83%), LCMS - m/z = 467.6

CA 02433950 2003-07-08
WO 02/055013 . PCT/SE02/00069
-90-
Examule 29
O
N \
N O ~ / N
O
N
O
4-[4-({ 1-[8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}-
amino)-phenyl]-
piperazine-1-carboxylic acid tart-butyl ester.
This compound was prepared from~8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-
2-carboxylic acid hydrochloride (Reference Example 1) and 4-(4-amino-phenyl)-
piperazine-
1-carboxylic acid tent-butyl ester (Reference Example 17) as prepared in
example 12, yielding
a yellow solid. (260 mg = 53%), LCMS - m/z = 548.6
Example 30
O
N
N O
N
N ~NH
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-piperazin-1-
yI-
phenyl)-amide.
4-[4-( ~ 1-[8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl }-
amino)
phenyl]-piperazine-1-carboxylic acid tart-butyl ester (Example 29) (160 mg,
0.3 mmol) was
dissolved ethyl acetate (20 mL) and cooled to 0°C. HCl gas was bubbled
in slowly fox 2
minutes. A solid began to precipitate. Methanol (3-4 mL) was added to dissolve
this solid
and HCl gas was bubbled in for another 2 minutes. The mixture was concentrated
under
reduced pressure and triturated with ether and dried under vacuum to yield a
tan solid (100
mg, 76%). LCMS/ m/z = 448.6

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-91-
Example 31
O
O
/ ~ N
O
N O ~ /. N
N ~O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
morpholin-
4-yI-phenyl)-amide:
6-Methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid
hydrochloride (Reference Example 2) (3.0g, 8.5 mmol), TBTU (5.5g, 17 mmol), 1-
hydroxybenztriazole (2.6g, 17 mmol), 4-dimethylaminopyridine (O.OSg,
catalytic) and
commercially available 4-morpholin-4-yl-aniline (1.66g, 9.3 mmol) were
dissolved in
dimethylformamide (100 mL). Triethylamine ( 3.5 mL, 25 mmol was added and this
mixture
stirred at room temperature for 17 hours. The reaction mixture was
concentrated under vacuum
and the residue was partitioned between chloroform (400 mL) and saturated
aqueous sodium
bicarbonate (50 mL). The organic layer was separated, dried (Na2S04), vacuum-
filtered and
concentrated under vacuum. The residue was purified by chromatography on
silica eluted with 2-
5% methanol in chloroform and then triturated with ether to yield a yellow
powder. (1.6 g = 39%)
LCMS - mlz = 479.5 mp = 234-236 °C.
Example 32
O
O
/ I N
O
N O I
N
C ~ N. ,
o S~~O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-
(4-
methanesulfonyl-piperazin-1-yl)-phenyl]-amide.
This compound was prepared from 6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 4-(4-
methanesulfonyl-

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-92-
piperazin-1-yl)-phenylamine (Reference Example 12) as prepared in example 1,
yielding a
yellow solid. GC/MS (EI, M+) rn/z = 556
Example 33
O
O
N CI
O
N O
N
N ~O
6-Methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-
chloro-4-
morpholin-4-yl-phenyl)-amide.
This compound was prepared from 6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chrornene-2-carboxylic acid hydrochloride (Reference Example 2) and
commercially
available 3-chloro-4-morpholin-4-yl-phenylamine (Maybridge) as prepared in
Example 12,
yielding a yellow solid. (45mg = 31 %) LCMS - m/z = 513.5
Example 34
O
/O
N~ \
N O
N
N ~O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-
fluoro-4-
morpholin-4-yl-phenyl)-amide.
This compound was prepared from 6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 3-fluoro-4-
morpholin-
4-yl-phenylamine (Reference Example 16) as prepared in Example 12, yielding a
yellow
solid. (SSmg = 61%), LCMS - m/z = 497.5

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
- 93 -
Example 35
/O
~~J
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (2-
methoxy-4-
morpholin-4-yl-phenyl)-amide.
This compound was prepared from 6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 2) and
commercially
available 2-methoxy-4-morpholin-4-yl-phenylamine (SALOR) as prepared in
Example 12,
yielding a yellow solid. (SSmg = 38%), LCMS - m/z = 510.5
Example 36
~O~N ~
N O ~ ~ N
N ~S
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
thiomorpholin-4-yl-phenyl)-amide.
This compound was prepared from 6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 4-
thiomorpholin-4-yl-
phenylamine (Reference Example 13) as prepared in Example 12, yielding a
yellow solid.
(99mg = 71 %), LCMS - m/z = 495.5

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-94-
Example 37
~J
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-
(2,6-
dimethyl-morpholin-4-yl)-phenyl]-amide.
This compound was prepared from 6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 2) and
commercially
available 4-(2,6-dimethyl-morpholin-4-yl)-phenylamine (Maybridge) as prepared
in Example
12, yielding a yellow solid. (70mg = 49%), LCMS - m/z = 507.5
Example 38
O .
O \
O
/ O I N \ N\/
N O I
N
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-
morpholin-
4-yl-phenyl)-amide.
This compound was prepared from 6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 3-morpholin-
4-yl~-
phenylamine (Reference Example 18) as prepared in Example 12, yielding a
yellow solid.
(80mg = 60%), LCMS - m/z = 479.5

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-95-
Example 39
,O
N
~ J ~N~\
OH
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oXO-4H-chromene-2-carboxylic acid {4-
[4-(2-
hydroxy-ethyl)-piperazin-1-yl]-phenyl ] -amide.
This compound was prepared from 6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 2-[4-(4-
amino-
phenyl)-piperazin-1-yl]-ethanol (Reference Example 19) as prepared in Example
12, yielding
a yellow solid. (80mg = 60%). mp = 211.5-212.2 (dec.), M,S - base peak at m/z
=492 by
positive ion and m/z =490 by negative ion CI
Example 40
O
O
/ O~ N \
~O
N O / N
O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-
(1-
morpholin-4-yl-methanoyl)-phenyl]-amide.
This compound was prepared from 6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
~ chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 1-(4-
amino-phenyl)-1-
morpholin-4-yl-methanone .(Reference Example 14) as prepared in Example 12,
yielding a
yellow solid. (170mg = 80%), LCMS - m/z = 507.5

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-96-
Example 41
O
O
/ I / I N
O
N O I /
N
N CN ~O
6-Methoxy-8-(4-methyl-piperazin-I-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-
cyano-4-
morpholin-4-yl-phenyl)-amide.
This compound was prepared from 6-methoxy-8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 5-amino-2-
morpholin-
4-yl-benzonitrile (Reference Example 15) as prepared in Example 12, yielding a
yellow solid.
(120mg = 57%), LCMS - m/z = 504.5
Example 42
O
/O ~ ~
I' o) N ~
N O. I / N
~N O
i .
4-[4-({ 1-[6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-
methanoyl }-
amino)-phenyl]-piperazine-1-carboxylic acid tent-butyl ester.
The 6-methoxy-8-(4-methyl-piperazin-1-yI)-4-oxo-4H-chromene-2-carboxylic acid
hydrochloride (Reference Example 2) (1.04 g, 2.93 mmol) was placed in a 250
rril 3-neck
flask under nitrogen and it was dissolved in 50 ml of DMF. The solution was
treated with
triethylamine (1.22 mL, 8.79 mmol) followed by HOBT hydrate (0.90 g, 5.9 mmol)
followed
by TBTU (1.88 g, 5.9 mmol) and then followed by DMAP (0.056 g, 0.46 mmol). The
mixture
was stirred for 10 minutes and then it was treated with 4-(4-Amino-phenyl)-
piperazine-I-
carboxylic acid test-butyl ester (Reference Example 17) (0.81 g, 2.9 mmol).
The mixture was
stirred for 15 minutes and. then it was treated with triethylamine (0.4I mL,
2.9 mmol). The

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-97-
mixture was stirred at room temperature for 18 hours and then it was
concentrated (1 mm Hg
pressure, 45 C bath) to give a dark liquid. The concentrate was treated with
80 mL of
saturated aqueous sodium bicarbonate and extracted with ethyl acetate forming
a suspended
yellow solid in the organic layer. The solid was filtered off, washed with
diethyl ether,
~ washed with water, and vacuum dried (O.lmm Hg pressure @ 25C) to give 0.36
gram of a
yellow solid, M.P. = 232.3-232.8 C.
Proton NMR and CI mass spectral analyses were consistent for the desired
product (mle =
578 by positive ion CI and m/e = 576 by negative ion CI).
The aqueous layer was extracted twice with ethyl acetate, dried over magnesium
sulfate,
filtered, and concentrated to give I.35 gram of a dark semisolid. It was
triturated with diethyl
ether and allowed to stand at room temperature as a solid formed. The solid
was filtered off,
washed with diethyl ether, and vacuum dried at room temperature to give 0.4816
gram of a
yellow solid. CI mass spectral analyses was consistent for the desired product
(M/Z = 578 BY
positive ion CI AND M/Z = 576 by negative ion CI).

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-98-
Example 43
/O
~"J
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
piperazin-
1-yl-phenyl)-amide. .
The 4-[4-({ 1-[6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]- v
methanoyl}-amino)-phenyl]-piperazine-1-carboxylic acid tent-butyl ester
(Example 42) (0.792
gram, 1.37 mmol) was placed in a 50 ml round flask under nitrogen and it was
dissolved iri 15
ml of methylene chloride. The solution was treated with 15 ml of
trifluoroacetic acid (195
mmol) to give a dark solution and it was stirred at room temperature for 18
hours. It was
concentrated to give a brown foam. The foam was treated with 30 ml of
saturated aqueous
sodium bicarbonate and it was stirred at room temperature as a yellow solid
formed. The solid
was filtered off, washed several times with water, air dried and dried under
high vacuum (0.1
mrn Hg pressure) to give 0.493 gram of a yellow solid, M.P. = 203.6-204.7 C.
Proton NMR and CI mass spectral analyses were consistent for the desired
product
(m/z = 478 by positive ion CI and m/z = 476 by negative ion CI).
Example 44-54
The following examples were prepared in parallel by acylation of 6-methoxy-8-
(4-
methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-piperazin-1-yl-
phenyl)-
amide (Example 43) in an Argonaut Quest synthesizer.
The piperazine side chain was derivatized in parallel fashion using eleven
different
commercially available acylating and sulfonating reagents. The resins used
were Argonaut
Tech polystyrene amine resins. Each 5 ml Quest tube was charged with 0.010
gram (0.021
mmol) of the starting N-H piperazine and 3m1 of methylene chloride followed by
4
equivalents (0.08 mmol) of PS-DIEA resin (diisopropylbenzylamine PS resin) to
scavenge
HCl. Each tube was then treated with an acyl chloride, sulfonyl chloride, or
isocyanate (2
equivalents of each) followed by a little more methylene chloride. The tubes
were sealed

CA 02433950 2003-07-08
WO 02/055013 . PCT/SE02/00069
-99-
under nitrogen, and stirred for 3 hours at room temperature. The mixtures were
then opened
and treated with about 4 equivalents (0.08 mmol) of PS-trisamine resin
(primary amine PS
resin) to scavenge any excess acylating or sulfonating reagent. The mixtures
were sealed and
stirred for 1.5 hours and then filtered directly into vials and concentrated
to give the products.
The products were characterized by. HPLC mass spectral analysis and were found
to be
greater than 90% pure by HPLC. The compounds were submitted to the 5-HTIb
binding
assay for determination of 5-HT receptor binding affinities and selectivities.
Example 44
O
O
/ I N
O
N O I / N
N ~N
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-
(4-
propionyl-piperazin-1-yl)-phenyl]-amide.
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-l-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available propionyl chloride (Aldrich) via the parallel synthesis described
above. MS - base
peak at m/z =534 by positive ion CI , .
Example 45
O
O
I / I N
p~
N O I
N
N ~N.
O O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chrornene-2-carboxylic acid [4-
(4-ethane
sulfonyl-piperazin-1-yl)-phenyl]-amide. MS - base peak at m/z =570 by positive
ion CI

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-1~0 -
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available ethanesulfonyl chloride (Aldrich) via the parallel synthesis
described above.
Examule 46
O
\
I / I N \
O
N O I /
N
N v N' N
O, O \
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-
(4-
dimethyl sulfamoyl-piperazin-1-yl)-phenyl]-amide.
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially.
available dimethylsulfamoyl chloride (Aldrich) via the parallel synthesis
described above. MS
-. base peak at m/z =585 by positive ion CI
Example 47
N
O
4-j4-({ 1-[6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-
methanoyl}-
amino)-phenyl]-piperazine-1-carboxylic acid dimethylamide.
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available dimethylcarbamyl chloride (Aldrich) via the parallel synthesis
described above. MS
- base peak at m/z =549 by positive ion CI

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-101-
Example 48
O
O
~ ~ N
O
N O ~ . N
N ~N N
4-[4-({ 1-[6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-
methanoyl}-
amino)-phenyl]-piperazine-1-carboxylic acid ethylamide. ,
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available ethyl isocyanate (Aldrich) via the parallel synthesis described
above.
MS - base peak at m/z =549 by positive ion CI.
Examule 49
,O
N
J - ~N
N
O
4-[4-({ 1-[6-Metho~cy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-
methanoyl}-
amino)-phenyl]-piperazine-1-carboxylic acid cyclohexylamide.
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available cyclohexyl isocyanate (Aldrich) via the parallel synthesis described
above. MS -
base peak at m/z =603 by positive ion CI

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-102-
Example 50
O
4-[4-({ 1-[6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-
methanoyl}-
amino)-phenyl]-piperazine-1-carboxylic acid cyclopentylamide.
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available cyclopentanecarbonyl chloride (Aldrich) via the parallel synthesis
described above.
MS - base peak at m/z =574 by positive ion CI.
Example 51
N
O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4-
[4-(1-
pyrrolidin-1-yl-methanoyl)-piperazin-1-yl]-phenyl } -amide.
This compound. was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-
4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available 1-pyrrolidinecarbonyl chloride (Aldrich) via the parallel synthesis
described above.
MS - base peak at mlz =575 by positive ion CI.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-103-
Example 52
O
O
(. / I N
O
N O I /
N
N ~N~S~/
O ~O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4-
[4-
(propane-2-sulfonyl)-piperazin-1-yl]-phenyl }-amide.
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide. (Example 43) and
commercially
available isopropylsulfonylonyl chloride (Aldrich) via the parallel synthesis
described above.
MS - base peak at m/z =584 by positive ion CI.
Example 53
/O
N
~ J ~N
N
O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4-
[4-(2-
methyl-propanoyl)-piperazin-1-yl]-phenyl}-amide.
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available isobutyryl chloride (Aldrich) via the parallel synthesis described
above. MS - base
peak at m/z =548 by positive ion CI.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-104-
Example 54
O
O \
/ I N \
O I ~O
N O / NJ
O
N
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid ~4-
[4-(1-
morpholin-4-yl-methanoyl)-piperazin-1.-yl]-phenyl}-amide.
This compound was prepared from 6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and
commercially
available morpholine-4-carbonyl chloride (Aldrich) via the parallel synthesis
described above.
MS - base peak at m/z =591 by positive ion CI.
Example 55 .
. O
F
I / oI N \
N O I / N
N ~.0
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
morpholin-4-
yl-phenyl)-amide.
This compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 4-morpholin-
4-yl-
phenylamine (Reference Example 20) as prepared in Example 1, yielding a yellow
solid. MS
(M+H) mlz = 467

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-105-
Example 56
F
N
~J~ ~N.~
o SvO
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-
methanesulfonyl-piperazin-I-yI)-phenyl]-amide.
This compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 4-(4-
methanesulfonyl-
piperazin-1-yl)-phenylamine (Reference Example 12) as prepared in Example l,
yielding a
yellow solid. MS (M+H) m/z = 544
Example 57
O
F
N
~O
N O
N
' I ,O
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-
acetyl-
piperazin-1-yl)-phenyl]-amide.
This compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 1-[4-(4-
amino-
phenyl)-piperazin-1-yl]-ethanone (Reference Example 11) as prepared in Example
1, yielding
a yellow solid. MS (M+H) m/z = 508

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-106-
Example 58
O
F
I / O I N ~ CI
N O I /
N
~O
N
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-
chloro-4-
morpholin-4-yl-phenyl)-amide.
. 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid
hydrochloride (Reference Example 3) (150 mg, 0.43 mmol), 1-
hydroxybenzotriazole (140
mg, 0.9 mmol), O-(1H-Benzotriazol-1-yl)-N,N,N',N'-pentamethylerie-uronium
tetrafluoroborate (290 mg, 0.9 mmol), 4-(dimethylamino)pyridine (10 mg,
catalytic),
triethylamine (0.2 mL, 1.5 mmol), and commercially available 3-chloro-4-
morpholin-4-yl-
phenylamine (Maybridge) were dissolved in dimethylformamide (2.5 mL) and
stirred at room
temperature overnight. At 17 h, water (20 mL) was added and the resulting
mixture was
stirred for 15-30 min. The mixture was vacuum-filtered and the residue washed
with water'
and a'ir-dried to yield a yellow powder (220 mg = quantitative yield). LC/MS -
m/z = 501.5
Example 59
O
F ~
N \ F
O
' N O I
N
N ' ~O .
6-Fluoro-8-(4-methyl-piperazin-I-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-
fluoro-4-
morpholin-4-yl-phenyl)-amide.
This compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-I-yl)-4-oxo-4H-
.
chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 3-fluoro-4-
morpholin-
4-yl-phenylamine (Reference Example 16) as prepared in Example 58, yielding a
yellow solid
(210 mg = 99%), LC/MS - m/z = 485.5 '

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-107-
Example 60
O
F
I / O I. N \ CN
N . O I / N
~O
C~
- N .
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-
cyano-4-
morpholin-4-yl-phenyl)-amide.
This compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yI)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 5-amino-2-
morpholin-
4-yl-benzonitrile (Reference Example 15) as prepared in Example 58, yielding a
yellow solid
(210 mg = 99%). LC/MS - m/z = 492.5
Examine 61 '
.~NJ o
~
6-Fluoro-8-(4-methyl-piperazin-1-yI)-4-oxo-4H-chromene-2-carboxylic acid [4-(1-
morpholin-4-yI-methanoyl)-phenyl]-amide.
This compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 1-(4-amino-
phenyl)-1-
morpholin-4-yl-methanone (Reference Example 14) as prepared in Example 58,
yielding a
yellow solid (220 mg = quantitative yield). LC/MS - m/z = 495.5
Example 62

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-10g-
H3
6-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
morpholin-4-
yl-phenyl)-amide.
This compound was prepared from 6-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 4) and 4-morpholin-
4-yl-
phenylamine (Reference Example 20) as prepared in Example l, yielding a yellow
solid.
LCMS - m/z = 463.6
Example 63
H3
6-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(1-
morpholin-4-yl-methanoyl)-phenyl]-amide.
This compound was prepared from 6-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 4) and 1-(4-amino-
phenyl)-1-
morpholin-4-yl-methanone (Reference Example 14) as prepared in Example 1,
yielding a
yellow solid. LCMS - m/z = 491.6
. O
f

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-109-
Example 64
H3C
IV
6-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-
fluoro-4-
morpholin-4-yl-phenyl)-amide.
, This compound was prepared' from 6-Methyl-8-(4-methyl-piperazin-l-yl)-4-oxo-
4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 4) and 3-fluoro-4-
morpholin-
4-yl-phenylamine (Reference Example 16) as prepared in Example 1., yielding a
yellow solid,
LCMS - m/z = 504.5
Example 65
~ ~o
N
6-Chloro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
morpholin-4-
yl-phenyl)-amide. _
This compound was prepared from 6-chloro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 5) and 4-morpholin-
4-yl-
phenylamine (Reference Example 20) as prepared in Example 1, yielding a yellow
solid.
LCMS - m/z = 483.3

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-11~-
Exameple 66
CH3 O
I / I N \
O
N O I ~ N
N ~O
5-Methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
morphblin-4-
yl-phenyl)-amide.
This compound was prepared from 5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chrornene-2-carboxylic acid hydrochloride (Reference Example 6) and 4-
morpholin-4-yl-
phenylamine (Reference Example 20) as prepared in Example l, yielding a yellow
solid (116
mg = 84%) LCMS- m/z = 463.5
Exam-ple 67 ~ .
w
5-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
morpholin-
4-yl-phenyl)-amide.
This compound was prepared from 5-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-
4H,
chromene-2-carboxylic acid hydrochloride (Reference Example 7) and 4-morpholin-
4-yl-
phenylamine (Reference example 20) as prepared in Example l, yielding a yellow
solid (149
mg = 50%) LCMS - m/z = 479.4
The following additional examples incorporate 4-substituted piperazine-1-yl-
phenyl amides
similar in structure to Examples 44-54

CA 02433950 2003-07-08
WO 02/055013 ~ PCT/SE02/00069
-111-
Example 68
N I
N OH,
O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4-
[4-(3-
hydroxy-propanoyl)-piperazin-1-yl]-phenyl }-amide:
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
piperazin-1-yl-phenyl)-amide (Example 43) (1.5 gram, 2.12 mmol) was placed in
a 100 mL
flask with 50 mL of CH2C12. This suspension was treated with triethylamine (4
equivalents,
1.2 mL, 8.5 mmol) and (3-propionylactone (0.2 mL, 3.2 mmol) and the reaction
stirred at room
temperature for 2 hours, then heated to 50°C for 2 hours. Then 0.8 mL
more of b-
propionylactone was added and the reaction heated for 4 hours more. The
reaction was
allowed to cool to room temperature and then concentrated (1 min Hg pressure).
The
concentrate was treated with saturated aqueous sodium bicarbonate and the
resulting solid
collected by vacuum filtration. The residue was purified by chromatography on
silica eluting
with 2% methanol in chloroform, then concentrated (lmm Hg pressure). Then
triturated with
either to yield a yellow powder with was dried under high vacuum for 48'h at
50°C (100 mg)
LCMS - m/z 550, mp = 195-197°C.
Example 69
O
F
/ of N \
N O I
N
~N O
4-[4-({ 1-[6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-
methanoyl}-amino)-
phenyl]-piperazine-1-carboxylic acid teat-butyl ester.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-112-
This compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 4 -(4-Amino-
phenyl)-
piperazine-1-carboxylic acid tent-butyl ester (Reference Example 17) according
to the method
of Example 42 to yield (1.65 grams, 64%) of a yellow powder LCMS - m/z = 556;
mp =
219-220°C. ..
Example 70
F
~NJ
4-[4-({ 1-[6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic
acid (4-
piperazin-1-yl-phenyl)-amide.
This compound was prepared from 4-[4-({ 1-[6-Fluoro-8-(4-methyl-piperazin-1-
yl)-4-
oxo-4H-chromen-2-yl]-methanoyl~-amino)-phenyl]-piperazine-1-carboxylic acid
tent-butyl
ester, as prepared in Example 69, using the method of Example 43 to yield a
yellow solid
LCMS - m/z = 466.
Example 71
O
F \
/ O ~ N . \
N O
N
C ~ N,
N ~ S~
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-
ethane
sulfonyl-piperazin-1-yl)-phenyl]-amide.
4-[4-({ 1-[6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic
acid
(4-piperazin-1-yl-phenyl)-amide ditrifluoroacetate (the free acid of which was
prepared as in
Example 70) (4.0 grams, 5.77 mmol) was placed in a flask with 50 mL of CH2Clz
and
triethylamine (3.2 mL and 23 mmol) and ethylsulfonyl chloride was added (0.6
mL, 6.35

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-113 -
mmol) portionwise (0.1 mL at a time) over 15 minutes and allowed to stir at
room
temperature for 20 hours.. The reaction was concentrated (1 mm Hg pressure)
and then
saturated aqueous sodium bicarbonate was added and extracted with CHCl3. The
organic
fractions were combined, washed with saturated sodium chloride, dried
(lVIgS04)
concentrated (1 mm Hg pressure) to give a yellow solid which was
recrystallized from'
methanol to give 1.33 grams of product LCMS - m/z = 558, mp = 233-
234°C.
Examule 72 .
F
O
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-
propionyl=
piperazin-1-yl)-phenyl]-amide.
4-[4-({ 1-[6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic
acid
(4-piperazin-1-yl-phenyl)-amide ditrifluoroacetate (the free acid of which was
prepared as in
Example 70) (0.69 grams, 1,00 mmol) was placed in a flask with 25 mL of CH2Clz
and
triethylamine (0.56 mL and 4 mmol) and propionyl chloride was added (0.95 mL,
1.1 mmol)
and the reaction allowed to stir at room temperature for 20 hours. The residue
was purif ed by
chromatography on silica eluting with 2% methanol in chloroform, then
concentrated (lmm
Hg pressure). The residue was triturated with either then digested with CHCl3
and the CHC13
concentrated to yield a yellow powder which was dried under high vacuum for 48
h at 45°C
(260 mg) LCMS - m/z = 522.
Example 73
F
N
~NJ ~N OH
O

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-114 -
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid f 4-
[4-(3-
hydroxy-propanoyl)-piperazin-1-yl]-phenyl}-amide.
This compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide and ~3-
propionylactone using the
method described above in Example 68 to yield 65 mg of a yellow powder LCMS -
m/z =
538, mp =195-199°C.
The following exemplifies a substituted chromene-2-"reverse amide" (or
substituted
chromene-2-yl-benzamide).
Example 74
IV
.
N-[8-(4-Methyl-piperazin-.1-yl)-4-oxo-4H-chromen-2-yl]-4-morpholin-4-yl-
benzamide.
8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride
Reference Example 1 (227 mg, 0.69 mmol), triethylamine (2 equivalents, 1.389
mmol, 0.193
mL) and diphenylphosphoryl azide (0.69 mmol, 0.15 rriL) were stirred in
toluene ~ ( 10 mL) at
65°C for 30 minutes. The reaction was allowed to cool to 22°C
and 4-morpholinobenzonoic
acid (0.7 mmol, 145 mg), more triethylamine.(0.051 mL, 0.7mmo1), and CH3CN (5
mL) were
added and the reaction heated to reflux for 1 hour. The reaction was
concentrated ( 1 mm Hg
pressure) the residue was partitioned between 1N methanesufonic acid.and
ether. The acid
layer was then basified with solid K2C03 and the product extracted in to
CHC13. The organic
layer was dried (MgS04) and concentrated under reduced pressure to leave a
yellow solid
which was further purified with silica chromatography using CHCl3 to 4% CH30H
in CHCl3.
Concentration of the fractions containing product yielded 13 mg of product
LC/MS - m/z =
449.
Enantiomers of 8-(4-Methyl-piperazin-1-yl)-chroman-2-carboxylic acid .
(4-morpholin-4-yl-phenyl)-amide.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-115-
Example 75
O N ~ \
N O /
N
N . ~O
racemic-8-(4-Methyl-piperazin-1-yl)-chroman-2-carboxylic acid (4-morpholin-4-
yl-phenyl)-
amide.
racemic-8-(4-Methyl-1-piperazin-1-yl)-chrornan-2-carboxylic acid hydrochloride
(Example 75a) (1.04 mmol) was dissolved in anhydrous N,N dimethylformamide (40
ml) and
the following were added in order: HOBt (0.17 g, 1.14 mmol), TBTU (0.37 g,
1.14 mmol)
then triethylamine (0.6 ml, 4.2 rnmol). After stirnng for 5 min at room
temperature, 4-(4-
morpholinyl)aniline (reference example 20) (0.185 g, 1.14 mmol) was added and
the reaction
stirred overnight at room temperature.
The solution was concentrated in vaeuo, the remains were partitioned between
chloroform,/
saturated sodium bicarbonate, extracted (x3) with chloroform, dried (MgSO4)
and
concentrated in vacuo to give the crude product.
The crude product was chromatographed on a Waters Delta Prep 4000 using 1
PrepPalc
cartridge (Porasil 37-55~m 125~r) eluting with 2.5 % methanol / chloroform.
The product
was collected to give a yellow oil. Ethyl acetate was added to the oil. The
solution was
refluxed then cooled the yellow solid was filtered to give 55 mg (12% yield)
of racemic-8-(4-
methyl-piperazin-1-yl)-chroman-2-carboxylic acid (4-mozpholin-4-yl-phenyl)-
amide (mp
215-216 °C). The mother liquor contained 76 mg that was used in.the
chiral separation
described below. LC/MS (M+1) m/z = 437. -
Example 75a
racemic-8-(4-Methyl-1-piperazin-1-yl)-chroman-2-carboxylic acid hydrochloride.
v Ethyl 8-(4-methyl-1-piperazin-1-yl)-4-oxo-4H-chromen-2-carboxylate
(Reference
Example 1) (0.74 g, 2.3 mmol) was dissolved in glacial acetic acid (50 ml) and
10
palladium on carbon (80 mg) was added. The mixture was hydrogenated on a Paar
apparatus
(50 psi) at 70 °C for 3 h. Then, concentrated HCl and 10 % palladium on
carbon (100 mg)
were added and the mixture was again subjected to hydrogenation (50 psi) at 70
°C for 1h.

CA 02433950 2003-07-08
WO 02/055013 ~ PCT/SE02/00069
-116 -
The reaction was allowed to cool, the catalyst was f ltered and the solution
was concentrated
in vacuo. Toluene was repeatedly added and the solution concentrated to give
racemic-8-(4-
Methyl-1-piperazin-1-yl)-chroman-2-carboxylic acid hydrochloride as a foam
that was used
without further purification in the next reaction. LC/MS (M+1) m/z = 277.
Example 76
/ p N \
N O ~ / N
N ~O
(+)-8-(4-Methyl-piperazin-1-yl)-chroman-2-carboxylic acid (4-morpholin-4-yl-
phenyl)-
amide.
The enantiomers of racemic-8-(4-Methyl-piperazin-1-yl)-chroman-2-carboxylic
acid
(4-morpholin-4-yl-phenyl)-amide (Example 75) (0.52 g, 1.19 mmol) were
separated by the
use of a chiral column (ChiralPak AD, 5 cm X 50 cm, 20 p,). The faster (+)
isomer (example
76) was eluted with 45 % isopropanol / hexane and the slower (-)isomer
(example 77) was
eluted with 75 % isopropanol / hexane.
The faster (+) isomer (example 76) was obtained as a white solid (250 mg, mp
206-
207 °C, ocD + 92.66 in dichloromethane). LC/MS (M+1) m/z = 437.
Example 77
/ O N \
N O I / N
C~ o
N
(-)-8-(4-Methyl-piperazin-1-yl)-chroman-2-carboxylic acid (4-morpholin-4-yl-
phenyl)-amide.
The enantiomers of racemic-8-(4-Methyl-piperazin-1-yl)-chroman-2-carboxylic
acid
(4-morpholin-4-yl-phenyl)-amide (Example 75) (0.52 g, 1.19 mmol) were
separated by the
use of a chiral column (ChiralPak AD, 5 cm X 50 cm, 20 ~,). The faster (+)
isomer (example

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-117 -
76) was eluted with 45 % isopropanol / hexane and the slower (-)isomer
(example 77) was
eluted with 75 % isopropanol l hexane.
The slower (-) isomer (example 77) was obtained as obtained as a light purple
solid
(260 mg, mp 205.5-207 °C, ccD - 91.08 in dichloromethane). LC/MS (M+1)
m/z = 437.
Enantiomers of 8-(4-methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic acid
(4-morpholin-4-yl-phenyl)-amide.
Example 78
O
\
/ O N \
N O ~ ~ / N
~O
C~
N
racemic-8-(4-methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic acid (4-
morpholin-4-yl-
phenyl)-amide.
Racemic-8-(4-methyl-1-piperazin-1-yl)- 4-oxo-chrbman-2-carboxylic acid
hydrochloride (Example 78a) (1.04 mmol) was dissolved in anhydrous N,N
dimethylformamide (40 ml) and the following were added in order: HOBt (0.17 g,
1.14
mmol), TBTU (0.37 g, 1.14 mmol) then triethylamine (0.6 ml, 4.2 mmol). After
stirnng for 5
min at room temperature, 4-(4-morpholinyl)aniline (reference example 20)
(0.185 g, 1.14
mmol) was added and the reaction stirred overnight at room temperature.
The solution was concentrated in vacuo, the remains were partitioned between
chloroform /
saturated sodium bicarbonate, extracted (x3) with chloroform, dried (MgS04)
and
concentrated iu vacuo to give the crude product.
The crude product was chromatographed on a Waters Delta Prep 4000 using 1
PrepPak cartridge (Porasil 37-SS~,m 125A) eluting with 2.5 % methanol /
chloroform. The
product was collected to give a yellow oil. Ethyl acetate was added to the
oil. The solution
was refluxed then cooled the yellow solid was filtered to give 55 mg (12%
yield) of racemic-
8-(4-methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic acid (4-rriorpholin-4-
yl-phenyl)-
amide (mp 215-216 °C). The mother liquor contained 76 mg that was used
in the chiral
separation described below. LC/MS (M+1) m/z = 451.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-118-
Example 78a
racemic-8-(4-Methyl-1-piperazin-1-yl)- 4-oxo-chroman-2-carboxylic acid
hydrochloride.
racemic-Ethyl-8-(4-methyl-1-piperazinyl)- 4-oxo-chroman-2-carboxylate (Example
78b) (0.33 g, 1.04 mmol) was dissolved in 6 M HCl (20 ml) and heated to 100
°C fox 1.5 h.
The reaction was allowed to cool. The solution was concentrated in vacuo and
anhydrous
toluene was added (x3) and the solution was again concentrated in vacuo to
give racemic-8-
(4-Methyl-1-piperazin-1-yl)- 4-oxo-chroman-2-carboxylic acid hydrochloride as
a yellow
foam (0.44 g, quantitative yield) that was used as is in the next reaction.
LC/MS (M+1)
m/z = 291
Example 78b
racemic-Ethyl-8-(4-methyl-1-piperazin-1-yl)- 4-oxo-chroman-2-carboxylate.
Racemic-Ethyl-8-(4-methyl-1-piperazin-1-yl)-4-hydroxy-chroman-2-carboxylate
(Example 78c) (0.43 g, 1.3 mmol) was dissolve in anhydrous dichloromethane (35
ml) and
manganese dioxide (1.2 g, 13 mmol) was added. The reaction stirred at room
temperature
overnight.
The reaction was filtered through diatomaceous earth and the solvent was
removed in
vacuo to give racemic-Ethyl-8-(4-methyl-1-piperazin-1-yl)- 4-oxo-chroman-2-
carboxylate as
a white solid (0.37 g, 86 % yield) that was used as is in the next reaction.
GC/MS {EI, M+)
m/z = 318.
Example 78c
racemic-Ethyl-8-(4-methyl-1-piperazin-1-yl)- 4-hydroxy-chroman-2-carboxylate.
Ethyl 8-(4-methyl-1-piperazin-1-yl)-4-oxo-4H-chroman-2-carboxylate (reference
example 1) (0.48 g, 1.5 mmol) was dissolved in glacial acetic acid (50 ml) and
10
palladium on carbon (100 mg) was added. The mixture was hydrogenated on a Paar
apparatus
(50 psi) at 70 °C for 3 h.
The reaction was allowed to cool, the catalyst was filtered and the solution
was
concentrated i~ vacuo. Ethyl acetate / saturated sodium bicarbonate was added
to the remains
and the mixture was extracted (x3) with ethyl acetate, dried (MgS04) and
stripped to give
racemic-Ethyl-8-(4-methyl-1-piperazin-1-yl)~ 4-hydroxy-chroman-2-carboxylate
(0.43 g, 90
% yield) as a yellow oil. GC/MS (EI, M+) m/z = 320.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-119-
Example 79
~"J
8-(4-Methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic acid (4-morpholin-4-yl-
phenyl)-
amide (faster running isomer).
The enantiomers of the racemic-8-(4-methyl-piperazin-1-yl)-4-oxo-chroman-2-
carboxylic acid (4-morpholin-4-yl-phenyl)-amide (Example 78) (100 mg, 0.22
mmol) were
separated by the use of a chiral column (ChiralPak AD, 5 cm X 50 cm, 20 ~,).
The isomers
were eluted with a gradient of 35-55 % isopropanol l hexane. The faster isomer
was obtained
as a light yellow solid (40 mg, mp 216 °C dec.) LC/MS (M+1) m/z = 451.
Example 80
~~J
8-(4-Methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic acid (4-morpholin-4-yl-
phenyl)-
amide (slower running isomer).
The enantiomers of the racemic-8-(4-methyl-piperazin-1-yl)-4-oxo-chroman-2-
carboxylic acid (4-morpholin-4-yl-phenyl)-amide( 100 mg, 0.22 mmol) were
separated by the
use of a chiral coluW n (ChiralPak AD, 5 cm X 50 cm, 20 ~,). The isomers were
eluted with a
gradient of 35-55 % isopropanol / hexane. The slower isomer was obtained as an
off white
solid (32 mg, mp 215 °C dec.) LC/MS (M+1) m/z = 451.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-120-
Example 81
O
F
N \
O
N O ~ ~ N
~N O
4-[4-({ 1-[6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-
methanoyl}-amino)-
phenyl]-piperazine-1-carboxylic acid ethylamide:
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-
piperazin-1-
yl-phenyl)-amide (Example 71) (150 mg, 0.216 mmol) was placed in a SO rxiL
flask with 10
mL of CH2C12. This suspension was treated with triethylamine (0.1 mL, 0.67
mmol) and
ethylisocyanate (0.21 mL, 18.7 mg, 0.26 mmol) and the reaction stirred at room
temperature
for 18 hours: The reaction was concentrated (1 mm Hg pressure) and the
concentrate purified
by chromatography on silica eluting with 1% methanol in chloroform, then
concentrated
(lmm Hg pressure). Then triturated with either to yield a yellow powder with
was dried
under high vacuum for 48 h at 50°C (79 mg) LCMS - AP+ 537.4, mp = 236-
238°C.
E~eample 82
,O
N
N
~.O
N
6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-oxo-4H chromene-2-carboxylic acid
(4-
morpholin-4-yl-phenyl)-amide:
Into a 100 mL round bottom flask equipped with a nitrogen inlet and magnetic
stirrer'
is added 327 mg (0.89 mmol, 1.0 equiv.) of 6-Methoxy-8-(4-methyl-[1,4]diazepan-
1-yl)-4-
oxo-4H chromene-2-carboxylic acid hydrochloride salt (Reference Example 23).
This
material is dissolved in 20 mL of DMF. and then 189 mg (1.06 mmol, 1.2 equiv.)
of 4-
morpholinoaniline is added. To the stirred solution is quickly added
simultaneously added

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-121-
568 mg (1.77 mmol, 2.0 equiv.) of TBTU and 239 mg (1.77 mmol, 2.0 equiv.) of
HOST. At
this point 457 mg, 577 ~,L (25.2 mmol, 4.0 equiv.) is added via syringe over 5
minutes. The
reaction is allowed to stir at room temperature for 18 hrs, then is
concentrated on a rotary
evaporator under high vacuum in order to remove the DMF. The residue is
triturated with
methanol and the crude solids are recovered by filtration. These residues are
then purified by
flash chromatography using a gradient of 5-10% methanol in methylene chloride
as eluent.
The eluted material, which is obtained from chromatography, is concentrated,
dried under
high vacuum, suspended in methylene chloride, dried over K~C03, concentrated,
then
crystallized from methanol to give the free base of the pure product as 345 mg
(79%) of a
yellow solid. Mass Spec.: calc. for [C27H32FN4O5+H~+ Theor. mlz = 393; Obs. =
393
Example 83
~O
N ~
N
c~ o
N
6-Ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-2-carboxylic acid (4-
morpholin-4-
yl-phenyl)-amide:
Into a 100 mL flask equipped with a nitrogen inlet and magnetic stirrer is
placed 133
mg (.748 mmol, 1.1 equiv.) of 4-morpholinoaniline, which is then dissolved in
20 mL of
methylene chloride. To this mixture is then added 290 mg, 367 ~,L (2.24 mmol,
3.3 equiv.) of
ethyldiisopropyl amine, followed by addition of a solution of 2~0 mg (0.68
mmol, 1.0 equiv.)
of 6-ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-2-carbonyl chloride
(Reference
Example 23) which has been dissolved in 10 ml of methylene chloride. The
reaction is
allowed to stir for 4 hr, after which no further formation of product was seen
by LC/MS. The
crude reaction was concentrated on a rotary evaporator, then triturated with
10 inL of
methanol. The crude solids were collected by filtration, then subjected to
flash
chromatography using a gradient of from 2 to 20% methanol in methylene
chloride.
Recrystallization from methylene chloride and hexanes afforded 55 mg (16%) of
the pure
product as a yellow solid.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-122-
Mass Spec.: calc. for [C27H32N4O5+H]+ Theor. m/z = 493; Obs. = 493
Example 84
CJ
6-Ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-2-carboxylic acid [4-(4-
propionyl-
piperazin-1-yl)-phenyl]-amide:
This compound was prepared from 250 mg (0.68 mmol, 1.0 equiv.) of 6-Ethoxy-8-
(4-
methyl-piperazin-1-yl)-4-oxo-4H chromene-2-carbonyl chloride (Reference
Example 23) and
175 mg (0.748 mmol, 1.1 equiv.) of 1-[4-(4-Amino-phenyl)-piperazin-1-yl]-
propan-1-one by
an analogous procedure to that used to prepare the 4-morpholino aniline
derivative, to give 45
mg (12%) of the desired product as a yellow solid.
Mass Spec.: calc. for [C3oH37N505+H]+ Theor. mlz = 548; Obs. = 54$
Example 85
/O
N \
a . N
O
N
6-Methoxy-4-oxo-8-piperazin-1-yl-4H chromene-2-carboxylic acid (4-morpholin-4-
yl-
phenyl)-amide:
Into a 50 mL round bottom flask equipped with a reflux condenser, nitrogen
inlet and
magnetic stirrer is placed 50 mg (0.115 mmol, 1.0 equiv.) of 6-Methoxy-8-(4-
methyl-
piperazin-1-yl)-4-oxo-4H chromene-2-carboxylic acid (4-morpholin-4-yl-phenyl)-
amide
(Example 31) and 10 mL of l, 2 dichloroethane. To this solution is then added
via syringe 49
mg, 37 ~,L (0.345 mmol, 3.0 equiv.) of 1-chloroethyl chloroformate. A
precipitate forms,
indicating formation of an intermediate. The reaction is heated to reflux for
3 days,

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-123-
whereupon an analysis of an aliquot by LC/MS indicates only a trace of product
has formed.
At this time 52 mg (0.345 mmol, 3.0 equiv.) of sodium iodide are added to the
refluxing
reaction.~LC/MS analyses then progressively show formation of demethylated
product over 5
additional days. The reaction is then cooled, concentrated on a rotary
evaporator, then dried
over K2C03 as a suspension in methylene chloride containing methanol, removal
of solids by
filtration, followed by flash chromatography of the solution, using a gradient
of 5 to 20%
methanol in methylene chloride, gives 34 mg (64%) of the pure product as a
reddish solid.
Mass Spec.: calc. for [CZSHZ8N405+H]~ Theor. m/z = 465; Obs. = 465
Example 86
O -
O
/ O~ N \
N O I / N
~O
N
6-Hydroxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H chromene-2-carboxylic acid (4-
morpholin-
4-yl-phenyl)-amide:
Tnto a 50 mL round bottom flask equipped with a reflux condenser, nitrogen
inlet and
magnetic stirrer is placed 50 mg (0.115 mmol, 1.0 equiv.) of 6-Methoxy-8-(4-
methyl-
piperazin-1-yl)-4-oxo-4H chromene-2-carboxylic acid (4-morpholin-4-yl-phenyl)-
amide
(Example 31) and 20 mL of methylene chloride. To this solution is added 1
mL~of a 1N
solution of boron tribromide in methylene chloride. The reaction is stirred at
room
temperature for 2.5 days at which time it is complete by LC/MS. The reaction
is concentrated
on a rotary evaporator, then methanol is added. The methanol is concentrated
and readded 5
times, until the BBr3 is removed as HBr and trimethyl borate. The solid
hydrobromide salt
residue, which is obtained, is >85% pure product by LC/MS. Mass Spec.: calc,
for
[CasHzsNaOs+H~+ Theor. m/z = 465; obs. = 465

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-124-
Example 87 (Method 1)
,O
I/
Ia
N H O /
N
N ~O
6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-oxo-1,4-dihydro-quinoline-2-
carboxylic acid
(4-morpholin-4-yl-phenyl)-amide.
To a solution of 6-methoxy-8-(4-methyl=[1,4]diazepan-1-yl)-4-oxo-1,4-dihydro-
quinoline-2-carboxylic acid (2.10 mmol) (Reference Example 25b) and
diisopropylethyl
amine (1.4 mL, 8.6 mmol) in 34 mL dimethylformamide was added TBTU (1.40 g,
4.36
mmol) and HOBt (0.588 g, 4.35 mmol) followed by the addition of 4-
morpholinoaniline
(0.463 g, 2.60 mmol). The resulting dark brown solution was stirred at room
temperature
under nitrogen for 19 hours. The reaction was concentrated in vacuo and the
resulting crude
product was taken up in methylene chloride/methanol. Filtration of the
resulting mixture
afforded some product as a yellow solid. The filtrates were concentrated and
partitioned
between methylene chloride and saturated aqueous sodium bicarbonate. The
organic layer
was washed with saturated sodium bicarbonate, dried (MgSO4), and concentrated
under
vacuum to afford a brown solid. This was suspended in methanol and filtered to
afford the
desired product as a yellow solid (0.714 g, 69%). 1H NMR (300 MHz, DMSO, d6) S
9.97 (bs,
1 H, N~, 7.67 (d, 2 H, J°= 8.8 Hz, ArH ~& H6~), 7.47 (bs, 1 H, ArH ),
7.00 (s, 1 H, C=Cue,
6.99 (d, 2 H, Jo 8.8 Hz, ArH ~& H5~), 6.71 (bs, 1 H, ArH7), 3.85 (s, 3 H, OCH
), 3.75 (t, 4 H,
J-- 4.6 Hz, OCH CHZN), 3.70 (bs, 2 H, ArNCH CH2CH2NCH3), 3.55 (bs, 2 H,
ArNCH CH2NCH3), 3.09 (t, 4 H, J-- 4.6 Hz, OCH2CH N), 2.95 (bs, 2 H,
ArNCH2CH NCH3), 2.73 (bs, 2 H, ArNCH2CHzCH NCH3), 2.36 (s, 3 H, NCH ), 2.07
(bs, 2
H ArNCH2CH CH2NCH3); Mass Spec.: calc. for [C27H33NSO4+H]+ Theor. m/z = 492;
Obs.
492.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-125-
Example 87 Method 2)
,O
O
\
I . N .
N ~ \
N H ~ I /
N
N ~O
6-Methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-oxo-1,4-dihydro-quinoline-2-
carboxylic acid
(4-morpholin-4-yl-phenyl)-amide.
A solution of 6-methoxy-8-(4-methyl-[1,4]diazepan-1-yl)-4-(2-trirnethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide
(Reference
Example 27d) (0.989 g, 1.59 mmol) in 20 mL methanol was poured into 300 mL
0.05 N
hydrochloric acid. The clear dark yellow solution became cloudy within 5
minutes. The
mixture was stirred at room temperature for 45 minutes and then adjusted to pH
7 with I O%
sodium hydroxide. The resulting yellow precipitate was isolated by filtration,
washed with
water, and dried under high vacuum to afford the desired product as a yellow
solid (0.629 g,
80%). IH NMR (300 MHz, ~DMSO, d6) S 9.97 (bs, 1 H,C(O)NH~, 7.67 (d, 2 H, Jo
8.8 Hz,
ArH ~& H6~), 7.47 (bs, 1 H, ArH )', 7.00 (s, 1 H, C=Cue, 6.99 (d, 2 H, Jo 8.8
Hz, ArH .&
H ~), 6.71 (bs, 1 H, ArH7), 3.85 (s, 3 H, OCH ), 3.75 (t, 4 H, J-- 4.6 Hz, OCH
CH2N), 3.70
(bs, 2 H, ArNCH CH2CH2NCH3), 3.55 (bs, 2 H, ArNCH CH2NCH3), 3.09 (t, 4 H, J--
4.6 Hz,
OCH2CH N), 2.95 (bs, .2 H, ArNCH2CH NCH3), 2.73 (bs, 2 H, ArNCHaCHaCH NCH3),
2.36 (s, 3 H, NCH ), 2.07 (bs, 2 H ArNCH2CH CH2NCH3); Mass Spec.: calc. for
[Cz~H33N50~+H]+ Theor. xn/z = 492; Obs. = 492. Analysis for
C27H33Ns04.1.OeqHCI.
0.3eqH20: Calculated C 60.79 H 6.54 N 13.13. Found C 60.82 H 6.53 N 13.17.
Example 88
,O
/ I N
~N ~ I \
N H p /
c~ N
N ~O

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-126-
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-2-carboxylic
acid (4-
morpholin-4-yl-phenyl)-amide.
The title compound was prepared from 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example
24c) according
to the procedures described in Reference Example 25a and in Example 87 (Method
1). A
yellow solid was obtained. Mass Spec.: calc. for [C26H3iNsOa+H]+ Theor. m/z =
478; Obs.
478.
Example 89
,O
O
I \ I H
/ N II N I \
N H O /
C~ N
N ~N O
6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-2-carboxylic
acid [4-(4-
propionyl-piperazin-1-yl)-phenyl]-amide.
The title compound was prepared from 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example
24c) according
to the procedures described in Reference Example 25a and in Example 87 (Method
1), except
that the amide was formed from 1-[4-(4-amino-phenyl)-piperazin-1-yl]-propan-1-
one. A
yellow solid was obtained. Mass Spec.: calc. for [C29H36IV6O4~H]+ Theor. m/z =
533; Obs.
533.
Examule 90
O
F
/ NI N \
N O . I / N
C~ .O
N
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-2-carboxylic
acid (4-
morpholin-4-yl-phenyl)-amide

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-127-
The title compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-
oxo-
1,4-dihydro-quinoline-2-carboxylic acid hydrochloride salt (Reference Example
26) using the
procedure described in Example 87 (Method 1). After chromatography, it is then
crystallized
from methanol to give the pure product as 150 mg (55%) of a yellow solid. Mass
Spec.: calc.
for [CZSH2$FN503+H]+ Theor. m/z = 466; Obs. = 466.
Example 91 ~ .
F
L'"1r'
6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-2-carboxylic
acid [4-(4-
propionyl-piperazin-1-yl)-phenyl]-amide.
The title compound was prepared from 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-
oxo-
1,4-dihydro-quinoline-2-carboxylic acid hydrochloride salt (200 mg, 0.59 mmol)
(Reference
Example 26) using the procedure described in Example 87 (Method 1). 31% yield.
Mass
Spec.: calc. for [C28H33FN603+H]+ Theor. m/z = 521; Obs. = 521.
Example 92
,O
I / . I N
_N .
,N H O / N
~N , ~O
8-[(2-Dimethylamino-ethyl)-methyl-amino]-6-methoxy-4-oxo-1,4-dihydro-quinoline-
2-
carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
The title compound was prepared from 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example
24c)
according to the procedures described in Reference Example 25a and in Example
87 (Method

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-128-
2), using N,N,N'-trimethyl ethylenediamine for the Pd catalysed coupling. A
yellow solid
was obtained. Mass Spec.: calc. for [C26H3sNs04+H]+ Theor. m/z = 480; Obs. =
480.
Example 93
,O
I~
,N . ~ I ~
,N H O ~ N
~N ~O
S 8-[(3-Dimethylamino-propyl)-methyl-amino]-6-methoxy-4-oxo-1,4-dihydro-
quinoline-2-
carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
The title compound was prepared from 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quirioline-2-carboxylic acid methyl ester (Reference Example
24c)
according to the procedures described in Reference Example 2Sa and in Example
87 (Method
2), using N,N,N'-trimethyl-1,3-propanediamine for the Pd catalysed coupling. A
yellow solid
was obtained. Mass Spec.:_ calc. for [C27H35N504+H]+ Theor. m/z = 494; Obs. =
494.
Example 94
,O
H
I
N
N
~O
-N
8-((3R)-(+)-3-Dimethylamino-pyrrolidin -1-yl)-6-methoxy-4-oxo-1,4-dihydro-
quinoline-2-
1 S carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
The title compound was prepared from 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl (Reference Example 24c)
according to
the procedures described in Reference Example 2Sa and in Example 87 (Method
2), using
(3R)-(+)-3-(dimethylamino)pyrrolidine for the Pd catalysed coupling. A yellow
solid was
obtained. Mass Spec.: calc. for [C27H33NSO4+H]+ Theor. m/z = 492; Obs. = 492.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-129-
Example 95
,O
H
I
N
iv h O
N
~O
-N
8-((3S)-(-)-3-Dimethylamino-pyrrolidin -1-yl)-6-methoxy-4-oxo-1,4-dihydro-
quinoline-2-
carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
The title compound was prepared from 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example
24c) according
to the procedures described in Reference Example 25a and in Example 87 (Method
2), using
3S)-(-)-3-(dimethylamino)pyrrolidine for the Pd catalysed coupling. A yellow
solid~was
obtained. Mass Spec.: calc. for [C27H33NSOd+H]+ Theor. m/z = 492; Obs. = 492.
Example 96
,O
H
I
N
/N n O ~ ~ N
O
N
6-Methoxy-8-[methyl-( 1-methyl-pyrrolidin-3-yl)-amino]-4-oxo-1,4-dihydro-
quinoline-2-
carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
The title compound was prepared from 8-bromo-6-methoxy-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example
24c) according
to the procedures described in Reference Example 25a and in Example 87 (Method
2), using
N,N'-dimethyl-3-aminopyrrolidine for the Pd catalysed coupling. A yellow solid
was
obtained. Mass Spec.: calc. for [C27H33NSO4+H]+ Theor. m/z = 492; Obs. = 492.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-130-
Example 97
/O
H
N \
N n O ~ / N
O
N
8-[Ethyl-( 1-ethyl-pyrrolidin-3-yl)-amino]-6-methoxy-4-oxo-1,4-dihydro-
quinoline-2-
carboxylic acid (4-morpholin-4-yl-phenyl)-amide.
The title compound was prepared from 8-bromo-6-metho~y-4-(2-trimethylsilanyl-
ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example
24c) according
to the procedures described in Reference Example 25a and in Example 87 (Method
2), using
3-diethylaminopyrrolidine for the Pd catalyzed coupling. A yellow solid was
obtained. Mass
Spec.: calc. for [C29H3~N504+H]~ Theor. mlz = 520; Obs. = 520.
Example 98
,O
\ \
N
~N
N
N O_ /
N ~O
4-Dimethylamino-6-methoxy-8-(4-methyl-piperazin-1-yl)-quinoline-2-carboxylic
acid (4-
morpholin-4-yl-phenyl)-amide.
To a suspension of 8-bromo-4-dimethylamino-6-methoxy-quinoline-2-carboxylic
acid
(4-morpholin-4-yl-phenyl)-amide (Reference Example 28b) (139.9 mg, 0.288
mmol), N-
methylpiperazine (48 ~,L, 0.43 mmol), and 4 A sieves in 15 mL anhydrous
toluene was added
Pd2 (dba) 2 (15.3 mg, 16.7 ~,mol), BINAP (63.0 mg, 0.101 mmol) and cesium
carbonate
(0.436 g, 1.345 mmol). The resulting wine colored mixture was heated at reflex
under
nitrogen for 20 hours. The reaction mixture was cooled to room temperature and
concentrated. The crude mixture was purified by flash chromatography on silica
geI using a
~N~

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-131-
gradient of 100:0 to 95:5 methylene chloride:methanol to afford the desired
product as a
yellow solid (96.9 mg, 67%). 1H NMR (300 MHz, DMSO, d6) 810.06 (s, 1 H,
C(O)NH), 7.69
(d, 2 H, Jo 9.0 Hz, ArH ~& H6~), 7.58 (s, 1 H, ArH3), 7.58 (d, 2 H, Jo 9.0 Hz,
ArH .& H5.),
6.95 (d, 1 H, Jm 2.7 Hz, ArH,; 6.76 (d, 1 H, Jm 2.7 Hz, ArH~), 3.90 (s, 3 H,
OCH ), 3.75 (t,
4 H, J 4.8 Hz, OCH CHaN), 3.37 (bs, 4 H, ArNCH CHaN), 3.10 (t, 4 H, J-- 4.8
Hz,
OCHZCH N), 3.01 (s, 6 H, N(CH ) 2), 2.71 (bs, 4 H, ArNCH2CH N), 2.35 (s, 3 H,
R2NCH3 );
Mass Spec.: calc. fox [CagH36N6O3+H]+ Theor. m/z = 505; Obs. = 505.5.
Example 99 ~ .
H,
,O
H
I
N \
i
~ J N~
N O
6-Methoxy-4-methylamino-8-(4-methyl-piperazin-1-yl)-quinoline-2-carboxylic
acid (4-
morpholin-4-yl-phenyl)-amide.
The title compound was prepared from 8-bromo-6-methoxy-4-oxo-1,4-dihydro-
quinoline-2-carboxylic acid (Reference Example 27b) according to the procedure
described
for Example 98 using N-methyl amine to prepare 8-bromo-4-methylamino-6-methoxy-
quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide. A glassy orange
solid was
obtained. Mass Spec.: calc. for [CZ~H34N6O3~-H]+ Theor. m/z = 491; Obs. =
491.5.
Examule 100
i
F
N, ~. '1! w
N O ~N
~O
N
6-Fluoro-4-methoxy-8-(4-methyl-piperazin-1-yl)-quinoline-2-carboxylic acid (4-
morpholin-4-
yl-phenyl)-amide.

CA 02433950 2003-07-08
WO 02/055013 PCT/SE02/00069
-132-
Into a 250 mL round bottom flask equipped with a nitrogen inlet and magnetic
stirrer
is added 2.01g (6.3 mmol, 1.0 equiv.) of 6-Fluoro-4-methoxy-8-(4-methyl-
piperazin-1-yl)-
quinoline-2-carboxylic acid hydrochloride salt. This material is dissolved in
20 mL of DMF
and then 1.35 g (7.56 mmol, 1.2 equiv.) of 4-morpholinoaniline is added. To
the stirred
solution is quickly added simultaneously added 4.05g (12.6 mmol, 2.0
equiv.),of TBTU (2-
(1H-benzotriazole-1-yl)-1,1,3,3tetramethyluroniumtetrafluoroborate) and 1.7 g
(12.6 mmol,
2.0 equiv.) of HOBT (1-hydroxybenzotriaole hydrate). At this point 3.25 g,
4.11 mL (25.2
mmol, 4.0 equiv.) is added via syringe over 5 minutes. The reaction is allowed
to stir at room
temperature for 18 hrs, then is concentrated on a rotary evaporator under high
vacuum in
order to remove the DMF. The residue is triturated with methanol and the crude
solids are
recovered by filtration. The material is then dissolved in methylene chloride
and extracted
with 10% sodium bicarbonate solution. The organic layer is dried and then
concentrated.
These residues are then purified by flash chromatography using a gradient of 5-
10% methanol
in methylene chloride as eluent. The material which is obtained from
chromatography, is then
crystallized from methanol to give the pure product as 2.83g (93%) of a yellow
solid.
Mass Spec.: talc. for [C26H3oFNs03+H]+ Theor. m/z = 480; Obs. = 480
Example 101
6-Flizoro-4-oxo-8-piperazin-1-yl-4H chromene-2-carboxylic acid (4-morpholin-4-
yl-phenyl)-
amide: made according to the general method of Howarth et. al. Tetrahedron,
1998, 54,
10899-10914. ~ '
Dry 6-flouro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid
[4-(4-
propionyl-piperazin-1-yl)-phenyl]-amide (Example 72)(1 g 1.9 mmol ) was added
to 100 mL
of rigorously dried 1,2-dichloroethane in a flask under N2 atmosphere and
magnetic stirnng.
The mixture was cooled to 0°C and freshly distilled 1-chloroethyl
chloroformate (650 u1, 858
mg, 6 mmol, 3 eq) was added drop wise. The reaction was then heated under
reflux for 5
hours at which time LC/MS revealed complete consumption of starting material.
NaI (1 g,
leq) was added and heating continued for 2 days more. The reaction was then
allowed to
cool and filtered and evaporated to dryness under reduced pressure. MeOH (100
mL) was
added and heated to reflux for 4h, filtered hot and evaporated to dryness. The
product was
isolated by chromatography using silica gel and CHC13/5% MeOH as an eluent.
This gave
700 mg of the product HCl salt as a yellow solid. LCMS - m/z = 508.

Representative Drawing